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“we have to remember that what we observe is not nature in itself, but nature 
exposed to our method of questioning” 








































































































































class	 of	 receptors,	 in	 drug	 research	 and	 development,	 has	 constantly	 increased	 and	 could	 not	 be	
overestimated.	 Fredriksson	 et	 al.	 identified	 802	 human	 7TMR	 (also	 termed	 G	 protein-coupled	
receptors	 or	 GPCR)	 genes	 and	 divided	 them	 into	 five	 families	 based	 on	 phylogenetic	 criteria.	 The	
families	 were	 termed	 Glutamate,	 Rhodopsin,	 Adhesion,	 Frizzled/Taste2	 and	 Secretin	 (this	
classification	 is	 shortened	 to	 GRAFS).2	 These	 proteins	 share	 two	 features;	 first	 they	 all	 have	 7	
stretches	of	25-35	amino	acids	with	high	degree	of	hydrophobicity,	which	enables	them	to	span	the	
cell	membrane.	The	second	feature	 is	their	ability	to	 interact	with	heterotrimeric	G	proteins.2,3	The	
Secretin	 receptor	 family	 consists	 of	 15	 members.	 All	 deorphanized	 members	 of	 this	 family	 bind	
peptide	 hormones.	 The	Adhesion	 receptor	 family	 consists	 of	 33	members	 and	 can	 be	 divided	 into	
eight	subgroups.	The	members	of	this	family	have	diverse	and	long	N-termini	with	a	proteolytic	site	
and	several	functional	domains.	Only	three	members	of	this	class	have	been	deorphanized	so	far.	The	
Glutamate	 receptor	 family	 consists	 of	 22	 7TMRs,	 8	 metabotropic	 glutamate	 receptors,	 2	 GABA	
receptors,	 one	 calcium-sensing	 receptor	 as	 well	 as	 7	 orphan	 receptors.	 The	 ligand-binding	 was	
compared	to	a	Venus	 flytrap	mechanism,	 in	which	the	two	 lobes	of	 the	extracellular	 region	form	a	
cavity	where	glutamate	binds	and	thereby	activates	the	receptor.	The	Frizzeld/Taste2	receptor	family	
consists	of	36	members.	The	Frizzeld	receptors	bind	the	family	of	Wnt	glycoproteins	and	control	cell	
fate,	 proliferation	 and	 polarity.	 With	 672	 members,	 the	 Rhodopsin	 receptor	 family	 is	 by	 far	 the	
biggest	7TMR	receptor	family.	This	family	has	been	further	divided	into	α,	β,	γ	and	δ	branches.	The	α	
branch	contains	many	important	drug	targets	like	histamine,	dopamine,	and	serotonin	receptors.	The	






or	 peptides,	 e.g.	 P2Y	 receptors,	 protease	 activated	 receptors	 (PAR),	 leukotriene	 as	 well	 as	 the	
olfactory	and	many	orphan	receptors.2,4	
The	 importance	of	 the	7TMRs	could	be	evident	by	their	ability	 to	bind	to	a	broad	range	of	 ligands,	
including	inorganic	ions,	small	organic	compounds,	lipid	metabolites,	peptides	and	even	proteins	and	
translate	the	binding	 into	 intracellular	 information.	This	class	of	proteins	has	 its	origins	 in	the	early	
evolution	 of	 eukaryotes.	 During	 evolution	 7TMRs	 underwent	 substantial	 expansion	 and	
pseudogenization.	This	made	some	7TMRs	essential	for	eukaryotic	life	and	enabled	many	organisms	
to	 readily	 adapt	 to	new	 sensory	 functions,	which	may	 represent	 an	evolutionary	 advantage.5,6	Not	
only	 is	 the	 physiological	 role	 of	 this	 protein	 family	 outstanding	 but	 also	 its	 current	 share	 in	 the	
druggable	human	genome.	Approximately	30%	of	the	marketed	drugs	target	a	7TMR,	which	makes	it	
the	most	successfully	addressed	protein	family	of	drug	targets.7,8	Nevertheless,	the	assumption	that	
7TMRs	 have	 achieved	 their	 full	 potential	 as	 drug	 targets	 cannot	 be	more	misleading.	 Taking	 into	
consideration	 that	 the	 pharmacology	 of	 7TMRs	 is	 complex	 and	 that	 the	 currently	 available	 drugs	







but	 current	 treatment	 is	 inadequate.	 It	 is	associated	with	 sensory	abnormalities,	 including	ongoing	
pain	 and	 paraesthesia	 (an	 abnormal	 sensation	 of	 tingling,	 prickling	 or	 burning	 of	 the	 skin	without	
apparent	physical	effect),	and	altered	stimulus–response	function,	including	allodynia	(such	that	low	
threshold	 stimuli,	 e.g.	 brushing	 of	 the	 skin,	 can	 evoke	 pain),	 hyperalgesia	 (increased	 sensitivity	 to	
noxious	stimuli),	and	loss	of	sensation	in	some	areas.11-13	The	most	common	etiologies	of	neuropathic	




mechanisms	 (multiple	 sclerosis),	 spinal	 cord	 injuries	 and	 alcoholism.14	 Itch	 (pruritus)	 is	 another	
unpleasant	 sensation,	which	was	 given	 a	 still-valid	 definition	more	 than	 340	 years	 ago	 by	 Samuel	
Hafenreffer	as	“unpleasant	sensation	that	elicits	the	desire	or	reflex	to	scratch”.	Clinical	relevance	is	
obviously	highest	in	chronic	itch	conditions	that	last	longer	than	3	months.	In	many	cases	such	as	dry	










































Although	 pain	 and	 itch	 are	 universal	 sensations,	 elucidating	 the	molecular	 underpinnings	 of	 these	












tetrodotoxin	 (TTX)	 insensitive	 sodium	channels	 consolidated	our	understanding	of	 nociception	 and	
itch,	but	the	discovery	of	mas-related	gene	receptors	in	2001	opened	new	avenues	in	the	elucidation	




Mas-related	 gene	 receptors	 (MRGs)	 belong	 to	 the	 7	 transmembrane	 receptors	 (7TMRs).	 These	
receptors	 are	 in	 the	δ	branch	of	 the	Rhodopsin	 receptor	 family	 together	with	purine,	 glycoprotein	
and	olfactory	receptors.2	This	receptor	family	was	discovered	independently	by	two	groups.	Dong	et	
al.	exploited	the	fact	that	mouse	embryos	lacking	the	transcription	factor	neurogenin1	fail	to	develop	
sensory	 neurons.	 By	 subtracting	 the	 cDNA	 from	 neonatal	 wild-type	 and	 deficient	 mice,	 signaling	
molecules	 involved	 in	 nociception	 emerged.	 In	 their	 first	 paper	 they	 reported	 31	 murine	 and	 8	
human	 intact	 coding	 sequences	 belonging	 to	 7TMR,	 which	 they	 designated	 mas-related	 gene	
receptors	(MRGs)	due	to	their	relatedness	to	the	mas	oncogene.17		Lembo	et	al.	discovered	the	same	
7TMR	 family	 during	 search	 in	 the	 RNA	 isolated	 from	 a	 primary	 culture	 of	 rat	 dorsal	 root	 ganglia	
(DRG).	 Due	 to	 their	 unique	 expression	 in	 small	 nociceptive	 sensory	 neurons,	 they	 were	 named	
sensory	 neuron-specific	 receptors	 (SNSRs).18	 In	 order	 to	 avoid	 any	 confusion,	 the	 HUGO	 Gene	




so	 far	 as	 shown	 in	 figure	 1.19	 The	 MRGPR	 family	 consists	 of	 38	 members	 (see	 table	 2)	 that	 are	
grouped	 into	nine	distinct	 subfamilies	 (MRGPRA	to	–H	and	–X)	and	belongs	 to	 the	δ	branch	of	 the	
Rhodopsin	 receptor	 family.	 According	 to	 our	 current	 knowledge,	 the	mrgprA	 subfamily	 consists	 of	
one	member	in	the	rat	and	18	protein-coding	genes	in	the	mouse	as	well	as	many	pseudogenes.	The	







found	 in	 human.	 The	 rat	mrgprF	 gene	was	 actually	 first	 reported	 in	 1990	 and	 named	 rat	 thoracic	
aorta	(RTA)	gene.	The	related	mas1L	gene	was	reported	in	1991.	The	last	subfamily	is	called	mrgprX	
and	 it	 is	 primate-specific	 and	 comprises	 only	 4	 members	 mrgprX1-4	 while	 the	 other	 reported	
sequences	are	polymorphisms	of	these	4	members.	All	the	members	are	still	considered	orphan	by	
the	International	Union	of	Basic	and	Clinical	Pharmacology	(IUPHAR)19,20	It	was	also	possible	to	clone	






that	 this	 family	 of	 genes	 has	 emerged	 after	 the	 divergence	 of	 bony	 fish	 from	 the	 line	 leading	 to	
Tetrapoda.	 MrgprH	 is	 the	 oldest	 gene	 since	 it	 includes	 a	 frog	 and	 two	 chicken	 members.	
Interestingly,	 all	 genes	 for	 mrgpr	 other	 than	 mas,	 mas1L,	 and	 mrgprH	 are	 located	 on	 a	 single	
chromosome	 in	 human	 (chromosome	 11),	 rat	 (chromosome	 1),	 and	 mouse	 (chromosome	 7)	 as	
shown	in	figure	2.20	In	addition,	an	evolutionary	analysis	on	the	mrgpr	gene	subfamilies	in	human	and	
mouse	 was	 performed.	 A	 pairwise	 comparison	 of	 the	 members	 within	 each	 subfamiliy	 was	
conducted	and	the	Ka/Ks	ratios	were	calculated	(the	ratio	between	nonsynonymous	and	synonymous	
substitution	 rates).	 Interestingly,	 the	 results	 showed	a	 robust	positive	 selection	 in	 the	extracellular	
regions,	 whereas	 the	 intracellular	 loops	 as	 well	 as	 7	 transmembrane	 helices	 were	 under	 negative	















mrgprA*	 18	 1	 n.a	
mrgprB**	 9	 7	 n.a	
mrgprC*	 1	 1	 n.a	
mrgprD	 1	 1	 1	
mrgprE	 1	 1	 1	
mrgprF	 1	 1	 1	
mrgprG	 1	 1	 1	
mrgprH	 1	 1	 n.a	













suggested	 model	 was	 that	 mrgprA	 and	 mrgprC	 had	 a	 common	 ancestor	 gene	 whereas	 mrgprB	
originated	from	a	different	ancestor.	Of	note,	according	to	the	model	mrgprX	receptors	should	have	
had	 the	 same	 ancestor	 as	mrgprA	 and	mrgprC.	 The	 expansion	 in	mice	 took	 place	 after	 rat-mouse	
speciation	due	to	retrotransposon-mediated	crossover	events.	The	findings	suggest	that	the	diversity	
of	mrgpr	 in	 rodents	 could	be	 reduced	 to	a	 core	 set	of	4	different	genes	approximating	 the	 limited	
mrgpr	diversity	 in	 humans.24	Unfortunately,	 despite	 the	probable	 redundancy	 in	 rodents,	 the	 later	
investigations	 revealed	 that	 it	 is	 not	 accurate	 to	 oversimplify	 the	 diversity	 of	mrgpr	 in	 rodents	 as	
discussed	below.		
The	expression	of	different	MRGPR	subfamilies	and	receptors	was	a	major	point	of	interest	since	the	
very	 discovery	 of	 these	 receptors.	 The	 restricted	 expression	 in	 dorsal	 root	 ganglia	 (DRG)	 is	 an	
indication	of	 involvement	in	nociception.	 In	more	details,	two	main	populations	of	sensory	neurons	




neurons	 are	 regulated	 by	 nerve	 growth	 factor	 (NGF)	 and	 its	 trk	A	 receptor.	 NGF	 enhances	 the	
expression	 of	 peptides	 like	 substance	 P	 and	 calcitonin	 gene-related	 peptide	 (CGRP).	 The	 second	
population	 is	 non-peptidergic	 neurons.	 These	 neurons	 are	 regulated	 by	 glial	 cell	 line-derived	
neurotropic	 factor	 (GDNF)	and	 its	ret	receptor.	These	neurons	do	not	contain	substance	P	or	CGRP	
but	they	express	P2X3	receptors.	Most	importantly,	the	non-peptidergic	neurons	bind	the	isolectin-
B4	 (IB4+).25,26	 Interestingly,	 IB4+	neurons	respond	preferentially	 to	non-noxious	 inputs,	which	are	a	
main	 characteristic	 of	 neuropathic	 pain	 as	well	 as	 an	 indication	 of	 the	 involvement	 in	 establishing	
chronic	 pain	 states.27,28	 This	 suggests	 that	 selectively	 targeting	 a	 biochemical	 molecule	 in	 IB4+	
neurons	may	be	an	approach	to	deal	with	neuropathic	pain.	Dong	et	al.	found	a	distinct	expression	
profile	 of	mouse	MRGPRA2-8	 receptor	 subtypes	 in	 different	 subpopulations	 of	 IB4+	 neurons	with	
some	overlapping	 in	 the	expression	at	 least	 at	birth.	Moreover,	 it	was	discovered	 that	 there	 is	 ca.	
15%	 overlapping	 between	 MRGPRA	 subtypes	 and	 MRGPRD	 receptor	 at	 birth.	 Nevertheless,	 in	
adulthood	 the	 expression	 will	 be	 segregated.17	 Most	 interestingly,	 MRGPRD+	 and	 MRGPRB4+	
neurons	 in	 adult	 mice	 innervate	 distinct	 peripheral	 targets,	 skin	 epidermis	 and	 the	 hairy	 skin,	
respectively.29,30	The	reason	behind	this	compartmentalized	expression	seems	to	be	the	runt	domain	
transcription	 factor	 Runx1.	 It	 turned	 out	 that	 MRGPRA/B/C	 expression	 persists	 only	 in	 Runx1	
negative,	whereas	the	MRGPRD	compartment	is	Runx1	positive	as	illustrated	in	figure	3.31		
	





In	 an	 approach	 to	 overcome	 the	 apparent	 complexity	 and	 potential	 gene	 redundancy,	 Liu	 et	 al.	
generated	 deficient	 mice	 with	 a	 deleted	 845-kilo	 base	 region	 (instead	 of	 knocking	 out	 individual	
genes)	 in	chromosome	7,	which	comprises	30	mrgpr	genes	and	pseudogenes	as	 shown	 in	 figure	2.	
More	 precisely,	 this	 region	 comprises	 12	 intact	 open	 reading	 frames	 (mrgprA1-A4,	 A10,	 A12,	 A14,	
A16,	A19,	B4,	B5	and	C11).	 	 The	deficient	mice	did	not	 show	any	difference	 compared	 to	wt	mice	
regarding	acute	noxious	heat,	cold	mechanical	and	chemical	stimulation.	The	L5	spinal	nerve	ligation	
model	 of	 neuropathic	 pain	 and	 histamine-induced	 itch	 induced	 the	 same	 responses	 in	 wt	 and	
deficient	 mice.	 Interestingly,	 the	 deficient	 mice,	 in	 contrast	 to	 wt	 mice,	 showed	 a	 significantly	
reduced	 itch	 response	 to	 the	 pruritogenic	 anti-malaria	 drug	 chloroquine.	 Further	 investigations	 of	
the	 individual	 knocked	 out	 genes	 revealed	 that	 only	MRGPRA3	 responded	 to	 chloroquine	with	 an	
EC50	of	27	µM.	This	indicated	that	MRGPRA3+	neurons	could	be	histamine-independent	itch-specific	
neurons	 and	 revealed	 its	 potential	molecular	mechanism	 for	 the	 first	 time.32	Wilson	et	 al.	 tried	 to	
further	 investigate	 the	 itch	mechanism,	 in	which	 it	was	 found	 that	 chloroquine	 and	BAM8-22,	 the	
agonists	at	murine	MRGPRA3	and	MRGPRC11,	respectively,	depend	on	transient	receptor	potential	
A1	 (TRPA1)	 for	 their	 itch	 transduction.	 Although	 TRPA1	 is	 expressed	 in	 a	 subset	 of	 TRPV1-positive	
neurons,	it	was	suggested	that	TRPV1	is	not	required	for	BAM8-22	and	chloroquine-dependent	itch.	
In	 contrast,	 TRPV1	 is	 necessary	 for	 histamine-related	 itch.	 Hence,	 selective	 TRPA1,	 MRGPRA3	 or	
MRGPRC11	antagonists	could	inhibit	itch	transduction.33		
In	an	interesting	paper,	it	was	described	that	MRGPRA3+	neurons	in	DRG	could	be	labeled	and	it	was	
demonstrated	 that	 they	 exclusively	 innervate	 the	 epidermis	 of	 the	 skin	 and	 confirmed	 that	 only	
MRGPRA3+	 neurons	 respond	 to	 chloroquine.	 It	 was	 also	 demonstrated	 that	 MRGPRA3+	 neurons	
represent	a	compartment	within	the	pain-related	TRPV1+	neurons.	Most	strikingly,	it	was	shown	that	













DRG	 and	 trigeminal	 ganglia.	 It	 has	 been	 found	 that	 only	 7	 %	 of	 mrgprX-positive	 cells	 expressed	
substance	 P	 or	 CGRP,	 whereas	 most	 of	 the	 mrgprX-positive-neurons	 bind	 IB4	 (76%)	 and	 many	
express	TRPV1	(56%)	indicating	that	mrgprX	receptors	are	associated	preferentially	with	the	IB4	class	
of	nociceptors.18	
In	 this	 thesis	 the	 main	 interest	 is	 the	 human	 MRGPRX	 subfamily.	 Hence,	 the	 ligands,	 signaling	
pathways	as	well	 as	physiologic	 functions	of	 the	members	of	 this	 family	will	 be	discussed	 in	detail	
(see	 below).	 Nevertheless,	 the	 knowledge	 about	 other	 human	 MRGPR	 subfamilies	 and	 rodent-
specific	 subfamilies	 could	provide	 insights	 into	 the	 functions	of	MRGPRX	 subfamily.	 Therefore,	 the	
current	knowledge	will	be	briefly	mentioned.	
The	 MRGPRD	 subfamily	 consists	 of	 only	 one	 member,	 which	 is	 conserved	 among	 rodents	 and	
humans.	Four	pairings	have	been	suggested	for	this	receptor,	the	first	with	ß-alanine	and	the	second	
with	alamandine	(Ala-angiotensin-1-7).36,37	Two	other	ligands	have	also	been	suggested	(GABA	and	ß-




constitutive	 activity.	 As	 mentioned	 above	 MRGPRD	 has	 its	 own	 compartment	 in	 DRG	 and	 the	














receptor	was	 found	 to	 be	 activated	by	 adenine.40,	41,	23	Dong	 et	 al.	 described	RF-amide	peptides	 as	
potential	 physiological	 neuropeptides	 for	 activating	 murine	 MRGPRA1	 and	 MRGPRA4	 receptors.	
MRGPRA1	was	activated	most	by	FLRFamide	peptide	with	an	EC50	of	20	nM,	whereas	MRGPRA4	was	
activated	 by	 NPAFamide	 with	 an	 EC50	 of	 60	 nM	 in	 calcium	 mobilization	 assay.	 Both	 receptors	
responded	similarly	 to	adrenocorticotropin	 (ACTH).17	The	search	 for	 ligands	confirmed	 that	distinct	
RF(Y)G	and/or	RF(Y)	amide-peptides	could	activate	MRGPRC11	as	well	as	MRGPRA1.	MRGPRC11	was	
found	 to	 be	 activated	 most	 potently	 by	 proopiomelanocortin	 (POMC)	 products	 γ1-	 and	 γ2-MSH	
(melanocyte	 stimulating	 hormone),	 dynorphine-14	 and	 BAM22	 (bovine	 adrenal	medulla)	with	 EC50	
values	in	the	low	nanomolar	range.42	The	rat	MRGPRC	receptor	was	also	activated	by	the	same	RF-
amide	peptides	and	it	turned	out	that	the	active	moiety	is	the	7-C-terminal	amino	acids	of	γ2-MSH.43	





HEK	 cells	 were	 activated	 both	 by	 the	 supernatant	 of	 IgE-sensitized	 RBL-2H3	 mast	 cells	 and	 by	
coculture	of	both	cells	after	IgE-sensitization	and	therefore	gave	support	to	this	hypothesis.44	Hin	et	
al.	developed	recently	small	molecules	as	peptidomimetic	agonists	at	MRGPRC	receptor	 in	both	rat	
and	 mouse.	 They	 synthesized	 short	 Arg-Phe-NH2	 derivatives	 in	 which	 the	 arginine	 residue	 is	
substituted	by	an	arginine	mimetic.	 Interestingly,	there	were	species	differences	within	the	rodents	
since	 some	 active	 derivatives	 in	 the	 mouse	 were	 inactive	 in	 the	 rat	 and	 vice	 versa	 as	 shown	 for	
compound	 1	 and	 2	 in	 table	 2.45	 This	 means	 there	 are	 interspecies	 differences	 on	 the	 medicinal	
chemistry	 level	 in	addition	to	the	 lack	of	clear	orthologs	between	humans	and	rodents.	Hence,	 the	
extrapolation	of	the	data	from	rodents	to	the	humans	should	be	conducted	with	great	caution	when	
it	 comes	 to	 physiological	 functions	 and	 ligand	 affinities	 of	 MRGPR	 receptors.	 Table	 3	 shows	 the	
structures	of	the	agonists	at	the	rodent	receptors.	
Table	3:	The	structure	of	the	most	potent	agonistic	compounds	at	the	rodent	MRGPR	receptors	















FLRFamide	 FLRFa	 mMRGPRA1	 20	nM17	
NPAFamide	 AGEGLNSQFWSLAAPQRFa	 mMRGPRA4	 60	nM17	



















According	 to	 IUPHAR,	 the	 suggested	putative	 ligands	 for	MRGPRX1	 and	MRGPRX2,	 bovine	 adrenal	
medulla-22	 (BAM22)	 and	 cortistatin-14,	 respectively,	 are	 neuropeptides.	 Hence,	 it	 is	 important	 to	
address	 these	 ligands	 in	 some	 detail	 before	 delving	 into	 both	 receptors.	 Cortistatin-14	 will	 be	
discussed	 in	detail	 later	 (see	below).	 It	 is	 important	to	keep	 in	mind	that	BAM22	 is	a	neuropeptide	
and	 neuropeptides	 are	 derived	 from	 larger	 proteins	 known	 as	 proneuropeptides	 or	 prohormones.	
These	precursors	undergo	proteolytic	processing	to	generate	the	smaller	active	neuropeptides.46	The	
proteolytic	 processing	 occurs	 usually	 at	 dibasic	 residues	 that	 flank	 the	 N-	 and	 C-termini	 of	
neuropeptides	 within	 their	 precursors.	 The	 dibasic	 residues	 Lys-Arg	 (KR)	 most	 often	 flank	 the	
neuropeptides	but	 also	KK,	 RR	 and	RK	occur.	 	 Processing	 at	 nonbasic	 residues	occurs	occasionally.	
This	 means	 proteolysis	 and	 tissue-specific	 processing	 of	 the	 proneuropeptides	 depend	 on	 the	
proteases	available	in	a	specific	tissue	in	the	first	place.47	
Since	the	discovery	of	the	enkephalins	in	1975,	many	other	opioids	have	been	described.	BAM20	as	
well	 as	 BAM22	 were	 isolated	 from	 bovine	 adrenal	 medulla	 and	 were	 designated	 “big”	 Met-
enkephalins	 at	 first.	 It	 is	 now	 clear	 that	 the	 opioid	 peptides	 belong	 to	 three	 peptide	 families,	
proenkephalin	 (also	 proenkephalin	 A),	 prodynorphin	 (also	 proenkephalin	 B)	 and	
proopiomelanocortin	(POMC).	Proenkephalin	A	is	processed	to	4	copies	of	Met-enkephalin,	one	copy	
of	 Leu-enkephalin,	 one	 copy	 of	 the	 heptapeptide	 Met-enkephalin-Arg-Phe,	 one	 copy	 of	 the	
octapeptide	 Met-enkephalin-Arg-Gly-Leu,	 in	 addition	 to	 peptide	 E	 and	 its	 fragments	 as	 shown	 in	
figure	5.48,49	Peptide	E	is	a	25	amino	acid	(aa)	peptide	with	Met-enkephalin	at	its	N-terminus	and	Leu-
enkephalin	 at	 its	 C-terminus.	 Its	 fragments	 are	 BAM22,	 BAM20	 and	 BAM12.	 These	 neuropeptides	





intestine.	 BAM22	was	 able	 to	 activate	 all	 three	 opioid	 receptor	 subtypes.50	 Further	 investigations	
revealed	 that	of	Proenkephalin	processing	 in	chromaffin	cells	plays	a	 role	 in	 immunomodulation	 in	
addition	to	nociception.	Using	MALDI-TOF	mass	spectrometrical	analysis,	it	was	feasible	to	unravel	16	
novel	 cleavage	 sites	 and	 30	 cleavage	 products.	 The	 role	 of	 these	 peptides	 was	 not	 clear	 and	 the	
possibility	that	these	novel	entities	were	due	to	the	extraction	procedure	could	not	be	excluded.51,52	
Nevertheless,	this	study	shows	that	there	could	be	many	peptides	still	to	be	characterized.	It	was	also	
found	 that	 BAM22	 is	 significantly	 elevated	 in	 the	 plasma	 of	 rats	 in	 a	 model	 of	 induced	 acute	
cholestasis.	This	could	have	a	biological	relevance	since	in	liver	cholestasis	there	are	abnormalities	in	
immune	 function,	 adrenal	 steroidogenesis	 and	 glucose	 homeostasis.	 BAM22,	 as	 a	 potent	 opioid,	
could	well	be	involved	in	these	abnormalities	(including	itch).53	
	
Figure	 5:	A:	 Schematic	 representation	 of	 proenkephalin	 and	 the	 dibasic	 amino	 acids	 flanking	Met-enkephalin	 (M),	 Leu-




















the	 human	 MRGPRX1	 are	 functional	 orthologs.	 In	 addition,	 it	 turned	 out	 that	 MRGPRC	 but	 not	
MRGPRX1	could	be	more	potently	activated	by	γ2-MSH,	a	POMC	cleavage	product	(see	figure	5	and	
table	2).	As	with	BAM22,	 the	active	moiety	of	 γ2-MSH	was	 found	 to	be	 in	 the	C-terminal	part.	 γ2-
MSH6-12	was	the	active	form	at	MRGPRC.42,43		
These	 interspecies	 differences	 should	 always	 be	 taken	 into	 account	 and	 this	 is	 especially	 the	 case	
when	it	comes	to	MRGPR	receptors.	Two	other	findings	demonstrate	this	point.	First,	Solinski	et	al.	





contradictory	data	 about	MRGPRX1,	 in	which	 they	 showed	BAM8-22-induced	endocytosis	 in	U2OS	
cells.55	 This	 contradiction	 could	 be	 due	 to	 the	 U2OS	 cell	 line.	 Second,	 Liu	 et	 al.	 investigated	 the	
relationship	 between	 protease	 activated	 receptor	 2	 (PAR2)	 and	 mMRGPRC11,	 which	 are	 both	
expressed	 in	 the	 same	neurons	 in	 the	DRG.	PAR2	 is	 activated	by	 trypsin,	 tryptase	or	 the	 synthetic	




independent	 itch,	 it	 was	 assumed	 that	 this	 effect	 is	 PAR2-dependent.	 However,	 PAR2-/-	 mice	 did	
scratch	more	significantly	than	wild-type	mice	after	SLIGRL-subcutaneous	administration.	This	proved	
that	 this	 peptide	 targeted	 other	 receptors	 than	 PAR2	 in	 order	 to	 induce	 itch.	 Upon	 further	
investigation,	it	was	found	that	SLIGRL	activated	exclusively	mMRGPRC11	with	an	EC50	of	10.1	µM.	In	
accordance,	 the	 previously	 mentioned	 mrgpr	 KO-mice32	 showed	 a	 reduced	 itch	 response	 to	 the	
peptide.	Most	 interestingly,	 the	human	corresponding	peptide	SLIGKV	was	not	able	 to	activate	 the	
functional	 ortholog	 MRGPRX1	 but	 MRGPRX2,	 revealing	 the	 complexity	 of	 the	 interspecies	
relationships	 between	 MRGPR	 members.56	 Despite	 these	 differences,	 it	 remains	 important	 to	 go	
through	the	known	 information	about	MRGPRC	receptor,	which	could	offer	 insights	 into	MRGPRX1	
and	 other	 human	 MRGPR	 members.	 It	 should	 be	 mentioned	 that	 the	 effect	 of	 BAM8-22	 on	
nociception	 was	 a	 matter	 of	 controversy	 with	 some	 publications	 attributing	 analgesic	 effects	 and	
other	algesic	effects	to	BAM8-22.	
The	effect	of	BAM22	on	c-fos-like	 immunoractivity	(an	 indication	of	nociceptive	 input	from	primary	
afferents)	 was	 investigated	 in	 the	 rat	 dorsal	 horn	 after	 thermal	 noxious	 stimulus.	 BAM22	 could	
inhibit	 the	 immunoreactivity	 in	 both	 opioid-dependent	 and	 opioid-independent	 manner.57	
Intrathecal	 (i.t)	 administration	 of	 BAM22	 potently	 and	 persistently	 increased	 the	 tail	 withdrawal	
latency.	 This	 effect	was	 only	 partially	 inhibited	 by	 naloxone.58	 The	 expression	of	 BAM22	 itself	was	
also	 investigated	 in	 an	 inflammation	 model	 using	 complete	 Freund’s	 adjuvant	 (CFA).	 BAM22	 was	
upregulated	 in	 the	spinal	cord	and	the	DRG	small	 to	medium	size	sensory	neurons.	 Inhibitory	anti-
BAM22	antibodies	reduced	the	mechanical	threshold	in	the	inflammation	model	but	not	in	the	naïve	




the	 analgesic	 effects	 of	 BAM8-22,	 it	 was	 suggested	 that	 BAM8-22	 can	modulate	 NMDA-mediated	




mrgpr	 genes32	 (see	 also	 figure	 2)	 by	 comparing	 its	 response	 to	 formalin	 injection	 (nociceptor	
activation	as	well	as	tissue	 inflammation)	with	the	response	of	wt-mice.	KO-mice	showed	a	greater	
increase	in	c-fos-expressing	neurons,	which	means	a	more	pronounced	inflammatory	pain	response.	
Hence,	at	 least	one	of	 the	12	MRGPRs	seems	 to	be	 involved	 in	 limiting	 the	excitability	of	neurons.	
Upon	 i.t	 administration	of	 BAM8-22	 there	was	 a	 significant	 decrease	 in	 both	 thermal	 hyperalgesia	
and	mechanical	allodynia	 in	 the	wt-mice	whereas	 the	KO-mice	were	unaffected.62	The	same	group	
further	investigated	both	BAM8-22	and	the	selective	MRGPRC	agonist,	compound	2	(see	table	2),	and	
found	out	 that	MRGPRC	agonism	at	 spinal	but	not	peripheral	 sites	 contributed	 to	 the	 inhibition	of	
hyperalgesia	and	neuropathic	pain.63	These	data	suggest	that	agonists	rather	antagonists	are	relevant	
as	drugs	at	MRGPRC	and	its	human	ortholog	MRGPRX1.	
On	 the	 other	 hand,	Grazzini	 et	 al.	 found	 that	 the	 selective	 rMRGPRC	 agonist	 γ2-MSH6-12	 induced	
hyperalgesia	 and	 allodynia	 after	 intradermal	 injection	 and	 hyperalgesia	 after	 central	 application.43	
BAM22	 was	 also	 found	 to	 increase	 noxious	 heat-induced	 calcitonin	 gene-related	 peptide	 (CGRP)	
release	as	an	indication	of	activation	of	a	large	nociceptor	population.64	In	another	study,	γ2-MSH6-
12	 was	 also	 found	 to	 induce	 hyperalgesia	 and	 allodynia	 in	 the	 rat	 upon	 intradermal	 application.	
siRNA	 was	 designed	 to	 knock	 out	 the	 mrgprC	 gene	 both	 in	 vivo	 and	 in	 vitro.	 This	 knockout	 was	





activate	 TRPV1	 in	 PKC-independent	manner,	 via	 diacylglycerol	 (DAG)	 and	 phosphatidylinositol-4,5-
bisphosphate	 (PIP2)	after	phospholipase	C	activation.67	The	 same	group	 investigated	 the	previously	
mentioned	hypothesis	that	the	biochemical	communication	between	mast	cells	and	sensory	neurons	
could	 provide	 insights	 into	 MRGPR	 receptor.44	 In	 their	 interesting	 study	 they	 demonstrated	 that	




CCR2,	which	 has	 been	 linked	 to	 neuropathic	 pain,	 in	 both	HEK	 and	dorsal	 root	 ganglia	 cells.	 Since	
MRGPRX1	 is	also	expressed	 in	 the	 immune	system,	BAM8-22	was	 investigated	at	LAD-2	mast	cells.	




It	 is	 difficult	 to	 reconcile	 all	 the	 previous	 data.	 The	 fact	 that	 MRGPR	 receptor	 induce	 itch	 via	
activation	of	the	neurons	and	simultaneously	inhibit	neuropathic	pain	could	not	be	easily	explained.	
It	is	also	noticeably	that	the	analgesic	and	algesic	effects	of	BAM22	and	BAM8-22	were	observed	in	
the	 same	 animal	 models.43,60,65,66	 These	 contradictions	 could	 be,	 at	 least	 partially,	 explained	 by	
different	 BAM8-22	 effects	 at	 the	 periphery	 vs.	 central	 terminals.	 Alternatively,	 BAM8-22	 could	
modulate	 cellular	 activities	 differently	 at	 cell	 bodies	 as	 compared	 to	 central	 termini.	 Differences	
could	also	occur	as	a	result	of	disparate	distribution	and	compartmentalization	of	MRGPR	receptors,	
different	singaling	machinery	(Gq	vs.	Gi)	and	unique	modulation	of	ion	channels.62	In	a	seminal	study	
on	 15	 healthy	 human	 volunteers,	 BAM8-22	 applied	 via	 cowhage	 spicules	 induced	 significant	 itch,	
which	was	occasionally	accompanied	by	hyperalgesia	but	no	wheal	or	neurogenic	flare	(histaminergic	
symptoms).	Thus,	the	only	 investigation	 in	humans	so	far	 indicates	that	BAM8-22	mediates	 itch	via	
MRGPRX1.69	
The	medicinal	chemistry	of	MRGPRX1	is	the	most	developed	among	the	MRGPRX	subfamily	members	
with	 potent	 agonistic	 and	 antagonistic	 compounds	 described.	 Wroblowski	 et	 al.	 discovered	 by	
calcium	 mobilization	 assay	 in	 a	 high	 throughput	 context	 a	 series	 of	 pyridazinones	 as	 active	
compounds	 at	 the	 MRGPRX1	 receptor.	 Modeling	 study	 of	 the	 receptor	 with	 the	 most	 active	
compound	(see	figure	7)	was	also	conducted	based	on	the	crystal	structure	of	bovine	rhodopsin.	The	






tetracyclic	 benzimidazoles,	 which	 demonstrated	 a	 high	 affinity	 for	 both	 MRGPRX1	 and	MRGPRX2	
receptors	 as	 shown	 in	 figure	 7.71	 It	 was	 also	 shown	 that	 chloroquine	 could	 activate	MRGPRX1	 in	
addition	to	mMRGPRA3	(see	above),	which	means	that	MRGPRX1	could	also	be	considered	as	related	
to	 both	mMRGPRA3	 and	mMRGPRC11.	 Nevertheless	 the	 affinity	 was	 10-fold	 lower	 at	 the	 human	
receptor	with	an	EC50	value	of	297	µM.32	Kunapuli	et	al.	developed	the	first	antagonists	at	MRGPRX1.	
The	 scaffold	was	 2,3-disubstituted	 azabicyclo-octanes.55	 Interestingly,	 this	 class	 of	 compounds	was	
found	 to	antagonize	MRGPRC	 receptors	as	well.63	The	most	active	 compound	 is	 shown	 in	 figure	7.		
Bayrakdarian	et	al.	developed	2,4-diaminopyrimidine	derivatives	as	potent	antagonists	after	finding	
an	 initial	 hit	with	 a	 quinazoline	 core.72	 	 Potent	 and	 selective	 positive	 allosteric	modulators	 (PAMs)	
have	been	recently	developed	for	the	MRGPRX1	receptor	based	on	2-(cyclopropanesulfonamido)-N-
(2-ethoxyphenyl)benzamide.	 These	 PAMs	 were	 human-specific	 with	 no	 activity	 at	 MRGPRC	
receptors.73	Figure	6	shows	the	most	potent	ligands	developed	so	far.	
There	are	still	two	important	unrelated	findings	about	MRGPRX1	receptor	in	the	literature.	The	first	



















terminus	 a	 remarkable	 similarity	 to	 somatostatin.	 Further	 investigations	 found	 that	 this	 protein	 is	
expressed	 mainly	 in	 the	 cerebral	 cortex	 and	 hippocampus	 and	 more	 precisely	 in	 the	 GABAergic	
interneurons.	 The	 novel	 neuropeptide	 reduced	 dramatically	 the	 electrical	 activity	 of	 the	 cerebral	
cortex.	Taking	 this	 inhibitory	property	and	 the	marked	expression	 in	 the	cortex	 into	 consideration,	
the	protein	was	named	preprocortistatin	and	the	mature	neuropeptides	were	named	cortistatin-14	
(CST-14)	and	cortistatin-29	(CST-29).76	Tostivint	et	al.	have	published	in	the	same	year	the	CST	of	the	
frog	but	 they	 figured	out	 that	 it	 is	a	 second	variant	of	 somatostatin	 in	 the	 tetrapods	and	named	 it	






IC50	 values	 in	 the	 cAMP	 assays	 as	 well	 as	 Ki	 values	 in	 the	 binding	 assays	 of	 CST	 at	 SST	 receptors	
showed	affinities	in	the	low	nanomolar	to	the	sub-nanomolar	range.	This	affinity	was	comparable	to	
that	 of	 SST	 itself.76-78	 This	 high	 affinity	 led	 to	 the	 assumption	 that	 CST	 and	 SST	 activate	 solely	 the	
same	receptors.	Nevertheless,	 some	observed	effect	of	CST	could	not	be	 induced	by	SST.	Mendez-
Diaz	 et	 al.	 found	 for	 example	 that	 CST	 could	 induce	 analgesia	 in	 rat	 but	 not	 SST.	
Intracerebroventricular	 administration	 of	 CST	 reduced	 pain	 perception	 using	 the	 Hot	 Plate	 test.79	
Such	findings	could	be	explained	by	the	binding	of	CST	to	its	own	receptor.	Several	years	later,	two	
targets	 have	 been	 identified	 to	 bind	 CST-14,	 namely	 the	MRGPRX2	 receptor	 and	 ghrelin	 receptor	
(also	known	as	GHS-R	or	growth	hormone	secretagogue	receptor).	CST-14	binds	to	these	receptors	
with	 less	potency	 than	to	SST	 receptors.	The	 IC50	and	KD	values	described	were	 two-digit	 figures	 in	
the	 nanomolar	 range.80,81	 The	 previous	 findings	 could	 explain	 that	 1)	 CST	 and	 SST	 are	 encoded	 by	
different	genes,	2)	CNS	neural	populations	expressing	 these	neuropeptides	do	not	 fully	overlap,	3)	









immune	 system	 and	 gastrointestinal	 tract	 as	 well	 as	 its	 ability	 to	 bind	 to	 more	 than	 one	 7TMR,	
promoted	the	search	for	a	unique	physiological	role	of	this	neuropeptide.	CST	was	proposed	to	take	
the	 role	of	a	 connecting	 link	between	different	 tissues	 (brain-gut	 communication	 for	 instance)	and	
was	 investigated	more	 rigorously	 in	 the	 immunology	 and	 endocrinology	 (both	 physiologically	 and	











CST-29	 could	 significantly	 reverse	 the	manifestations	of	 CD.	 Interestingly,	 CST-29	 reversed	 the	 lost	




endotoxemia.	 CST-29	 could	 attenuate	 the	 production	 of	 the	 inflammatory	 mediators	 of	 activated	
macrophages.91	 In	 a	 recent	 interesting	 study	 CST	 KO-mice	 were	 generated.	 The	 lack	 of	 CST	
significantly	exacerbated	pain	in	acetic	acid	induced	visceral	pain,	CFA-induced	chronic	inflammatory	






indicate	 an	 interesting	 potential	 of	 CST	 in	 the	 therapy	 of	 several	 diseases.	 Nevertheless,	 it	 should	









neurons	 of	 the	 DRG	 and	 play	 a	 role	 in	 nociception.17,18	 Like	 other	 human	 MRGPRX	 receptors,	
MRGPRX2	does	not	have	a	direct	ortholog	in	rodents	but	orthologs	have	been	found	in	macaque	and	
rhesus	monkeys.22,23	This	member	 is	 less	characterized	than	MRGPRX1	regarding	both	physiological	
functions	 and	 medicinal	 chemistry.	 Nontheless,	 it	 is	 far	 better	 understood	 than	 MRGPRX3	 and	
MRGPRX4.	 Although	 all	 MRGPRX	members	 are	 still	 officially	 orphans,	 the	 first	 putative	 ligand	 for	
MRGPRX2,	CST-14,	was	put	forward	by	Robas	et	al.	in	2003.	CST-14	showed	an	EC50	value	of	25	nM	in	
calcium	assay	in	HEK	cells,	whereas	SST-14	showed	an	EC50	of	780	nM.	In	addition,	it	was	found	that	
the	 receptor	 has	 a	 sole	 Gq	 coupling.19,81	 Kamohara	 et	 al.	 demonstrated	 that	 MRGPRX2	 can	 be	
activated	 by	 another	 physiological	 ligand,	 namely,	 proadrenomedullin	 N-terminal	 peptide.	 The	
powerful	hypotensive	proadrenomedullin	N-terminal	20	peptide	 (PAMP-20)	and	 its	 truncated	 form	
PAMP-9-20/PAMP-12	activated	MRGPRX2	in	calcium	assays	with	an	EC50	value	like	that	of	CST-14.	It	
has	also	been	shown	that	MRGPRX2	is	also	expressed	in	the	adrenal	chromaffin	cells	besides	DRG.	In	
that	 paper	 it	 was	 reported	 that	 MRGPRX2	 expressed	 in	 CHO	 cells	 is	 both	 Gq	 and	 Gi	 coupled.93	




µM	CST-14	 or	 100	 µM	morphine.94	 	 In	 a	 screening	 campaign	 it	was	 possible	 to	 identify	 TAN-67,	 a	
potent	δ	opioid	agonist,	as	an	agonist	at	MRGPRX2	receptor	with	an	EC50	value	of	ca.	1	µM	in	both	ß-
arrestin	 and	 calcium	 mobilization	 assays.95	 A	 recent	 paper	 described	 the	 natural	 product	
complanadine	A	as	a	selective	MRGPRX2	agonist	after	screening	it	at	165	7TMRs	(see	figure	7).	The	
EC50	 value	 was	 5.5	 µM	 in	 calcium	 assays.96	 The	 only	 novel	 synthetic	 agonists	 for	 MRGPRX2	 were	
proposed	 by	 Malik	 et	 al.	 (also	 for	 MRGPRX1	 as	 mentioned	 above).	 These	 agonists	 were	 not	
peptidergic	 but	 have	 a	 tetracylic	 benzimidazole	 scaffold	 as	 illustrated	 in	 figure	 7.71	 These	 data	





al.	 have	 found	 that	 monocytes,	 macrophages	 and	 dendritic	 cells	 produce	 CST	 and	 express	 SST2	
receptors	 but	 not	 mrgprX2,	 whereas	 thymus	 expresses	 SST1,	 2,	 3	 and	 mrgprX2	 receptors	 on	 the	
mRNA	 level.88	 In	 fact	 immunology	 turned	 out	 to	 be	 the	 field	 with	 the	 most	 extensive	 research	
concerning	MRGPRX2	functions	and	ligands.	The	only	cells	in	the	immune	system,	which	undoubtedly	
express	MRGPRX2	receptors	on	the	protein	level,	are	mast	cells.	
Mast	 cells	 express	 beta2	 adrenergic	 receptors,	 adenosine	 receptors,	 several	 chemokine	 receptors,	
GPR34,	 Histamine	 H4,	 several	 nucleotide	 receptors	 as	 well	 as	 MRGPRX1	 and	 MRGPRX2.	 The	
activation	 of	 some	 of	 these	 receptors	 leads	 to	 degranulation	 of	 the	 mast	 cells,	 which	 means	 a	
potential	 to	 treat	 diseases	 like	 asthma	 and	 urticaria.	 MRGPRX2	 is	 one	 of	 these	 potential	 target	
receptors.97	 Mast	 cells	 can	 release	 its	 inflammatory	 mediators	 via	 IgE-dependent	 and	 IgE-
independent	 pathway.	 The	 IgE-independent	 pathway	 involves	 the	 activation	 via	 basic	
secretagougues	 (substance	 P,	 mast	 cell-degranulating	 peptide,	 neuropeptide	 Y,	 compound	 48/80	
etc.).	Since	no	receptor	for	basic	secretagougues	was	found,	 it	was	suggested	that	these	mediators	




It	 is	 also	 noteworthy	 to	mention	 that	 the	 LAD2	mast	 cell	 line	 is	 a	 suitable	 cell	 line	 to	 investigate	
natively	expressed	MRGPRX1	and	MRGPRX2.	Up	to	date	there	is	no	known	cell	 line	able	to	natively	
express	MRGPRX3	or	MRGPRX4	receptors.19	
Subramanian	 et	 al.	 have	 demonstrated	 that	 the	 C5a	 receptor	 antagonist	 PMX-53,	 a	 cyclic	
hexapeptide	based	on	the	terminal	amino	acid	sequence	of	C5a,	behaves	as	an	agonist	at	MRGPRX2	
receptor.	 PMX-53	 (see	 table	 5)	 could	 induce	 mast	 cell	 degranulation	 and	 a	 calcium	 signals	 via	
MRGPRX2	 receptor	 and	 this	 effect	 could	 not	 be	 detected	 in	 a	murine	 cell	 line	 due	 to	 the	 lack	 of	
MRGPRX2	receptors.	The	EC50	value	of	PMX-53	was	not	determined	in	this	paper.99	The	same	group	




degranulation,	 thus	behaving	as	 a	dual	 agonist	 at	MRGPRX2	and	C3a	 receptors	 as	well.100	Another	
component	 of	 the	 immune	 system,	 which	 was	 reported	 to	 act	 via	 MRGPRX2	 receptors,	 is	 the	
antimicrobial	 peptide	 LL-37	 (see	 table	 5).	 LL-37	 was	 previously	 reported	 to	 induce	 chemokine	
production	and	mast	cell	degranulation	via	unknown	mechanisms.	In	this	study,	it	was	also	suggested	
that	MRGPRX2	 is	 one	of	 the	 few	7TMRs	 that	 are	 resistant	 to	phosphorylation,	 desensitization	 and	
internalization.101	 It	 is	 noteworthy	 to	mention	 that	 the	 resistance	of	MRGPRX2	 to	 phosphorylation	
means	 that	 no	 ß-arrestin	 recruitment	 can	 take	 place.	 This	 is	 apparently	 not	 true	 since	we,	 in	 our	
group,	 are	 able	 to	 conduct	 ß-arrestin	 assay	 using	 the	 MRGPRX2	 cell	 line	 with	 very	 clear	 positive	
results.	 In	 this	 publication,	 a	 cell-based	 radioactive	 phosphorylation	 assay	 was	 employed	 to	
investigate	 the	 phosphorylation.	 The	 text	 in	 this	 paper	 described	 a	 resistance	 to	 phosphorylation.	
Intriguingly,	 in	 the	 same	paper	a	 figure	 showed	a	CST-induced	phosphorylation.	Although	 the	CST-
induced	phosphorylation	was	less	pronounced	than	C3a-induced	phosphorylation,	it	does	not	mean	
that	 MRGPRX2	 is	 phosphorylation	 resistant	 since	 the	 degree	 of	 phosphorylation	 is	 7TMR-




















common	at	 first	 glance.	 In	 order	 to	 elucidate	 this	 agonism,	Nothacker	 et	 al.	 have	 investigated	 the	
similarity	 between	 the	most	 potent	 agonists	 CST-14	 and	 PAMP-12.	 An	 active	 core	 consisting	 of	 2	
aromatic	 amino	 acids	 and	 a	 basic	 amino	 acid	 at	 the	 C-terminus	 arranged	 in	 a	 specifically	 spaced	
manner	seems	to	be	important	to	activate	MRGPRX2	(amino	acids	in	bold	in	table	5).105	It	is	also	clear	
from	 the	 later	 reported	 agonists	 that	 aromatic	 as	 well	 as	 positively	 charged	 amino	 acids	 are	
important	(see	table	5).	
Efforts	to	identify	a	peer	for	MRGPRX2	in	rodents	have	also	been	made.	Tatemoto	et	al.	investigated	
rat	 MRGPR	 receptors	 in	 mast	 cells	 and	 could	 detect	 the	 mRNA	 of	 mrgprB1,	 mrgprB2,	 mrgprB3,	
mrgprB6,	mrgprB8	and	mrgprB9.	Nevertheless,	only	MRGPRB3	was	reported	to	be	activated	by	basic	
secretagogue	in	a	reporter	gene	assay	and	calcium	assay.98	McNeil	et	al.	suggested	that	MRGPRB2	is	
the	 murine	 ortholog	 of	 MRGPRX2	 using	 pharmacological	 and	 expression	 data.	 MRGPRB2	 was	
activated	by	CST-14,	PAMP-9-20	as	well	 as	 compound	48/80	 (and	other	basic	 secretagougues)	and	
expressed	 exclusively	 in	 connective	 tissue	 mast	 cells	 (but	 not	 mucosal	 mast	 cells).	 Importantly,	
MRGPRB2	was	involved	only	in	IgE-independent	histamine	release.	This	led	to	investigation	of	drugs	
which	 show	allergic	adverse	 reactions	with	 low	 IgE-titre	and	have	structure	 relatedness	 to	cyclized	
compound	48/80	(more	potent	mast	cell	activator	than	compound	80/48).	At	first,	peptidergic	drugs	
like	 icatibant,	 cetrorelix	 and	 mastoparan	 were	 considered.	 Secondly,	 the	 motif	
tetrahydroisoquinoline	 (THIQ)	was	 searched	 for	 in	approved	drugs.	This	 led	 to	 the	 identification	of	
non-steroidal	neuromuscular	blocking	drugs	(nicotine	receptor	antagonists).	By	expanding	the	search	
to	dihydroquinolines,	 the	 fluoroquinoline	antibiotics	were	 identified.	 Interestingly,	 the	 investigated	





























It	 is	 obvious	 that	 the	 signaling	 as	well	 as	 physiological	 and	 pathological	 roles	 of	 this	 receptor	 still	
need	to	be	further	investigated.	Hence,	more	drug-like	pharmacological	tools	would	be	of	high	value.	
In	 the	 case	 of	MRGPRX2,	 unlike	MRGPRX1,	 antagonists	 seem	 to	 have	more	 therapeutic	 potential	










MRGPRX3,	 (accession	number:	NM_054031.3),	 is	 the	third	member	of	MRGPRX	subfamily.	There	 is	




swelling	 of	 the	 lens	 fiber	 cells.	 Focal	 skin	 desquamation	 was	 also	 observed	 in	 these	 rats.	 In	 both	
epidermis	 and	 lens,	 an	 increase	 in	 cell	 proliferation	was	 detected.107	 Another	 study	 detected	 SVA	
(SINE-VNTR-Alu)	elements	in	the	5’	untranslated	region	of	mrgprX3	gene.	SVA	elements	are	capable	
of	generating	individual	variation	in	gene	expression	at	loci	in	which	they	are	present	and	they	cause	
various	human	diseases	 like	 insertional	mutagens.108	 SVA	belong	 to	 the	 retroelements,	which	have	
been	 suggested	 to	 have	 caused	 the	 expansion	 of	 the	 mrgpr	 subfamilies	 in	 mice24	 (see	 above).	 A	
recent	 paper	 has	 shown	 the	 expression	 of	 mrgprX3	 on	 mRNA	 and	 protein	 level	 in	 the	 corneal	
endothelial	cells.	This	protein	was	suggested	as	a	molecular	marker	for	this	cell	type	since	it	was	not	
found	in	other	cell	types	in	the	eye.109	These	findings	suggest	a	physiological	role	of	MRGPRX3	in	the	
eye,	 in	 addition	 to	 nociception.	 A	 study	 in	 epigenetic	 changes	 (methylation)	 in	 newborns	 has	
revealed	that	mrgprX3	gene	undergoes	 increase	 in	methylation	with	age	and	with	periconceptional	
environment	 (micronutrient	 supplementation).	 Interestingly,	 these	 epigenetic	 changes	 were	
detected	only	 in	male	newborns,	 suggesting	a	potential	 sexual	dimorphism	 (genetic	differentiation	
between	men	and	women)	of	mrgprX3	gene	regulation.110	A	recent	genome-wide	association	study	









is	 no	 reported	 endogenous	 ligand	 till	 now	 but	 recently	 Kroeze	 et	 al.	 reported	 nateglinide,	 a	 KATP-
channel	 blocker	 (see	 figure	 8),	 as	 an	 agonist	with	 an	 EC50	 value	of	 9.1	µM	 in	 a	 ß-arrestin	 assay.112	
Burstein	et	 al.	 predicted	a	 sole	Gq	 coupling	of	 the	 receptor.23	Gylfe	et	 al.	 have	detected	MRGPRX4	
receptor	 in	 colorectal	 cancer	 tissue	 samples	 and	 identified	 this	 gene	 as	 a	 potential	 oncogene.113	
Recently	 two	 new	 proteomics	 data	 banks,	 humanproteomemap.org	 and	 proteomicsdb.org,	 were	
introduced.	 Both	 are	 based	 on	mass	 spectrometrical	 techniques.114,115	 According	 to	 the	 new	 data,	
MRGPRX4	 is	 expressed	 in	 CD8+	 T-lymphocytes.	 This	 could	 simplify	 the	 investigation	 of	 MRGPRX4	
since	T-lymphocytes	are	easier	to	culture	than	sensory	neurons.	In	addition,	this	could	reveal	a	new	
way	 of	 communication	 between	 neurons	 and	 the	 immune	 system	 via	 MRGPRX4	 receptors.	 Data	
107,113	indicate	that	MRGPRX3	and	MRGPRX4	could	play	a	role	as	oncogenes.	
	





step	was	 to	 search	 for	 pharmacological	 tools,	 taking	 advantage	 of	 the	 diverse	 compound	 libraries	
available	in	the	pharmaceutical	chemistry	department.	Further	optimization	of	the	found	ligands	was	







beginning	of	 this	 thesis.	Hence,	 the	aim	was	 to	 find	agonistic	 tool	 compounds	and	 then	 search	 for	
antagonistic	ones.	The	initial	tools	were	intended	to	be	further	optimized	to	ideally	reach	the	highest	
feasible	affinity	and	selectivity.	
Having	 found	 tools,	 the	 goal	 was	 to	 employ	 them	 for	 a	 pharmacological	 characterization	 using	
several	 assays	 like	 ß-arrestin,	 cAMP,	 calcium	 mobilization	 assay	 in	 order	 to	 further	 elucidate	 the	
signal	transduction	of	these	poorly	understood	receptors.		
It	should	be	noted	that	MRGPRX4	was	of	central	interest	from	the	very	beginning.	Therefore,	thesis	
aimed	 at	 deepening	 the	 characterization	 of	 this	 particular	 receptor	 regarding	 its	 physiological	 and	
pathological	 role,	 searching	 for	 cell	 lines	 with	 native	 expression,	 in	 addition	 to	 the	 synthesis	 of	 a	
radioligand	as	a	valuable	pharmacological	tool.	
In	essence,	we	aspired	to	pave	a	new	way	to	investigate	the	MRGPRX	receptors.	This	could	open	new	









The	 medicinal	 chemistry	 of	 the	MRGPRX1	 receptor,	 with	 several	 moderately	 potent	 agonists	 and	
antagonists,	 is	 the	 most	 advanced	 one	 among	 the	 four	 members	 of	 the	 MRGPRX	 receptor	





In	 order	 to	 identify	 potential	 antagonists,	 the	 compound	 libraries	 1-8	were	 screened	 (see	 chapter	




































possible	 to	 conduct	 ß-arrestin	 assays	 using	 chloroquine	 as	 an	 agonist	 because	 no	 signal	 could	 be	
detected	upon	screening	at	100	µM	(data	not	shown).	The	described	EC50	value	of	297	µM	in	calcium	





compound	 libraries	 would	 always	 be	 reviewed	 and	 expanded,	 the	 reported	 results	 concerning	
MRGPRX1	applies	to	the	status	of	compound	libraries	in	April	2014.	
The	 screening	of	 compound	 libraries	 3-7	 (see	 chapter	 4.10)	 resulted	 in	no	hit	 (data	not	 shown).	 It	
should	here	be	mentioned	that	the	glycoside	digitonin	from	the	compound	library	7	blocked	80%	of	













The	 most	 potent	 hits	 were	 identified	 in	 the	 compound	 library	 1.	 The	 three	 hits	 were	 MIRA-1,	
cantharidin	and	ZM39923,	and	their	structures	are	shown	 in	table	6.	Taking	the	chemical	structure	
and	biological	activity	 into	account,	 it	seemed	that	there	could	be	 instability	 (cyclic	acid	anhydride)	
and	 non-specific	 activity	 (kinase	 inhibition)	 issues.	 Therefore,	 it	was	 decided	 to	 further	 investigate	
the	 compounds.	 The	 effect	 of	 cantharidin	 on	 cells	 was	 first	 investigated	 because	 it	 is	 a	 toxin.119	
Cantharidin	turned	out	to	be	too	toxic	since	the	cells	died	within	30	minutes	of	the	addition	of	the	






Restores	 wild-type	 function	 of	
mutant	 p53	 and	 promotes	





Toxin	 inhibitor	 of	 protein	
phosphatases	 1	 and	 2A	with	 Ki	













It	 is	 noteworthy	 that	 ZM39923	 would	 break	 down	 in	 neutral	 buffer	 (t1/2=36	 min,	 pH=7.4)	 to	
ZM449829120	 (see	 table	 5).	 Owing	 to	 the	 long	 incubation	 time	 in	 ß-arrestin	 assay,	 the	 detected	
inhibition	is	probably	due	mainly	to	ZM449829.	Since	this	compound	could	interact	with	amino	acids	





So	 far,	 this	 seems	to	be	 the	most	promising	antagonist	 to	be	 found	at	MRGPRX1,	especially	 that	 it	
seems	to	be	relatively	selective	since	it	was	not	reported	as	a	hit	at	other	receptors.	Nonetheless,	it	is	
inferior	 to	 the	best	antagonists	mentioned	 in	 the	 literature.	MIRA-1	should	be	 further	 investigated	
since	 this	 compound	 is	 an	ester,	which	means	 it	will	 probably	be	degraded	upon	 contact	with	 the	
cells.	Since	this	compound	could	induce	apoptosis,	it	is	important	to	exclude	this	effect	(cell	death	or	
decrease	 in	 cell	 number)	 as	 a	 cause	of	 signal	 inhibition.	 This	 result	 should	be	 viewed	with	 caution	
because	the	inhibition	was	only	noticeable	at	a	high	concentration	of	10	µM	as	seen	in	figure	11.	



















It	 should	 be	 added	 that	 the	 compound	 library	 9	 was	 screened	 at	 10	 µM	 both	 as	 agonists	 and	
antagonists	but	no	hit	could	be	found	(data	not	shown).	
Since	MRGPRX1	and	MRGPRX2	could	both	be	activated	by	tetracyclic	benzimidazole	derivatives71,	it	
is	 also	 plausible	 that	 both	 could	 also	 be	 inhibited	 by	 benzimidazole	 derivatives.	 Hence,	 the	
synthesized	 compounds	 for	 the	 MRGPRX2	 project	 (till	 CB39)	 (see	 MRGPRX2,	 chapter	 2.2,	 for	 all	
compounds)	were	screened	at	MRGPRX1	 receptor	both	as	agonists	and	antagonists.	The	screening	
for	 antagonists	 led	 to	 very	weak	 inhibition	or	no	 inhibition	at	 all.	 The	best	 inhibitors	 are	 shown	 in	























The	 results	 of	 screening	 for	 agonists	 are	 shown	 in	 table	 8.	 Only	 two	 hits	 have	 been	 found.	 CB16	
turned	out	to	be	a	partial	agonist.	The	normalized	curves	of	BAM22	and	CB16	are	given	in	figure	13.	
It	 could	be	 interesting	 to	 test	derivatives	of	CB16	with	a	 substituted	benzyl	 group	or	a	 longer	 side	














































chosen	 for	 further	 investigations.	 In	 addition,	 a	 systematic	 search	 for	 antagonists	 using	 the	 then	
available	compound	 libraries	has	been	done.	The	results	 indicate	a	difficulty	 in	 identifying	a	potent	
antagonist	 at	 MRGPRX1	 receptor.	 This	 is	 a	 general	 problem	 with	 the	 MRGPRX	 receptor	
subfamily.121,122	 Nevertheless,	 it	 was	 possible	 to	 single	 out	 one	 candidate	 (MIRA-1)	 as	 a	 potential	
antagonist.	MIRA-1	 should	 be	 further	 investigated	 to	 verify	 its	 activity.	 Calcium	mobilization	 assay	
could	 in	 principle	 be	 performed	 since	 this	 receptor	 is	 Gq	 coupled.23	 Due	 to	 the	 fact	 that	 calcium	
mobilization	assays	are	real-time	assays	and	the	incubation	time	is	considerably	shorter,	it	could	be	
advantageous	 to	 investigate	MIRA-1	 using	 this	 kind	 of	 assay	 to	 avoid	 any	 toxicity	 due	 to	 the	 long	





was	 pretty	 low.	 This	 raised	 the	 question	 about	 the	 suitability	 of	 the	 CHO	 expression	 system	 for	
carrying	 out	 an	 effective	 calcium	 assay.	 This	 point	 still	 needs	 to	 be	 addressed	 and	 since	MRGPRX	






In	 addition,	 two	weakly	 potent	 xanthine	derivatives	 have	been	 found.	 This	 could	 be	 interesting	 to	
follow	since	many	such	derivatives	are	available	in	our	department	and	the	compound	library	2	is	in	
constant	 expansion.	 The	 MRGPRX2	 ligands	 provided	 another	 source	 of	 screening	 for	 MRGPRX1	
receptor.	 Having	 screened	 many	 derivatives,	 it	 was	 not	 possible	 to	 identify	 any	 interesting	
antagonist.	 Nonetheless,	 it	 was	 possible	 to	 find	 a	 weak	 partial	 agonist	 (CB16).	 Since	 MRGPRX2	






























MRGPRX2	 receptor	 is	 the	 only	 member	 of	 MRGPRX	 subfamily	 that	 is	 reported	 to	 be	 expressed	
outside	 the	DRG.	 It	 is	expressed	 in	 the	mast	cells,	a	component	of	 the	 immune	system,	and	 in	 the	
adrenal	 chromaffin	 cells.93,98	 The	 described	 agonist	 at	 this	 receptor,	 cortistatin-14,	 could	 activate	
three	7TMRs	(somatostatin,	ghrelin	and	MRGPRX2)	as	mentioned	in	the	introduction.	Hence,	it	could	
be	interesting	to	develop	selective	and	potent	agonists	at	MRGPRX2	without	activating	the	other	two	
7TMRs.	 The	MAS-related	 gene	 receptors	 share	 characteristics	 like	 a	 big	 expansion	 in	 the	 rodents	
(especially	in	the	mouse)	and	the	ability	to	be	activated	by	very	heterogeneous	ligands	ranging	from	
the	small	adenine	to	large	peptides	like	BAM22.	In	addition,	it	is	difficult	to	define	orthologs	between	
species	 based	 on	 the	 sequence	 of	 these	 genes.17,23	 However,	 a	 recent	 study	 suggested	 that	 the	





































1-7	and	 the	 compound	 library	10	have	been	 screened.	 The	 screening	was	done	at	10	µM	using	ß-




14)	 from	 the	 compound	 library	 7	 seemed	 to	demonstrate	 reproducible	 results.	 The	 IC50	 value	was	
determined	to	be	5.39	±	1.51	µM	as	shown	in	figure	15.		
	























Menadione	 (2-methyl-1,4-naphthoquinone)	 is	 a	 yellow	 powder	 but	 its	 stock	 solution	 in	 DMSO	 is	
colorless.	Due	to	these	results	it	would	be	interesting	to	test	other	1,4	naphthoquinone	derivatives	in	
order	 to	 investigate	 both	 toxicity	 and	 potency	 of	 these	 derivatives.124	 Menadione,	 also	 known	 as	







(ROS).	Oxidative	 stress	 in	high	 levels	produces	oxidative	damage	 in	 cell	 structures	 (lipids,	 proteins,	
RNA	and	DNA)	leading	to	apoptosis	or	necrosis	of	the	cells.	Because	of	this	property	menadione	has	
been	widely	used	with	cancer	chemotherapeutic	agents,	since	 it	 is	effective	 in	killing	tumor	cells.	 It	
has	also	been	demonstrated	that	it	kills	preferentially	fast	growing	cells.	Since	tumor	cells	have	this	
characteristic,	 its	toxicity	towards	normal	cells	is	much	lower.	Nowadays	menadione	is	only	used	as	
anticancer	 agent.	 Its	 applications	 on	 coagulation	 problems	 and	 vitamin	 deficiency	 are	 not	 advised	









(data	 not	 shown).	 The	 hits	 are	 from	 different	 scaffolds.	 SL381	 is	 a	 xanthine	 derivative;	 H351	 is	 a	
pyrimidine	 derivative,	whereas	 CB8	 is	 tricyclic	 benzimidazole	 derivative	 (see	 figure	 16).	 SL381	 and	
H351	 showed	 a	 complete	 inhibition	 at	 their	 highest	 concentration,	 but	 CB8	 showed	 only	 75%	






























































































It	was	decided	 to	 take	CB8	as	a	 lead	compound	 to	develop	more	potent	derivatives.	The	chemical	
synthesis	was	done	in	collaboration	with	Professor	Herdewijn	and	his	coworkers.	In	order	to	establish	
























































































































with	an	 IC50	of	0.583	 ±	0.049	µM	but	 the	maximal	 inhibition	was	 reduced	 to	63%.	CB23	 showed	a	
limited	 maximal	 inhibition	 despite	 the	 good	 potency	 as	 shown	 in	 figure	 17.	 These	 initial	 results	
indicate	 that	 the	 left	 side	of	 the	molecule	 should	not	have	bulky	substituents,	while	methyl,	ethyl,	
propyl	or	isopropyl	seem	to	be	appropriate.	
	














































































































































































These	 results	 confirm	 the	 suggested	 initial	 SAR.	 CB33	 showed	 approximately	 9-fold	 increase	 in	
potency.	 CB34	 demonstrated	 11-fold	 increase	 in	 potency	 compared	 with	 CB8.	 Both	 compounds	
showed	 an	 almost	 total	 inhibition	 at	 10	 µM.	 The	 second	 shipment	 contained	 also	 two	 important	
compounds,	CB36	and	CB37,	which	showed	a	considerable	increase	in	potency.	
At	this	point	of	time	there	was	an	optimization	of	ß-arrestin	assay	protocol	was	introduced.	Hence,	in	
order	 to	have	a	better	 comparison	and	 to	make	a	better	 choice,	compounds	CB33	and	CB34	were	
tested	again	according	to	the	new	protocol.	The	results	showed	a	slight	difference	as	given	in	figure	





































































































the	 results	 are	 shown	 in	 table	 11.	 From	 the	 results	 it	 is	 clear	 that	 only	 CB44	 is	 of	 interest	 in	 this	
series.	More	 importantly,	CB44	 is	a	mixture	of	 two	region-isomers	with	a	ratio	of	1:1.	CB40	has	no	



























Although	 CB44	 is	 not	 a	 derivative	 of	 CB33,	 CB44	 could	 give	 an	 indication	 of	 the	 benefits	 of	
substitution	of	aryl	 ring	 since	CB44	contains	a	methylated	aryl	 residue	 in	comparison	 to	CB14.	The	
results	show	a	3-fold	increase	in	potency	of	CB44	compared	with	CB14,	which	is	a	good	indication	of	
the	possibility	of	developing	potent	antagonists	via	an	appropriate	substitution	of	the	aryl	residue.	
Two	 further	 sets	 of	 compounds	 were	 tested	 as	 shown	 in	 table	 12	 but	 these	 derivatives	 do	 not	































































by	S	 is	beneficial	 since	CB60	showed	ca.	22-fold	 increased	potency	compared	 to	CB14	as	well	 as	a	
complete	inhibition	of	the	MRGPRX2	receptor.		
The	 sixth	 and	 seventh	 set	 of	 compounds	 contained	 potent	 antagonists	 as	 shown	 in	 table	 13,	 in	
particular	 CB63	 and	 CB64,	which	 are	methylated	 derivatives	 of	 CB36	 and	 CB33,	 respectively.	 Both	
compounds	were	mixtures	of	 regio-isomers	and	not	a	single	compound.	CB63	with	an	 IC50	value	of	
6.38	 nM	 could	 be	 the	 basis	 for	 preparing	 a	 radioligand.	 Unfortunately,	 this	 high	 potency	 was	
accompanied	by	very	bad	solubility	of	the	compounds.	In	order	to	avoid	the	issue	of	regio-isomers,	
methylation	 of	 both	 positions	was	 conducted	 as	 demonstrated	 in	 CB66	 and	 CB67.	 The	 insolubility	
problem	 was,	 unfortunately,	 evident	 with	 CB66	 and	 even	 more	 with	 CB67.	 The	 low	 inhibitory	
potency	of	CB67	compared	to	closely	related	compounds	may	be	partially	due	to	 its	bad	solubility.	
The	compounds	with	an	 isopropyl-substitution	had	a	better	 solubility	 than	 their	propyl-substituted	








































methyl	 group.	 CB70	 and	 CB71	 with	 fluorine	 substitution	 showed	 the	 highest	 potency.	 Fluoro	


































These	were	 all	 the	 compounds,	which	 have	 been	 tested	 so	 far	within	 this	 thesis	 as	 antagonists	 at	
MRGPRX2	receptor.	The	curves	of	the	best	three	synthesized	antagonists	are	presented	in	figure	21.	























































































The	 ADME	 (absorption,	 distribution,	 metabolism	 and	 excretion)	 profile	 is	 important	 for	 in	 vivo	
studies.	Therefore,	some	of	the	best	antagonists	were	investigated	 in	vitro	by	Pharmacelsus	GmbH,	
Saarbrücken;	 a	 contract	 research	 organization	 specialized	 in	 such	 studies.	 Three	 compounds	were	




BBB	 CB63	 CB64	 CB66	
Structure	
	 	 	









PPB	 CB63	 CB64	 CB66	
mouse	 99.86%	 99.41%	 99.66%	
rat	 99.86%	 99.81%	 99.51%	
human	 99.72%	 99.86%	 99.65%	
PPB	(plasma	protein	binding):	The	test	was	done	at	1	µM	
	




CYP	Inhibition	(µM)	 CB63	 CB64	 CB66	
CYP1A2	 2.7	 <1	 5.2	
CYP2B6	 >>5	 >>5	 >>10	
CYP2C9	 >5	 >5	 >10	
CYP2C19	 >5	 >5	 >10	
CYP2D6	 >>5	 >>5	 >>10	







enzymes	 is	 an	 important	 source	 of	 drug-drug	 interactions.	 CB63	 shows	 a	 moderate	 inhibition	 of	


















mouse	 6.5	 213.3	 5.3	 261.6	 7.4	 187.3	
rat	 11.9	 116.5	 9.2	 150.7	 10.7	 129.6	




limitation	 in	 drug	 development.	 The	 next	 step	 will,	 therefore,	 be	 to	 develop	 metabolically	 more	




The	 observation	 that	 the	 MRGPRX2	 agonist,	 CST-14,	 is	 a	 peptide	 consisting	 of	 14	 amino	 acids	
containing	 two	disulfide	bridges,	while	 the	antagonists	are	pretty	 small	molecules,	prompted	us	 to	
investigate	 the	 mode	 of	 action	 of	 the	 synthesized	 antagonists.	 The	 aim	 was	 to	 know	 if	 the	
antagonism	 is	 allosteric	 or	 orthosteric.	 To	 address	 this	 question,	 curves	 of	 CST-14	 with	 varying	
concentrations	 of	 the	 antagonist	 were	 plotted	 and	 compared	 with	 the	 CST-14	 curve	 without	 any	













































CST-14 + 10 nM CD63
CST-14 + 1 nM CD63
CST-14 + 100 nM CD63


















reserve.	 In	 such	 systems	 the	 depression	 of	 the	maximal	 response	 for	 insurmountable	 antagonists	
(irreversible	 or	 allosteric)	 occurs	 only	 at	 higher	 concentrations	 of	 the	 antagonists	 after	 an	 initial	
“pure”	 rightward	 shift	 for	 the	 lower	 concentrations.132	 Another	 possibility	 for	 not	 reaching	 the	
maximal	 response	 is	 that	despite	 the	competitive	nature	of	antagonism,	a	maximal	 response	could	
not	 be	 reached	due	 to	 the	 inability	 to	 increase	CST-14	 concentration	 (more	 than	 100	µM)	 so	 that	
CST-14	 could	 displace	 CD63.	 In	 order	 to	 interpret	 these	 data	 a	 Gaddum/Schild	 EC50	 shift	 was	




other	 than	one	 for	 cooperative	 antagonism.133	 The	determined	 Schild	 slope	 for	 the	 curve	 in	 figure	
21a	was	1.08,	which	is	a	clear	indication	of	the	orthosteric	nature	of	the	antagonism.	Another	usual	
characteristic	(but	not	always)	of	allosteric	modulation	can	be	the	shallow	SAR,134,135	which	was	not	
the	 case	 for	 the	 tricyclic	 benzimidazole	 derivatives	 as	 shown	 above.	 Our	 findings	 indicate	 an	
orthosteric	mode	of	action	for	these	antagonists,	with	respect	to	the	peptide	agonist	CST-14,	which	




Antagonists	were	 the	main	 focus	of	 this	 study.	However,	 several	 interesting	agonists	have	 recently	
been	described	in	the	literature	as	reported	in	the	introduction.	Some	of	these	agonists	were	drugs	








































Figure	 23:	 The	 normalized	 mean	 of	 three	 curves	 of	 ciprofloxacin	 and	 morphine	 as	 agonists	 at	 the	MRGPRX2	 receptor.	








Further	 attempts	 in	 investigating	 the	 MRGPRX2	 receptor	 were	 based	 on	 the	 seminal	 findings	 of	
McNeil	 et	 al.106	 in	 which	 they	 suggested	 the	 mouse	 MRGPRB2	 (accession	 number:	 NM_175531)	
receptor	 as	 a	 functional	 ortholog	 of	 the	 human	 MRGPRX2.	 Our	 aim	 was	 to	 investigate	 if	 our	




GATC	 Biotech	 AG	 in	 Konstanz,	 Germany,	 in	 order	 to	 check	 for	 any	mutations.	 All	 sequences	were	
aligned	with	the	reference	sequence	and	no	mutation	was	found.	The	amplification	of	the	genes	and	
the	insertion	into	the	four	ß-arrestin	vectors	were	done	as	described	in	chapter	4.3.4.	The	Pyrobest™	
DNA-Polymerase	 from	TAKARA	BIO	 Inc.	was	applied	to	amplify	 the	genes.	A	sequence	analysis	was	




CST-14	 was	 used	 as	 the	 standard	 agonist.	 Unfortunately,	 it	 was	 not	 possible	 to	 detect	 any	 signal	
when	 using	 CST-14	 up	 to	 100	 µM	 concentration.	 The	 transfection	 was	 repeated	 but	 the	 results	
remained	negative	for	all	generated	MRGPRB2	constructs	in	the	four	ß-arrestin	vectors.	Hence,	it	 is	
for	 now	not	 possible	 to	 investigate	 any	 antagonistic	 activity	 of	 our	 novel	MRGPRX2	 ligands	 at	 the	
mouse	receptor.	 It	 should	be	mentioned	that	 in	 reference	106	CST-14	showed	an	EC50	value	of	21.3	















for	 the	physiological	 function	of	 this	 receptor	 if	 these	peptides	actually	 function	as	 agonists	under	
(patho)physiological	 conditions.	 One	 interesting	 explanation	 is	 a	 kind	 of	 similarity	 of	 MRGPR	
receptors	 to	 olfactory	 and	 taste	 receptors	 which	 are	 able	 to	 detect	 an	 extraordinary	 range	 of	





Menadione,	 from	the	drug	 library,	was	the	 first	detected	antagonist	with	an	 IC50	value	of	5.39	µM.	
This	could	be	an	interesting	and	inexpensive	pharmacological	tool.	The	ability	to	modify	the	molecule	
could	also	be	an	option	to	increase	the	potency	of	this	antagonist.	In	order	to	verify	and	substantiate	
the	 findings	 and	 reduce	 the	 toxicity	 of	 menadione	 on	 the	 cells	 during	 ß-arrestin	 assays,	 calcium	
mobilization	assays	could	be	performed.	Two	other	antagonists,	H351	and	SL318	(see	figure	15),	have	












Figure	24:	The	established	structure-activity	 relationships	at	 the	MRGPRX2	 receptor	after	 synthesizing	a	 large	number	of	
antagonists.	
	
The	 best	 antagonist	 so	 far,	 CB63,	 has	 an	 IC50	 value	 of	 6.38	 nM.	 This	 potency	 could	 be	 suitable	 to	
develop	a	 radioligand,	which	would	be	a	powerful	pharmacological	 tool	 for	 further	studies.	Hence,	
developing	 a	 radioligand	 could	 be	 a	 plausible	 next	 step	 in	 investigating	 the	 MRGPRX2	 receptor.	
However,	this	should	take	place	after	further	investigation	of	SARs;	especially	in	positions	7	and	8	of	
the	benzimidazole	ring	because	this	could	lead	to	even	more	potent	antagonists.	Hence,	the	first	step	
in	 the	 chemical	 synthesis	 is	 to	 find	an	approach	 to	get	 rid	of	 the	 regio-isomer	problem	and	 to	get	
single	 compounds.	 The	 nature	 of	 antagonism	 was	 also	 investigated	 and	 turned	 out	 to	 be	 an	




antagonists	 were	 also	 screened	 at	MRGPRX1	 and	 turned	 out	 to	 be	 selective	 against	MRGPRX1.	 A	
further	 investigation	of	 the	selectivity	of	 the	new	antagonists	against	MRGPRX4	receptor	would	be	





	Having	 established	 SARs	 for	 antagonists	 and	 developed	 potent	 ones,	 our	 aim	 was	 then	 directed	
towards	 expanding	 the	 investigation	 to	 a	 pre-clinical	 stage	 through	 a	mouse	model.	 This	 could	 be	
based	on	the	recent	finding	that	the	mouse	MRGPRB2	receptor	could	be	the	functional	ortholog	of	
the	 human	MRGPRX2	 receptor.	 As	 a	 first	 step,	 ADME	 profiles	 of	 the	 best	 three	 antagonists	 were	
generated	in	vitro.	The	obtained	results	make	clear	the	difficulties	throughout	stages	of	developing	a	




may	 lead	 to	drug-drug	 interactions.131	 The	CNS	accessibility	 seems	 to	be	 acceptable	 (for	 CB63	and	
CB64)	but	 the	expression	profile	of	MRGPRX2	 in	mast	 cells	 and	DRG	neurons	does	not	 necessarily	
require	BBB	penetration	depending	on	the	indication	pursued.	This	leads	us	to	further	requirements	






receptor	 in	 the	 ß-arrestin	 assay.	 This	 could	 be	 explained	 by	 the	 rather	 unimpressive	 EC50	 value	 of	
CST-14,	which	was	reported	in	a	calcium	assay.106	Therefore,	the	less	sensitive	ß-arrestin	assay	would	
not	enable	satisfying	concentration-response	curves	to	be	plotted.	Addressing	this	issue	could	be	via	







































This	member	 of	 the	MRGPRX	 subfamily	 appears	 to	 be	 the	most	 enigmatic	 one.	 The	 expression	 is	






been	disclosed.	 The	 cDNA	of	mrgprX3	was	provided	by	OriGene	Technologies	 Inc.,	USA.	 The	cDNA	
was	sequenced	by	GATC	Biotech	AG	in	Konstanz,	Germany,	 in	order	to	check	for	any	mutations.	All	
sequences	were	aligned	with	the	reference	sequence	and	no	mutation	was	found.	The	amplification	
of	 the	 genes	 and	 the	 insertion	 into	 the	 four	 ß-arrestin	 vectors	was	 done	 as	 described	 below	 (see	
chapter	 4.3.4).	 The	 Pyrobest™	 DNA-Polymerase	 from	 TAKARA	 BIO	 Inc.	 was	 applied	 to	 amplify	 the	




















this	 search	 and	due	 to	 the	need	 for	 an	 agonist	 as	 indispensible	 tool	 for	 further	 investigations,	 the	
screening	 was	 done	 at	 10	 µM	 and	 an	 S/N	 ratio	 of	 as	 low	 as	 1.3	 was	 considered	 as	 a	 hit.	 The	




1.5	 and	 1.3	 (IDs:	 6265708	 and	 6258069,	 respectively)	 as	 shown	 in	 figure	 26.	 The	 screening	 was	
repeated	three	times	and	could	be	reproduced.	 	 Interestingly,	the	hits	from	the	compound	library	3	
share	 a	 benzimidazole	 scaffold	 like	 the	 other	 CB	 ligands	 for	 the	MRGPRX2	 receptor.	 All	 three	 hits	





the	 expected	 mass	 because	 there	 was	 a	 degradation	 of	 all	 three	 compounds.	 An	 LC-MS	 was	
conducted	using	 the	mother	plates,	 the	 results	 showed	no	 signs	of	 degradation	 (data	not	 shown).	








































show	any	 increase	 in	activity	 (data	not	 shown).	The	measurements	of	 the	compounds	with	 the	 ID:	
6265708	and	6258069	showed	a	molecular	weight	of	200.2	and	256.29,	respectively.	This	led	to	the	
assumption	that	the	oxadiazole	ring	was	degraded	and	yielded	cyano	derivatives	as	shown	in	figure	
26.	 The	 proposed	 degradation	 products	 have	 molecular	 weights	 that	 are	 in	 harmony	 with	 the	
detected	 molecular	 weights	 but	 they	 were	 not	 commercially	 available	 according	 to	 a	 search	 in	
Scifinder.	 Yet	 a	 similar	 compound	 (figure	26)	was	 found	and	ordered	 from	Princeton	BioMolecular	
Research	 and	 designated	 Prin01.	 This	 compound	was	 screened	 three	 times	 but	 did	 not	 show	 any	














an	antibody	against	 the	ProLink	 segment	and	 the	cell	 line	of	MRGPRX3	 in	 the	ARMS2	plasmid	was	
chosen	for	pharmacological	assays	due	to	the	high	expression	of	the	receptor	in	the	cell	membrane.	
The	 compound	 libraries	 1-5	 and	7-10	were	 screened	 in	 search	 for	 an	 agonist	 at	 this	 receptor.	 The	
search	was	done	according	to	the	status	of	the	compound	 libraries	 in	September	2014.	The	search	
led	 to	 no	 clear	 identification	 of	 a	 hit.	 Three	 compounds	 were	 found	 to	 be	 active	 but	 they	 were	
degraded	compounds.	The	active	moiety	remains	elusive	for	now.	Interestingly,	two	of	the	assumed	
hits	 showed	 a	 benzimidazole	 structure.	 The	 difficulty	 in	 finding	 an	 agonist	 for	MRGPRX3	 receptor	
could	be	due	to	several	reasons.	
The	 first	 reason	 could	 be	 the	 unsuitability	 of	 the	 ß-arrestin	 assay.	 This	 is	 difficult	 to	 explain	 but	 it	
could	 be	 the	 reason	 why	 DiscoverX®	 does	 not	 offer	 this	 cell	 line.	 The	 other	 reason	 could	 be	 the	
inability	to	have	a	stable	expression	in	the	cell	membrane,	which	has	already	been	described121	or	a	
rapid	 decrease	 in	 the	 expression	 of	 the	 receptor	 in	 the	 cell	membrane.	 In	 addition	 to	 the	 general	
difficulty	in	finding	a	ligand	for	the	MRGPRX	subfamily,	which	is	reflected	in	the	paucity	of	described	
ligands	 so	 far.	 To	 address	 these	 issues	 it	 is	 plausible	 to	 switch	 the	 screening	 assay	 to	 a	 calcium	
mobilization	assay	because	MRGPRX3	is	Gq	coupled	and	by	using	FACS	techniques	it	could	be	possible	
to	 pick	 a	 monoclone	 (e.g.	 m-Cherry	 approach)	 and	 have	 a	 potentially	 more	 reliable	 system.	 The	
screening	of	the	compound	libraries	should	be	repeated	using	higher	concentration	(e.g.	30	or	even	
100	µM)	because	 it	 is	 important	 to	have	even	a	weak	 initial	 tool	and	 then	 there	could	be	ways	 to	
improve	 the	 potency.	 The	 ligands	 at	MRGPRX2	 should	 be	 tested	 at	MRGPRX3	 as	 agonists	 as	well.	







or	 (should	 there	 be	 no	 acceptable	 antibody)	 subjecting	 a	 membrane	 preparation	 sample	 to	









MRGPRX4	 is	 a	 poorly	 investigated	 receptor.	No	 pharmacological	 tools	 had	 been	 described	 for	 this	
7TMR	at	the	beginning	of	this	thesis	and	the	physiological	role,	apart	from	apparent	involvement	in	







expanded	mas-related	 gene	 receptors	 in	 rodents.	Although	 there	 are	no	direct	 orthologs	between	
human	MRGPRX	subfamily	and	the	rodents’	receptors19,20,	the	relatedness	(sequence	identity)	could	
give	 an	 indication	 to	 a	potential	 shared	 ligand.	 From	 the	deorphanized	 rodents’	MAS-related	gene	
receptors,	MRGPRA9/A10	(accession	number:	NM_001288801,	JN662396)	and	rat	MRGPRA	(also	rat	
MRGPRX3,	 accession	 number:	 NM_145787)	 and	 the	 Chinese	 hamster	 adenine	 receptor	 (accession	
number:	 KC202822.1)	 showed	 the	 highest	 sequence	 identity	 of	 66%.	 Rat	 MRGPRA	 and	 mouse	
MRGPRA9/10	 receptors	 demonstrated	 sequence	 identity	 of	 64%,	 63%	 and	 65%,	 respectively,	 as	













Human	MRGPRX4	 64%	 63%	 65%	 66%	
	
Adenine	has	been	already	shown	to	have	interesting	physiological	effects.	Yoshimi	et	al.	reported	an	





this	 neurotrophic	 effect	 remained	 elusive.136	 The	 oldest	 observation	 was,	 nevertheless,	 that	 1-
methyladenine	acts	as	a	maturation-inducing	hormone	in	starfish	oocytes.137	The	effect	of	adenine	in	
the	dorsal	horn	was	found	to	be	pronociceptive	since	the	spinal	administration	of	adenine	in	the	rat	
increased	 the	 excitability	 of	 C-fibres	 in	 a	 concentration	 dependent	manner.	 The	mechanism	 could	
also	not	be	 readily	 correlated	 to	mas-related	genes	 since	 these	 receptors	are	not	expressed	 in	 the	








the	ß-arrestin	assay.	The	ß-arrestin	cell	 line	was	a	commercial	one	 from	DiscoverX®.	The	 results	of	
the	testing	showed	no	increase	in	signal	even	when	the	concentration	of	adenine	was	as	high	as	500	
µM.	This	 is	 a	 clear	 indication	 that	adenine	 could	not	activate	MRGPRX4	 receptor	at	 least	 in	 the	ß-
arrestin	pathway.	Since	MRGPRX4	 is	also	Gq	coupled,	calcium	mobilization	assay	was	also	tried	but	
the	results	were	negative	as	well	as	shown	in	figure	28.	




































In	 order	 to	 further	 our	 investigations,	 binding	 assays	 have	 been	 conducted	 to	 detect	 a	 possible	















Since	 the	 screening	 of	 the	 available	 compound	 libraries	 and	 the	 adenine-based	 deorphanization	
approach	 were	 not	 fruitful,	 it	 was	 necessary	 to	 find	 a	 new	 approach.	 The	 most	 interesting	
characteristic	of	the	mas-related	genes	is	their	restricted	expression	in	the	DRG.17,18	One	way	would	
be	 the	 screening	 of	 different	 tissue	 extracts	 of	 the	 DRGs	 (reverse	 pharmacology	 approach).	 The	
active	fractions	could	then	be	further	fractioned,	purified	and	analyzed	(e.g.	peptide	fraction	etc.)	till	
an	 active	metabolite	 is	 found.	 	 Such	an	approach	has	been	 carried	out	 successfully	 and	 led	 to	 the	
deorphanization	of	several	7TMRs	and	to	the	identification	of	important	endogenous	neuropeptides.	
Opioid	receptor-like	1	(ORL1)	was	deorphanized	via	rat	brain	extracts	and	nociceptin	was	identified	
as	 a	 ligand.142,143	 The	 peptides	 orexin	 A	 and	 B	were	 identified	 and	 paired	 to	 their	 receptors	 in	 an	





and	APJ	 receptors,	 respectively.146,147	 Interestingly,	 ghrelin	was	 identified	 in	 a	 stomach	extract	 and	
found	to	be	an	endogenous	ligand	at	its	7TMR,	which	is	mainly	expressed	in	the	brain.148	In	order	to	
realize	 such	 an	 approach	 for	 MRGPRX4	 receptor,	 human	 or	 monkey	 DRGs	 should	 be	 available	 in	
relatively	big	amount	since	the	native	ligand	is	usually	found	in	a	very	low	concentration.	This	was	a	
main	 hurdle	 for	 this	 approach.	 Another	 way	was	 to	 investigate	 the	 cerebrospinal	 fluid	 (CSF).	 This	
could	be	plausible	because	the	DRGs	are	surrounded	by	CSF.	In	addition,	CSF	has	been	approached	to	
determine	biologically	 active	proteins	 in	pathological	 conditions.149	 The	CSF-based	approach	would	
work	 provided	 that	 the	 native	 ligand	 is	 able	 to	 leak	 from	 the	 DRG	 tissue	 to	 CSF	 in	 a	 reasonable	
amount	 to	 be	 detected.	 If	 so,	 this	 approach	 could	 be	 advantageous	 because	 it	 reduces	 the	
complexity	of	a	tissue	extract	and	circumvents	the	difficulties	of	obtaining	human	DRG	tissues.	
Professor	Urlich	Wüllner	from	the	Neurology	Department	in	the	University	Clinic	in	Bonn	provided	us	
kindly	with	6	 samples	of	CSF.	One	sample	had	been	 taken	directly	and	split	 into	 two	samples.	The	
first	 sample	 was	 treated	 with	 a	 protease	 inhibitor	 (identity	 not	 disclosed)	 and	 the	 other	 was	 left	
untreated	and	both	were	 then	 frozen.	These	samples	were	 tested	on	MRGPRX4	and	a	weak	signal	
was	observed	(data	not	shown).	Since	the	concentration	of	a	potential	ligand	in	the	CSF	is	lower	than	
within	 the	DRG	tissue,	 it	was	decided	to	concentrate	 the	CSF	by	 the	 factor	of	10	via	 lyophilization.		














450000 Patient 1 without protease inhibitor



















the	96-well	plate.	 Interestingly,	 there	was	a	 considerable	difference	 in	 the	 induced	signal	between	
the	 samples	 of	 different	 origins.	 While	 some	 samples	 like	 sample	 6	 could	 induce	 a	 robust	 and	
reproducible	 signal,	 sample	 3	 could	 not	 cause	 any	 increase	 in	 signal.	 It	 is	 not	 possible	 to	make	 a	
confident	 conclusion	 out	 of	 these	 data	 but	 it	 is	 tempting	 to	 suggest	 that	 there	 is	 an	 agonist	 of	
MRGPRX4	 in	 the	CSF	 and	 this	 ligand	 is	 present	 at	 varying	 concentrations	 in	 the	different	 samples.	
Taken	 into	 consideration	 that	MRGPRX	 receptors	 are	 proposed	 to	 play	 a	 role	 as	 pain	 detectors23,	
these	 varying	 results	 could	 reflect	 a	 nociceptive	 input	 in	 the	 different	 samples.	 It	 could	 also	 be	
noticed	that	the	addition	of	protease	inhibitor	did	not	have	any	inhibitory	effect	on	the	signal.	This	
could	mean	 that	 the	agonist	 is	not	a	peptide	or	 that	 it	 is	a	 relatively	 small,	 stable	peptide	with	no	
cleavage	site	for	a	potential	protease.		










receptor-dependent,	 it	 was	 decided	 to	 compare	 the	 order	 of	 efficiency	 of	 the	 signal	 via	 the	







coupling	 according	 to	 Burstein	 et	 al.23	 should	 be	 Gq	 only,	 while	 according	 to	 the	 prediction	 tool	
(http://athina.biol.uoa.gr/bioinformatics/PRED-COUPLE2/)	 MRGPRX4	 should	 be	 Gq	 and/or	 Gi-
coupled.	 	 Therefore,	 screening	of	 the	CSF	 samples	 via	 cAMP	and	 calcium	mobilization	assays	were	


































90	°C	 for	5	minutes	did	not	 change	 the	 signal	 in	 the	ß-arrestin	assay,	which	means	 that	 the	active	
entity	is	stable	under	these	condition.	
These	 findings	seemed	to	be	encouraging	to	continue	the	search	 for	a	 receptor	agonist	 in	 the	CSF.	
Since	 the	 search	 should	 be	 based	 on	 an	 assumption	 of	 the	 nature	 of	 the	 agonist	 in	 order	 to	
determine	further	steps,	our	assumption	was	that	the	agonist	could	be	a	peptide.	Although	MRGPR	
receptors	 could	be	activated	by	a	variety	of	agonists	of	different	nature	 that	do	not	have	much	 in	
common	 (adenine,	 ß-alanine,	 CST-14,	 BAM-22,	 several	 RF-peptides)122,	 the	 reported	 agonist	 at	
human	receptors	are	all	peptides.	Therefore,	it	was	decided	to	digest	the	peptides	using	a	protease	
and	 see	 if	 the	 signal	 would	 disappear.	 Trypsin	 is	 a	 serine	 protease,	 which	 cleaves	 predominantly	
proteins	 at	 the	 carboxyl	 side	 (or	 "C-terminal	 side")	 of	 the	 amino	 acids	 lysine	 and	 arginine	 except	
when	either	is	bound	to	a	C-terminal	proline.151	Trypsin	was	chosen	as	a	protease	because	of	its	wide	
specificity	and	availability.	CSF	samples	were	 incubated	with	trypsin	for	30	minutes	at	37	°C	before	
screening.	 There	 was	 a	 decrease	 in	 the	 signal	 of	 CSF	 but	 given	 that	 trypsin	 is	 used	 for	 cell	
detachment,	 it	 was	 not	 clear	 if	 the	 decrease	 in	 signal	 is	 due	 to	 a	 harmful	 effects	 of	 trypsin	 (e.g.	
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PBS	 93368	 109760	 106912	 103347	±	5056	 1	
Sample	M.D.	<	3	kDa	 159752	 181056	 193768	 178192	±	9923	 1.72	
Sample	M.D.	>	3	kDa	 110680	 94744	 92440	 99288	±	5734	 0.96	
Sample	U.P.	<	3	kDa	 185712	 141464	 167160	 164778	±	12828	 1.59	





Thus,	 it	 is	 clear	now	 that	 the	active	entity	 in	CSF	 is	pretty	 stable	 at	high	 temperature	and	 it	 has	 a	











this	 work)	 is	 the	 Kunitz	 trypsin	 inhibitor	 (STI,	Mr	 of	 about	 20	 kDa,	 two	 disulfide	 bridges	 between	
amino	acids	39-86	and	amino	acids	136-145),	which	belongs	to	the	clan	IC	and	to	the	family	I3	in	the	
MEROPS	database.152,153	The	inhibitors	from	this	family	are	tight-binding,	reversible	inhibitors	with	ß-
trefoil	 structure.	 The	 members	 of	 this	 family	 show	 inhibition	 of	 serine,	 cysteine	 and	 aspartic	
proteases.154	STI	can	be	hydrolyzed	by	trypsin,	 the	cleavage	site	being	situated	between	Arg63	and	
Ile64	and	the	interaction	is	a	one-to-one	stoichiometry.	This	leads	to	a	conversion	of	the	single	chain	
inhibitor	 to	 two	 chains	 held	 by	 a	 single	 disulfide	 bond	 between	 residues	 number	 39	 and	 86.	 The	
complex	of	 STI	with	 trypsin	has	neither	 tryptic	nor	 inhibitory	activity;	 the	cleaved	 inhibitor	has	 full	
inhibitory	activity.155,156	
The	 active	 (<3	 kDa)	 fraction	 was	 assumed	 to	 cause	 the	 signal	 via	 a	 peptide.	 To	 check	 this	 out,	
incubation	with	trypsin	and	then	STI	each	for	30	minutes	was	done.	For	this	experiment	not	only	PBS	
should	be	considered	as	a	negative	control	but	also	trypsin/STI	and	STI	alone.	The	results	could	not	
be	 interpreted	 because	 the	 signal	 of	 CSF	 after	 treatment	with	 trypsin/STI	was	 considerably	 higher	
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These	 findings	 indicate	 that	 STI	 is	 inducing	 the	 robust	 signal	 at	 MRGPRX4	 receptor.	 This	 was	





PBS	 1830176	 1692568	 1750048	 1757597	±	39902	 1	
CST-14	(10	µM)	 18900952	 17086272	 18715528	 18234250	±	576479	 10	
CST-14,	Try,	STI	 2320800	 2187640	 2336384	 2281608	±	47198	 1.2	
STI	 1975152	 2012016	 1843080	 1943416	±	51284	 1.1	
	
Conducting	 a	 two-tailed	 t	 test,	 the	 difference	 in	 signal	 between	 PBS	 and	 STI	 was	 statistically	
significant	 (p	 value	of	0.045),	 the	difference	between	PBS	and	 the	CST-14	plus	 trypsin	and	STI	was	
also	 statistically	 significant	 (p	 value	 of	 0.0011).	 Despite	 this	 statistical	 significance,	 the	 increase	 in	
signal	is	minimal	compared	to	the	signal	induced	by	CST-14	at	MRGPRX2	receptor.	It	was	concluded	
that	trypsin	could	cleave	CST-14	and	that	STI	can	be	added	to	inhibit	the	harmful	effect	of	trypsin	on	
the	 cells.	 These	 results	 show	 also	 that	 STI	 does	 not	 have	 an	 agonistic	 effect	 on	MRGPRX2.	 Taking	
these	 findings	 into	 account,	 STI	was	 investigated	 as	 a	 potential	 agonist	 at	MRGPRX4	 receptor.	 STI	
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the	 active	 fraction	 is,	 unlike	 CSF,	 >	 3	 kDa	 (data	 not	 shown).	 This	 led	 to	 the	 testing	 of	 an	 STI	
preparation	with	 high	 purity	 and	 the	 result	was	 identical	 (data	 not	 shown).	 These	 results	 indicate	
that	 STI	 is	 causing	 the	 signal	 and	 not	 a	 small	 peptide.	 Since	 STI	 is	 a	 plant	 protein	 and	 MRGPRX	
receptors	are	human	7TMRs,	a	search	for	similarity	between	STI	and	human	proteins	revealed	that	
such	a	similarity	was	based	on	the	ß-trefoil	structure	as	a	common	denominator.	
ß-Trefoil	 structures	 have	 relevance	 in	 human	 proteins	 and	 some	 proteins	 with	 high	 functional	
versatility	share	this	structure.	The	proteins	with	this	conserved	ß-trefoil	structure	interact	selectively	
with	 their	 different	 targets	 due	 to	 the	 low	 sequence	 homology	 among	 them.	 These	 targets	 are	
divided	 into	the	following	six	groups	according	to	their	biological	activity	 (first,	hydrolase	 inhibitors	
like	peptidase	inhibitors;	second,	interleukins	belonging	to	IL-1	family;	third,	fibroblast	growth	factors	
(FGFs);	fourth,	lectins	and	carbohydrate-binding	modules;	fifth,	fascin,	an	actin	cross-linking	protein;	
sixth,	multi-domain	 DNA-binding	 protein	 LAG-1,	 which	 acts	 as	 repressor	 or	 activator	 in	 the	 Notch	
signaling	pathway).157	 	From	these	six	groups	only	the	interleukin-1	family	seemed	to	be	interesting	
due	 to	 its	 role	 in	 pain	 and	 its	 expression	 in	 DRG	 (see	 chapter	 2.4.5).	 This	 led	 to	 a	 third	
deorphanization	attempt	(see	chapter	2.4.5).	Lastly,	it	should	be	stressed	that	the	increase	in	signal	
by	 STI	 did	not	 reach	 a	plateau	even	 in	 a	 concentration	up	 to	 200	µM.	 This	 looked	 like	 an	 artifact.	
Therefore,	STI	was	investigated	at	100	µM	using	GPR55	and	GPR35	cell	lines.	Both	receptors	showed	











a	 non-binding	 signaling	 accessory	 protein	 have	 been	 identified.158,159	 Until	 recently,	 IL-1	 RI	 was	
considered	a	signal	 transducing	 receptor,	while	 IL-1	RII	was	believed	 to	be	a	dummy	receptor.	 It	 is	
now	known	that	 IL-1	signaling	 is	not	generated	by	the	 IL-1	RI	molecule,	but	by	an	 IL-1	RI	accessory	
protein	 that	 only	 interacts	 with	 IL-1	 RI.160,161	 The	 IL-1ß	 is	 a	 potent	 pleiotropic	 proinflammatory	
cytokine,	whose	concentration	in	the	CSF	is	commonly	monitored	in	neurological	disorders	including	
neuropathic	 pain	 and	 complex	 regional	 pain	 syndrome.162	 In	 the	 CNS,	 endogenous	 IL-1ß	 levels	
increase	 in	 neuropathic	 pain	 and	 cause	 release	 of	 excitatory	 glutamate	 in	 the	 dorsal	 horn	 via	
sphingomyelinase	 and	 Src-kinase	pathways.163,164	A	neuropathic	 pain-induced	 increase	 in	 IL-1ß	was	
also	 found	 in	 the	DRG	and	 trigeminal	 ganglia,	both	 in	 the	neurons	as	well	 as	 in	glial	 cells	 (satellite	
cells).165,166	In	addition	to	the	various	indirect	activation	mechanisms,	IL-1ß	was	suggested	to	act	as	a	
direct	 sensitizer	 of	 nociceptors	 via	 augmenting	 sodium	 currents.167	 This	 imminent	 role	 of	 IL-1ß	 in	
neuropathic	pain	led	us	to	investigating	it	as	a	potential	MRGPRX4	ligand.	
Initially,	 mouse	 IL-1α	 and	 rat	 IL-1ß	 (acquired	 through	 Biomedizin	 Forum	 of	 the	 Uni	 Bonn)	 were	
screened	 at	 concentrations	 from	 100	 nM	 till	 5	 nM	 but	 did	 not	 show	 any	 activity	 at	 MRGPRX4	
receptor	(data	not	shown).	Due	to	the	low	sequence	identity	of	murine	IL-1α	and	rat	IL-1ß	with	their	
corresponding	 human	 counterparts,	 screening	 of	 human	 IL-1ß	 seemed	 necessary.	 IL-1ß	 was	





























Figure	 34:	 The	 mean	 curve	 of	 four	 independent	 ß-arrestin	 assays	 of	 interleukin-1ß	 (IL-1ß)	 at	 MRGPRX4	 receptor.	 The	
determined	EC50	value	was	739	±	180	nM	
	
This	 interesting	result	encouraged	us	 to	subsequently	 test	a	more	pure	 IL-1ß	preparation	since	 the	
one	purchased	from	InvitrogenTM	was	only	of	85%	purity.	5	µg	from	R&D	systems	were	ordered	but	
surprisingly	 no	 agonism	 could	 be	 detected,	 but	 rather	 a	 small	 decrease	 in	 the	 basal	 activity.	 For	
confirmation	another	95%	pure	5	µg	from	InvitrogenTM	were	tested	and	once	again	no	agonism	could	
be	 detected	 but	 only	 a	 decrease	 in	 the	 signal	 (data	 not	 shown).	 These	 findings	 led	 us	 to	 the	
assumption	 that	 the	 15%	 impurity	 was	 causing	 the	 increase	 in	 signal.	 The	 impurities	 were	
investigated	 using	 SDS-PAGE	 gel	 und	 were	 found	 to	 have	 a	mass	 of	 less	 than	 3	 kDa.	 Hence,	 two	
fractions	 (more	 and	 less	 than	 3	 kDa)	 of	 the	 IL-1ß	 solution	 were	 separated	 and	 tested.	 The	 result	
showed	that	only	the	less	than	3	kDa	fraction	was	active	as	shown	in	figure	35.	
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the	 active	 IL-1ß	 fraction.	 PD	 Dr.	 Anke	 Schiedel	 sent	 IL-1ß	 as	 well	 as	 a	 CSF	 sample	 to	 Freiburg	 for	








fraction	of	 less	 than	3	 kDa	of	 CSF	 after	 digestion	with	 trypsin.	 The	 individual	 peptides	 are	 given	 in	 different	
colors	and	their	location	within	the	mature	IL-1ß	is	shown	in	the	last	row	of	the	table.	
CSF	 Sequence	 intensity	 mass	








fraction	of	 less	than	3	kDa	of	 IL-1ß	after	digestion	with	trypsin.	The	 individual	peptides	are	given	 in	different	
colors	and	their	location	within	the	mature	IL-1ß	is	shown	in	the	last	row	of	the	table.	
IL-1ß	 Sequence	 intensity	 mass	

















functions168,169,	 the	 fate	 of	 IL-1ß	 could	 provide	 an	 insight	 into	 identifying	 structures	with	 potential	






can	 degrade	 IL-1ß	 but	 only	 MMP-3	 could	 effectively	 and	 completely	 degrade	 IL-1ß.	 The	 primary	
cleavage	site	of	IL-1ß	was,	nevertheless,	only	determined	for	MMP-2	and	turned	out	to	be	between	













kDa	 showed	 pronounced	 sequences	 from	 IL-1ß,	 especially	 of	 the	 N-	 and	 C-terminus	 as	 shown	 in	
table	25.	
Table	 25:	 The	 sequences	 of	 IL-1ß	 fragment	 peptides,	 their	 confidence	 levels	 and	 their	 masses,	 which	 were	
found	in	the	fraction	of	less	than	3	kDa	of	IL-1ß	without	trypsin	digestion.	The	individual	peptides	are	given	in	
different	colors	and	their	location	within	the	mature	IL-1ß	is	shown	in	the	last	row	of	the	table.		
IL-1ß	 Sequence	 Confidence	level	 mass	











These	 results	 further	 supported	 the	 potential	 that	 an	 N-terminal	 fragment	 of	 IL-1ß	 could	 be	 the	






could	 be	 due	 to	 the	 very	 low	 amount	 of	 this	 fragment	 as	well	 as	 the	 lack	 of	 tryptic	 degradation,	





peptide	 at	 MRGPRX1	 and	 MRGPRX2	 did	 not	 show	 any	 activity	 either	 (neither	 agonism	 nor	
antagonism).	 A	 second	 custom	 peptide	 was	 ordered	 according	 to	 the	 sequencing	 results	 of	
untrypsinated	 IL-1ß.	 This	 sequence	 (APVRSLNCTLRD)	was	N-terminal	 as	well	 as	 shown	 in	 table	 24.	
The	second	peptide	was	also	inactive	at	MRGPRX4	and	other	MRGPRX	receptors	as	well.	
These	 negative	 results	 led	 to	 the	 search	 for	 other	 degradosome	 products	 as	 potential	 ligands	 for	
MRGPRX4	 receptor.	 MMP-3	 seemed	 to	 be	 the	 most	 suitable	 protease	 candidate	 owing	 to	 the	
observation	 that	 MMP-3	 can	 degrade	 IL-1ß	 completely	 into	 small	 fragments.170	 In	 the	 first	




in	 500	µl	 (30	µl	 PBS	 and	 470	µl	water)	 and	 incubated	 for	 2	 h	 at	 37	 °C.	 Both	 the	 digested	 inactive	
fraction	and	the	control	MMP-3	were	fractioned	via	an	Amicon®	Ultra.	The	fraction	of	less	than	3	kDa	
was	 lyophilized	 and	 then	dissolved	 in	 30	µl	 PBS	 and	 tested	 in	ß-arrestin	 assays.	 The	digestion	was	
immediately	stopped	after	2	h	through	freezing	of	the	sample	in	liquid	N2.	Since	it	was	not	possible	to	
determine	 the	 concentration	 of	 the	 resultant	 digestion	 products,	 the	 concentration	 in	 ß-arrestin	
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Figure	36:	The	resultant	curves	of	one	ß-arrestin	assay	after	 incubation	of	 the	 inactive	 fraction	of	 IL-1ß	with	MMP-3	and	
subsequent	fractionation	into	more	and	less	than	3	kDa	fractions.	The	curve	of	MMP-3	alone	was	also	plotted	as	a	control.		
	
The	previous	 results	may	 suggest	 that	 the	 inactive	 fraction	of	 IL-1ß	was	digested	by	MMP-3	 to	 an	
active	species	at	MRGPRX4	receptor.	The	experiment	was	repeated	twice,	once	with	the	same,	less	
pure	 IL-1ß	(InvitrogenTM)	and	another	time	with	highly	pure	 IL-1ß	(R&D	systems).	 In	both	cases	the	
same	MMP-3	(Sigma	Aldrich)	was	used.	In	one	experiment,	the	less	pure	IL-1ß	was	treated	in	exactly	




both	 fractions	>3	kDa	and	<3	kDa	were	 lyophilized,	dissolved	 in	30	µl	PBS	and	 tested	 in	ß-arrestin	
assays	as	shown	in	figure	37B.	
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have	 limitations	 (see	 chapter	 2.4.6)	 but	 they	 indicate	 the	 ability	 of	 MMP-3	 to	 produce	 an	 active	









The	 investigation	 of	 MRGPRX4	 began	 with	 a	 hypothesis,	 based	 on	 sequence	 identity,	 that	 this	
receptor	could	be	the	human	receptor	for	the	nucleobase	adenine.	Screening	adenine	in	functional	
assays	(ß-arrestin	and	calcium	mobilization	assay)	did	not	show	any	activity	 in	spite	of	the	fact	that	
very	 high	 concentrations	were	 employed.	 Capitalizing	 on	 the	 availability	 of	 [3H]adenine	 in	 our	 lab	
competition	binding	studies	have	also	been	attempted	to	investigate	any	binding	of	adenine	(role	as	
a	modulator	 or	 an	 antagonist).	 These	 also	 have	 proven	 that	 adenine	 does	 not	 bind	 to	MRGPRX4.	






ligand	 for	MRGPRX4	very	dim.	The	 inability	 to	 find	an	agonist	 through	screening	of	 small	molecule	
libraries	might	have	been	due	to	the	possibility	of	a	native	peptidergic	agonist	requiring	interaction	





assumption	 is	 substantiated	 by	 BAM22	 and	 CST-14	 being	 the	 cognate	 ligands	 at	 the	 related	













soybean	 trypsin	 inhibitor	 (STI)	 was	 added	 that	 caused	 an	 unspecific	 increase	 in	 signal,	 which	
confounded	the	signal	induced	by	CSF.	In	principle,	this	approach	is	an	interesting	one	but	the	search	
did	 not	 show	 a	 clear	 results	 and	 no	 peptide	 has	 been	 found	 so	 far.	 The	 search	 for	 neuropeptides	
combines,	as	from	the	above	mentioned	publications,	a	tissue	extract	and	then	extensive	analytical	
work	to	separate	and	fractionate	this	extract.	Such	an	approach	requires	a	hypothesis	of	the	nature	
of	 the	 ligand	 (peptide,	 fatty	 acid	etc.)	 in	order	 to	use	 the	 suitable	extraction	 solvent	 and	 then	 the	
application	 of	 several	 chromatographic	 methods	 (RP-HPLC,	 size	 exclusion	 chromatography,	 ion	
exchange	and	desalting	methods)	followed	by	LC-MS/MS	detection	(NMR	could	also	be	beneficial	for	
clarifying	the	structure).	The	yield	is	usually	very	limited;	for	instance	16	µg	of	ghrelin	were	extracted	







The	 search	 for	 an	 agonist	 took	a	new	 turn	by	 investigating	 IL-1ß.	Upon	 investigating	 this	 cytokine,	
more	than	one	important	player	in	neuropathic	pain	came	into	play,	namely,	the	cross-talk	between	
cytokines,	opioid	and	MRGPRX	 receptors,	 in	addition	 to	 the	 role	of	proteases,	especially	MMPs,	 in	
neuropathic	pain	and	in	modifying	chemokine	signaling.	Our	results	after	investigating	IL-1ß	showed	
that	the	observed	activity	of	an	IL-1ß	preparation	at	MRGPRX4	did	not	result	from	the	mature	IL-1ß	
but	 from	an	entity,	which	 is	 less	 than	3	kDa	and	may	be	an	 impurity	or	another	constituent	of	 the	
tested	 solution.	 This	 impurity	 could	 be	 due	 to	 proteolysis	 of	 IL-1ß	 during	 extraction	or	 it	 could	 be	
from	 the	host	 in	which	 IL-1ß	 is	 produced	 (E.Coli	 in	 this	 case).	 The	degradome	of	 IL-1ß	 is	 not	well-
understood	 but	 it	 seems	 that	 MMP-2,	 MMP-3	 and	 MMP-9	 play	 a	 role	 in	 it.	 Since	 MMP-3	 was	









pain	 and	 astroglial	 activation.176	 In	 rat	models	 of	 paclitaxel-induced	 neuropathy,	MMP-3	 has	 been	
demonstrated	 to	 be	 up-regulated.177	 Moreover,	 a	 cross-talk	 between	 MRGPRX1	 and	 chemokine	
receptor	 2	 has	 been	 described.	 BAM8-22,	 the	 selective	 MRGPRX1	 agonist,	 could	 up-regulate	
chemokine	receptor	2	expression,	which	has	been	linked	to	neuropathic	pain,	in	both	HEK	and	a	rat	
dorsal	root	ganglia	cell	line.	BAM8-22	was	investigated	at	LAD-2	mast	cells	and	it	could,	interestingly,	





activate	 glial	 cells	 in	 the	 DRG	 and	 cause	 an	 up-regulation	 of	 MMP-9,	 which	 causes	 an	 enhanced	
release	 of	 IL-1ß	 and	 result	 in	 an	 analgesic	 effect.178,179	Moreover,	 the	 role	 of	MMPs	 in	 proteolytic	
processes	 of	 chemokines	 has	 been	 studied	 extensively.	MMP-2	 seems	 to	 play	 the	most	 important	
role	in	trimming	the	N-termini	of	chemokines	and	thus	regulating	their	activities.	This	could	lead	to	
inactivation	 and	 transforming	 agonists	 into	 antagonists	 (CCL2,	 CCL4,	 CCL7,	 CCL8,	 CCL11,	 etc)	 or	 to	
activating	other	chemoattractants	 (CCL16	and	CCL23).180-182	 In	 fact,	 it	 is	now	established	that	all	54	
human	chemokines	are	modified	regarding	to	their	biological	activity	via	MMP	members.183	In	order	
to	 highlight	 the	 pervasiveness	 of	 proteolytic	 processing	 in	 general,	 the	 origin	 of	 the	 N-terminal	





chemokines.187	 In	 another	 important	 paper,	 a	 new	 concept	 of	 protease	 activated	 7TMR	 was	 put	
forward,	 in	which	 a	 protease	 cleaves	 the	 N-terminus	 of	 a	 7TMR	 and	 thus	 induces	 conformational	
changes	that	causes	downstream	signaling	without	any	tethered	or	diffusible	ligand.	It	was	suggested	
that	cathepsin	S	could	cleave	the	N-terminus	and	activate	mouse	MRGPRC11	receptor	with	an	EC50	
value	of	 140	nM.	 It	was	 also	 reported	 that	 cathepsin	 S	 could	 activate	MRGPRX2	and	papain	 could	
activate	MRGPRX1	but	no	EC50	values	were	given.188	All	the	interesting	previous	findings	investigated	
the	proteolytic	process	and	the	resultant	truncated	protein	but	any	potential	activity	of	the	cleaved	








MMP-3	 and	 IL-1ß	 were	 incubated.	 These	 high	 concentrations	 of	 proteases	 represent	 extreme	




high	 concentrations	 (see	 figure	 32).	 In	 the	 case	 of	 degraded	 IL-1ß	 the	 concentration	 remains	 low	
even	if	there	were	no	loss	during	the	filtration	via	Amicon®	Ultra	and	the	plateau	could	possibly	be	
reached	 if	higher	concentrations	were	 tested.	 In	more	details,	 the	concentration	of	 IL-1ß	 in	syovial	
fluid	is	reported	to	be	100	pg/ml189	and	in	the	CSF	to	be	50	pg/ml190	but	we	should	keep	in	mind	that	
the	concentration	at	inflammatory	sites	is	probably	considerably	higher.	Moreover,	IL-1ß	has	a	very	
high	 potency	 at	 its	 receptors	 in	 the	 lower	 nanomolar	 range	 and	 not	 in	 the	 picomolar	 range.	
According	to	literature	the	KD	value	is	in	the	range	between	1-3	nM.191,192	It	is	plausible	to	expect	such	
a	 value	 for	 a	 cleavage	 product	 at	 MRGPRX4	 receptor	 as	 well.	 Our	 experiments	 do	 not	 allow	 the	
calculation	of	a	molar	concentration	because	no	estimate	of	the	amount	of	the	active	moiety	could	
easily	be	made.	Another	aspect	is	often	the	lower	sensitivity	of	the	ß-arrestin	assay	due	to	the	lacking	
of	 the	phenomenon	of	a	“receptor	reserve”.	 It	should	be	mentioned	that	an	 IL-1ß	preparation	was	
further	tested	in	calcium	assays	and	in	a	native	cell	line	expressing	MRGPRX4.	The	result	was	always	
positive,	 which	 indicates	 the	 existence	 of	 a	 real	 agonist	 and	 not	 an	 artifact.	 The	 search	 for	 a	
peptidergic	 ligand	 is	 tedious	 and	 frustrating	 but	 the	 finding	 that	 nateglinide,	 a	 phenylalanine	
derivative,	 is	 an	 agonist	 at	MRGPRX4	 is	 an	 indication	 that	 this	 receptor	might	 be	 activated	 by	 an	
endogenous	peptide.	Nateglinide	shows	some	similarity	to	the	tripeptide	GFL.	GFL	should	be	a	not-










Due	 to	 the	 lacking	 success	 with	 the	 hypothesis-driven	 deorphanization	 approaches,	 further	
compound	 libraries	 (not	 available	 at	 the	 first	 screening	 in	 2012)	 were	 screened;	 these	 were	
compound	 library	 2,	 7,	 8,	 10	 and	 11	 (see	 chapter	 4.10).	 All	 screenings	 were	 performed	 at	 a	 final	
concentration	of	 10	µM	unless	 the	 solubility	 of	 the	 compound	did	not	 allow	 the	 screening	 at	 that	
concentration.	
In	the	compound	library	11	lithocholic	acid	induced	a	signal	but	that	was	probably	an	artifact	since	no	
plateau	 could	 be	 reached	 even	 up	 to	 a	 concentration	 of	 100	 µM	 (data	 not	 shown).	 The	 lipophilic	
nature	 of	 this	 agonist	 could	 be	 responsible	 for	 inducing	 this	 non-specific	 signal.	 In	 the	 natural	







































light-induced	 E/Z-	 isomerization.196,197	 Due	 to	 this	 instability,	 a	 new	 stock	 solution	 of	 MSX-3	 was	
prepared	 and	 a	 concentration-response	 curve	 was	 plotted	 as	 demonstrated	 in	 figure	 39.	 The	
determined	EC50	 value	was	175	±	28	nM.	This	 represented	a	breakthrough	as	 a	 first	 agonist	 and	a	
relatively	potent	one	as	well.	






























did	 not	 show	 any	 inhibition	 of	 human	 NTPDase	 1,	 NTPDase	 2,	 NTPDase	 3,	 NTPDase	 8.	 Thus,	
selectivity	was	ensured.	
Interestingly,	 MSX-3	 is	 prodrug	 of	 an	 A2A	 adenosine	 receptor	 antagonist	 and	 at	 MRGPRX4	 it	 is	 a	
potent	agonist.	This	led	us	to	investigating	the	actual	drug	MSX-2	and	other	related	compounds	like	
MSX-4,	 another	 prodrug	 of	 MSX-2	 coupled	 to	 valine,	 and	 Istradefylline,	 which	 shares	 the	 8-
styrylxanthine	 structure	with	MSX-2198,	 as	 well	 as	 preladenant	 as	 shown	 in	 figure	 40.	 All	 of	 these	
compounds	were	not	active	at	all.	Therefore,	MSX-3	represents	an	active	entity	at	MRGPRX4	and	the	
phosphate	 is	 essential	 for	 the	 agonistic	 activity	 and	 cannot	 be	 replaced	 e.g.	 by	 valine.	 In	 order	 to	
further	our	SAR	understanding,	related	8-ethinylxanthine	derivatives	like	NT	021071,	NT	021033,	NT	
02109,	NT	020052199	(figure	40)	were	screened	and	all	were	inactive.	The	NT	compounds	show	some	
differences	 to	 MSX-3.	 They	 possess	 a	 triple	 bond	 in	 their	 linker	 and	 they	 have	 a	 di-methoxy	
subsituent;	 only	 NT	 021071	 has	 a	 phosphorylated	 substitution	 at	 N3	 of	 its	 xanthine	 moiety.	 The	
inactivity	 could	 be	 due	 to	 the	 additional	 methoxy	 group	 or	 the	 triple	 bond.	 JH	 14021	 was	 an	
interesting	compound	since	its	only	difference	to	MSX-3	is	the	triple	bond	in	its	linker.	Thus,	it	has	no	
light	sensitivity	problem.	This	compound	was	considerably	less	potent	than	MSX-3	with	an	EC50	value	
of	more	 than	 10	 µM,	 and	 its	 efficacy	 was	 also	 lower	 than	 that	 of	MSX-3.	 This	 demonstrated	 the	
importance	of	the	double	bond	being	superior	to	the	triple	bond.	The	decrease	 in	activity	could	be	


























































may	 take	 place.	 Therefore,	 it	was	 decided	 to	 inhibit	 ecto-5ʹ-nucleotidase	 and	 to	 compare	 the	 S/N	







receptor.	 Phosphonates	 instead	 of	 phosphates	 seemed	 to	 be	 the	most	 reasonable	 solution.	 Yet	 it	
was	 not	 easy	 to	 synthesize	 suitable	 derivatives.	 The	 first	 synthesized	 phosphonate,	 JH	 14102,	
















































from	ß-arrestin	assays.	Therefore,	 the	Gq	coupling	was	confirmed.	The	 fraction	of	 IL-1ß	 less	 than	3	
kDa	induced	a	robust	calcium	signal	as	well	(data	not	shown).	
Utilizing	 JH	14102,	 it	was	decided	 to	 investigate	 the	Gs	and	Gi	 coupling	via	 cAMP	assays.	 JH	14102	
could	not	induce	any	cAMP	accumulation	at	1	µM	final	concentration,	which	means	that	MRGPRX4	is	






































Herewith	 it	was	 possible	 to	 confirm	 the	 findings	 of	 Burstein	 et	 al.23	 for	 a	 sole	Gq	 coupling	 using	 a	
potent,	selective	pharmacological	tool	for	the	first	time.	While	conducting	these	experiments,	Kroeze	









More	 than	 one	 series	 of	 compounds	 have	 been	 synthesized	 as	 agonists	 at	MRGPRX4	 receptor.	 It	
should	also	be	noted	that	in	all	assays	from	now	on	a	modified	protocol	for	the	ß-arrestin	assay	has	











Table	 26:	 The	 structures,	 the	 EC50	 values	 and	 S/N	 ratios	 (efficacy)	 of	 the	 synthesized	 compounds	 with	 an	
ethylene	linker		
Compounds	that	have	an	ethylene	linker	























































Table	 27:	 The	 structures,	 the	 EC50	 values	 and	 S/N	 ratios	 (efficacy)	 of	 the	 synthesized	 compounds	 with	 an	
ethenyl	linker	
Compounds	that	have	an	ethenyl	linker	
















































































Table	 28:	 The	 structures,	 the	 EC50	 values	 and	 S/N	 ratios	 (efficacy)	 of	 the	 synthesized	 compounds	 with	 a	
methylene	linker	
Compounds	that	have	a	methylene	linker	(8-benzyl	derivatives)	







































Both	Yazh	449	and	Yazh	496	are	phosphonates	and	 they	 indicate	 that	a	 cyclopentyl	 is	equally	well	
tolerated	 as	 an	 aryl	 group	 if	 the	 linker	 is	 omitted.	 Interestingly,	 Yazh	 449	 showed	 a	 considerably	
weaker	potency	than	MSX-155;	its	phosphate	analog.	This	means	that	the	phosphate	is	necessary	for	
the	compounds	without	a	 linker	whereas	phosphonates	 showed	better	potency	and	efficacy	when	
there	was	 linker	with	 a	 double	 bond	 (MSX-3	 vs.	 JH	 14102).	 This	 could	 implicate	 that	 omitting	 the	
linker	changes	 the	mode	of	binding	of	 the	 ligands	 to	MRGPRX4.	This	hypothesis	and	 its	 interesting	
consequence	were	 confirmed	 later	when	conducting	 calcium	mobilization	assays	 in	 LN229	cell	 line	
(see	chapter	2.4.12).		


















appears	 to	 be	 essential	 for	 the	 activity.	 Both	 compounds	 are	 prodrugs	 and	 after	 hydrolysis	 they	
interact	with	adenosine	receptor.	Addition	of	a	phosphate	to	these	competitive	adenosine	receptors	
ligands	 produced	 potent	 MRGPRX4	 ligands.	 So	 what	 would	 happen	 if	 adenosine	 was	
phosphorylated?	This	approach	results	in	AMP.	Therefore,	AMP	was	screened	at	MRGPRX4	initially	in	
the	 suspension	 format	 of	 the	 calcium	 assay	 at	 1	 mM.	 AMP	 indeed	 induced	 a	 reproducible	 and	
selective	 signal	 at	MRGPRX4	 but	 not	 at	MRGPRX1,	MRGPRX2,	MRGPRX3	 or	 ß-arrestin	 empty	 cells	
(data	 not	 shown).	 AMP	 is	 a	 physiological	 metabolie	 that	 can	 be	 degraded	 by	 several	
ectonucleotidases	and	phosphatases	(see	chapter	2.4.14).	Moreover,	calcium	mobilization	assays	are	
difficult	 to	 conduct	 using	 CHO	 cells.	 Nevertheless,	 AMP	 considerably	 and	 reproducibly	 induced	 a	
signal	at	1	mM,	and	it	was	possible	to	obtain	a	complete	concentration-response	curve	as	shown	in	
figure	45.	The	determined	EC50	value	was	61.7	±	22.7	µM.	
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Testing	 of	 AMP	using	 the	 ß-arrestin	 assay	was	 subsequently	 attempted.	 Screening	 conducted	 at	 1	



































have	 any	 effect	 on	 the	 results	 (data	 not	 shown).	 The	 results	 indicate	 a	 lower	 EC50	 value	 in	 the	 ß-
arrestin	 assay	 than	 in	 the	 calcium	assay.	 This	 is	 unexpected	because	 the	 incubation	 time	 in	 the	ß-
arrestin	assay	 is	 longer.	This	could	 indicate	that	an	optimization	of	calcium	assay	conditions	should	
be	done.	The	ß-arrestin	assays	were	 later	 switched	 to	another	protocol,	 in	which	 the	EC50	value	of	
AMP	was	214	µM	(see	table	30),	which	is	considerably	higher.	Radioligand	binding	experiments	using	
[3H]AMP	 were	 tried	 but	 were	 not	 successful	 probably	 due	 to	 the	 low	 affinity	 of	 the	 radioligand.	
Moreover,	an	unspecific	binding	of	[3H]AMP	to	the	GFB	filters	was	observed	(data	not	shown).	
Next	 we	 investigated	 other	 nucleotides	 and	 related	 compounds.	 ATP,	 ADP,	 cAMP,	 cGMP,	 UMP,	
dAMP	 and	AMPαS	were	 also	 screened	 at	 1	mM	but	were	 not	 active.	GMP	 showed	 an	 increase	 in	
signal	at	1	mM	but	a	complete	curve	could	not	be	plotted.	Several	AMP	derivatives	were	available	for	
screening	at	MRGPRX4	receptor.	All	of	 these	derivatives	were	 inactive	 (no	complete	curve	without	









































The	 results	 showed	 that	only	 8-Br-AMP	 (figure	47)	 is	more	 active	 than	AMP	as	 shown	but	no	 SAR	
analysis	can	be	proposed	at	present	because	no	systematic	ligand	synthesis	of	AMP-derivatives	have	
been	conducted	yet.	




























The	search	 for	a	cell	 line	 that	natively	expresses	MRGPRX4	went	 into	 three	directions	according	 to	








relevant	 publications	 are	 found.202-204	 The	 protocol	 of	 Young	 et	 al.204	 was	 mainly	 adopted	 in	 the	
attempted	differentiation.	Two	different	variations	were	 tried,	 in	which	all	MRGPRX	subtypes	have	
been	detected	on	the	mRNA	 level.	The	 first	protocol	seemed	to	be	more	efficient	 than	the	second	
one	 beauce	 the	 DNA	 bands	 are	 clearer	 at	 the	 same	 number	 of	 qPCR	 cycles	 as	 demonstrated	 in	
figure	48.	 It	 seems	 that	 the	 expression	 is	 restricted	 in	 time	 since	 the	 fixation	 at	 day	 35	 did	 show	













The	 second	 direction	was	 focused	 on	 investigating	MRGPRX4	 in	 the	 immune	 system,	 especially	 in	
CD8+	lymphocytes.114	In	order	to	do	this,	collaboration	with	Prof.	Nattermann	was	started.	The	first	
step	was	to	confirm	the	finding	that	MRGPRX4	is	expressed	in	lymphocytes.	This	was	suggested	to	be	
performed	 by	 fluorescence-activated	 cell	 sorting	 (FACS),	 in	 which	 a	 limited	 number	 of	 cells	 will	
suffice.	 FACS	 is	 advantageous	 because	 these	 lymphocytes	 are	 native	 cells	 isolated	 from	blood	 and	
Western	 bloting	 (WB)	would	 be	more	material	 consuming.	 The	 problem	was	 the	 inavailibility	 of	 a	
commercial	FACS-validated	antibody	(Ab).	Therefore,	an	immunofluorescence	(IF)	Ab	was	employed	










In	order	 to	 confirm	 the	 initial	 data	 the	peripheral	blood	mononuclear	 cells	 (PBMC)	 from	8	healthy	
subjects	were	investigated	via	FACS	and	the	results	showed	that	CD56Bright	NK	cells	have	the	highest	





















are	 difficult	 to	 treat.	 Several	 mRNA	 samples	 of	 glioblastoma	 cell	 lines	 were	 obtained	 from	 Prof.	
Scheffler,	Life	&	Brain	(Bonn),	and	it	was	decided	to	investigate	the	expression	of	MRGPRX	receptors	




Cell	line	 MRGPRX1	 MRGPRX2	 MRGPRX3	 MRGPRX4	 hNT5E	 hGAPDH*	 hß-actin*	
LN229	 >35	 >35	 32.19	 29.57	 27.0	 21.19	 19.35	
T98G	 >35	 >35	 >35	 >35	 31.6	 19.14	 18.52	
U138	 >35	 >35	 >35	 >35	 28.65	 20.80	 17.49	
106Z	 >35	 >35	 >35	 32.67	 28.06	 19.56	 18.14	
46Z	 >35	 >35	 >35	 34.68	 25.04	 19.56	 17.36	





Fortunately,	 the	 group	 of	 Prof.	 Scheffler	 provided	 us	 with	 an	 aliquot	 of	 the	 LN229	 cell	 line.	 This	
enabled	the	investigation	of	MRGPRX4	on	the	protein	level.	The	previously	mentioned	Ab	against	the	
C-terminus	 was	 used.	 Immunofluorescence	 experiments	 in	 an	 overexpressing	 cell	 line	 (ß-arrestin)	
and	the	native	LN229	glioma	cell	 line	were	conducted.	The	results	from	the	overexpressing	cell	 line	
indicate	that	this	Ab	is	able	to	detect	the	receptor	in	a	very	effective	manner.	The	experiment	in	the	


















The	 first	 experiments	were	 conducted	with	a	measurement	 time	of	60	 seconds	per	well.	 Yazh	473	
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robust	 increase	 in	 signal	 up	 to	 19,000	 units,	 which	 is	 comparable	 or	 even	 better	 than	 that	 in	 the	
overexpressing	cell	 lines.	The	120	seconds	per	well	was	initially	adopted	since	the	increase	in	signal	







as	 a	 rule	 of	 thumb:	 a	 confluent	 175	 cm2	 flask	 is	 enough	 for	 1.5	 96-well	 plates.	 The	 time	 of	
measurement	was	later	reduced	to	80	seconds	per	well.	
After	 reaching	 suitable	 conditions,	 several	 compounds	 were	 investigated	 using	 this	 new	 cell	 line.	
These	compounds	have	already	been	characterized	via	ß-arrestin	assay	and	have	been	shown	to	be	
active,	 including	8-Br-AMP,	MSX-3	and	MSX-155,	but	also	newly	 suggested	P2X	 receptor	agonist	 (a	
locked	AMP	analog)	MRS2339	was	also	 tested.205	All	 of	 these	 compounds	were	active	as	 shown	 in	
figure	53.	The	EC50	values	for	MSX-3,	MRS2339	and	8-Br-AMP	were	460	±	13	nM,	257	±	28	and	152	±	
23	µM,	respectively.		





















































































EC50	value	of	11.6	±	1.3	nM	as	demonstrated	 in	figure	54.	 Intriguingly,	 this	value	 is	higher	than	the	
potency	determined	in	the	overexpressing	ß-arrestin	cell	line.	


























































be	 due	 to	 ectonucleotidase/phosphatase	 activities	 in	 this	 cell	 line.	 Ecto-5´-nucleotidase	 is	 more	
highly	expressed	on	the	mRNA	level	in	this	cell	line	than	MRGPRX4	as	shown	in	table	30.	It	was	tried	
to	use	HBSS	buffer	with	50	µM	final	 concentration	of	 the	Ecto-5´-nucleotidase	 inhibitor	AMP-CP	 in	
the	assay	but	this	did	not	have	an	effect	on	the	signal	of	AMP	in	the	calcium	mobilization	assay	(data	
not	shown).	The	active	 fraction	of	 IL-1ß	 induced	a	 robust	signal	at	a	concentration	of	10	µl/100	µl.	
This	 indicates	clearly	that	the	active	moiety	 in	the	IL-1ß	is	not	the	nucleotide,	AMP,	due	to	the	 low	
concentration	in	this	fraction.	ATP	(1	mM)	induced	a	signal,	whereas	adenosine	(1	mM)	and	the	non-









controvertial,	 with	 some	 groups	 suggesting	 no	 sensitization54,101	 and	 other	 groups	 suggesting	 the	






1	µM	 Yazh	 473	 (EC80	 value).	 The	 change	 in	 the	 signal	was	 compared	 to	 the	 signal	 induced	 by	 cell	























































This	observation	 led	us	 to	 shorten	 the	measurement	 time	 to	80	 sec	per	well	 as	mentioned	above.	













































an	 antagonist.	 The	 compound	 libraries	 1,	 2,	 7	 and	 12	 were	 screened	 using	 ß-arrestin	 assay.	
Interestingly,	 several	 hits	 have	 been	 identified	 in	 our	 search,	 which	 indicates	 that	 finding	 an	
antagonist	will	be	easier	 than	 finding	an	agonist.	 In	 the	compound	 library	7	 the	non-steroidal	anti-
inflammatory	 drug	 oxyphenbutazone	 was	 identified208,209;	 in	 the	 compound	 library	 2	 KD162	 and	
KD165	 were	 identified;	 in	 the	 compound	 library	 1,	 the	 serotonin	 receptor	 antagonist	 and	 ß3-










Some	 of	 these	 antagonists	 were	 further	 investigated.	 Oxyphenbutazone	 showed	 an	 IC50	 value	 of	




IC50	 value	 of	 38.6	 µM,	 KD165	 demonstrated	 an	 IC50	 value	 of	 20	 µM.	 SDZ	 220-040	 was	 the	 best	
investigated	 antagonist	 at	 MRGPRX4	 receptor	 in	 calcium	mobilization	 assay	 with	 an	 IC50	 value	 of	
6.36	±	0.96	µM	as	shown	in	figure	59.	



























have	 already	 been	 screened	 at	 the	 related	MRGPRX1	 and	MRGPRX2	 and	 showed	 no	 activity	 (see	





After	 the	 different	 unsuccessful	 deorphanization	 and	 screening	 attempts,	 a	 second	 screening	





us	 to	 test	 related	 compounds	 to	 investigate	 the	 activation	 of	 the	 MRGPRX4	 receptor.	 The	 most	
important	 finding	was	 that	 a	 phosphate	 or	 phosphonate	 is	 essential	 for	 potency.	 Investigating	 the	
linker	of	MSX-3	revealed	that	the	higher	the	rigidity	of	the	linker,	the	lower	were	both	potency	and	
efficacy.	 Thus	 the	 8-ethinylxanthine	 derivative	 JH	 14021	 was	 virtually	 inactive	 and	 the	 8-
styrylxanthine	derivative	MSX-3	was	considerably	more	potent.	Moreover,	the	8-phenethylxanthine	
derivative	 Yazh	 473	 was	 the	 most	 potent	 and	 efficacious	 phosphate	 derivative	 so	 far.	 These	
observations	 are	 tempting	 to	 suggest	 that	 Yazh	473,	due	 to	 the	 linker	with	 an	ethylene	bond,	 can	
rotate	freely	and	bind	with	the	highest	affinity	in	the	binding	pocket	of	the	receptor.	MSX-3	can	only	
form	 E/Z	 isomers	 and	 this	 limited	 flexibility	 is	 responsible	 for	 the	 lower	 potency	 and	 efficacy	
compared	to	Yazh	473.	JH	14021	with	the	rigid	triple	bond	has	the	least	ability	to	fit	into	the	binding	
pocket	 of	 MRGPRX4	 and	 consequently	 the	 lowest	 potency	 and	 efficacy.	 This	 SAR	 is	 particulary	
important	 because	 it	 distinguishes	MRGPRX4	 receptor	 from	 the	 A2A	 receptor,	 for	 which	 both	 the	
double	and	triple	bond	seem	to	have	comparably	high	potency.198,199	MSX-155	was	also	identified	as	
an	 agonist	with	 an	 EC50	 value	 of	 351	 nM.	 This	was	 highly	 unexpected	based	on	 the	 SARs	 of	 other	
agonists	 since	 the	 linker	 is	 omitted	 and	 the	 aryl	 at	 position	 8	 is	 substituted	 by	 a	 cyclopentyl	 ring.	
MSX-155	provides	a	 clue	 that	activating	MRGPRX4	 is	 feasible	without	a	 linker	and	an	 indication	of	
possibly	distinct	interactions	with	the	amino	acids	of	the	receptors.	In	fact,	MSX-155	is	a	prodrug	of	
DPCPX,	a	potent	A1	adenosine	receptor	antagonist.	DPCPX	can	also	bind	to	A2A	adenosine	receptor	
but	with	much	 lower	 affinity.200,216	 The	 ability	 of	 these	 prodrugs	 to	 bind	 to	MRGPRX4	 could	 be	 of	
interest	 for	 a	 future	 mutagenesis	 experiments	 for	 defining	 the	 binding	 pocket	 of	 this	 receptor.	
Phylogenetically	MRGPRX4	is	more	related	to	the	P2Y12	receptor	since	both	are	in	the	δ	group	of	the	
Rhodopsin	 receptor	 family	 of	 the	 7TMR	 tree2,4	 but	 for	 identifying	 the	 binding	 pocket	 not	 only	 the	
P2Y12	X-ray	structure	but	also	those	of	adenosine	A2A	and	possibly	the	A1	receptor	could	be	used	as	a	
template	despite	a	lower	relatedness.	The	rationale	is	the	ability	of	MSX-2	and	DPCPX	to	bind	to	A2A	






to	 represent	 a	 stable	 alternative	 to	 the	 phosphates.	 Thus	 far	 only	 few	 phosphonates	 have	 been	
synthesized	due	to	the	challenging	synthesis	and	purification.	The	phosphonate	JH	14102	exhibited	
the	best	potency	at	MRGPRX4	in	both	ß-arrestin	and	calcium	assay	thus	far.	It	represents	a	valuable	
tool	 in	 investigating	this	orphan	receptor.	A	 future	phosphonate	analog	of	Yazh	473	would	be	very	
interesting.	 Unfortunately,	 such	 an	 analog	 could	 not	 be	 synthesized	 within	 the	 timeframe	 of	 this	










the	 effect	 of	 pertussis	 toxin	 on	 the	 calcium	 signal	 has	 not	 been	 tested,	 which	 could	 be	 a	 further	
confirmation	 of	 the	 sole	 Gq	 coupling.	 Further	 optimization	 of	 the	 calcium	 mobilization	 assay	 is	
urgently	needed	 in	 the	 future.	 The	overexpressing	CHO	ß-arrestin	 cell	 line	was	not	an	optimal	 cell	
line	for	conducting	calcium	assays	because	the	induced	signal	was	weak	and	not	easily	reproducible.	
Therefore,	generating	a	new	cell	 line,	e.g	HEK	cells	overexpressing	MRGPRX4,	 could	 result	 in	more	
reproducible	and	robust	calcium	mobilization	assay	signals.		
Since	the	only	DRG	neuronal	 immortalized	cell	 line	 is	 from	the	rat222,	our	aim	to	 identify	a	cell	 line	







MRGPRX	 receptors	 on	 the	 protein	 level.	 This	 could	 be	 done	 using	 Ab	 for	 an	 IF	 or	WB	 approach.	
Further	steps	could	be	investigating	the	functionality	of	the	receptors	using	a	neuron	calcium	imaging	









an	 expression	 in	 CD8+	 lymphocytes	 as	 described	 previously.114	 Our	 preliminary	 data	 suggest	 that	






dim)	 and	 presence	 or	 absence	 of	 CD16.227	 CD56Bright	NK	 cells	 are	 a	minority	 of	NK	 cells	 in	 blood	
(10%)	 but	 a	 majority	 in	 secondary	 lymphoid	 tissues.	 CD56Bright	 NK	 cells	 are	 abundant	 cytokine	
producers	 but	 exhibit	 a	 weak	 cytotoxicity.228	 The	 wide	 expression	 could	 be	 a	 manifestation	 of	
unknown	 roles	 of	 the	MRGPRX4	 in	 the	 immune	 system,	 which	 have	 yet	 to	 be	 characterized.	 Our	
novel	pharmacological	tools	would	enable	future	 investigation	of	possible	roles	of	MRGPRX4	 in	the	
different	cell	types.	The	expression	in	other	immune	cells	like	macrophages,	mast	cells	and	dendritic	




markers	should	be	 investigated	before	being	able	 to	put	 forward	any	hypothsis	 regarding	a	 role	of	
MRGPRX4	 in	 the	 immune	system.	Another	perspective	 for	a	potential	physiological	 role	could	be	a	
change	 in	 the	 expression	 pattern	 of	MRGPRX4	 in	 immune	 cells	 in	 health	 and	 disease	 (e.g.	 HIV	 or	
HCV).	
Tumor	cell	lines	were	our	last	area	for	searching	a	cell	line	with	native	expression.	The	motive	behind	
this	 search	 was	 the	 finding	 that	 MRGPRX4	 was	 proposed	 as	 a	 candidate	 oncogene	 in	 colorectal	
cancer.113	This	is	apparently	a	vast	area	for	searching	since	more	than	35	human	colorectal	tumor	cell	
lines	 are	 commercially	 available	 according	 to	 the	 ATCC®	 database.	 In	 addition,	 the	 search	 could	
theoretically	 include	all	human	tumor	cell	 lines.	That	could	be	very	time-consuming	and	expensive.	
Luckily,	 the	 glioblastoma	 cell	 line	 LN229	 was	 already	 available	 and	 upon	 investigation	 it	 showed	
positive	 results	 both	 on	 mRNA	 and	 protein	 level.	 The	 LN229	 cell	 line	 is	 usually	 used	 to	 study	
apoptosis.229	
The	 most	 interesting	 aspect	 in	 this	 cell	 line	 was	 the	 excellent	 calcium	 mobilization	 assay	 signal	
regarding	 reproducibility	and	amplitude.	The	 reason	behind	 this	exceptional	 signal	despite	 the	 low	
expression	(see	figure	50)	was	not	clear	but	could	be	due	to	an	efficient	coupling	to	G	protein230	 in	





completely	 lacks	 Gq	 protein	 signaling.	 The	 lack	 of	 G	 protein	 coupling	 implicates	 a	 distinct	 binding	
mode	 to	MRGPRX4	 as	well	 as	 a	 different	 induced	 conformation	 of	 the	 receptor	 compared	 to	 the	
conformation	 induced	by	MSX-3	 and	 related	 compounds.	 The	different	binding	mode	 can,	 in	 turn,	
shed	light	on	SAR	and	explain	the	decreased	potency	of	the	phosphonate	analog	of	MSX-155	(Yazh	
499)	 despite	 the	 increased	 potency	 of	 the	 phosphonate	 analog	 of	 MSX-3	 (JH	 14102).	 All	 these	







arrestin	 signal.	 The	 signal	 bias	 could	 have	 important	 implications	 like	 eliminating	 a	 side-effect.	
Activating	the	ß-arrestin	signal	of	the	opioid	receptors	for	instance	results	in	respiratory	depression.	
Hence,	a	biased	opioid	agonist	towards	the	G	protein	signaling	could	be	advantageous.231,232	On	the	
other	 hand,	 the	 biased	 angiotensin	 ligand	 TRV	 120027	 blocks	 G	 protein	 coupling	 but	 activates	 ß-
arrestin	pathway-bound	benefits	 like	the	increase	in	cardiac	performance.233-235	A	further	possibility	
is	 to	 investigate	 if	 MRGPRX4	 is	 a	 real	 oncogene	 as	 suggested	 by	 Gylfe	 et	 al.	 and	 to	 investigate	
possible	mutations	like	the	proposed	Ser114Arg	and	Ala115Thr113	mutations	(both	at	the	end	of	TM3	
according	 to	 uniprot.org)	 and	 a	 potential	 role	 of	 such	mutations	 in	 increasing	 their	 signaling	 that	





The	 search	 for	 antagonists	was	 initiated	 and	 some	 preliminary	 results	 have	 been	 obtained.	 It	was	
interesting	to	find	several	hits,	although	not	all	available	compound	libraries	have	been	screened	yet.	
This	 is	 an	 advantage	 because	 several	 scaffolds	 could	 be	 obtained	 and	 more	 room	 for	 chemical	
synthesis	 would	 be	 available.	 These	 antagonists	 should	 be	 investigated	 by	 plotting	 concentration-
response	curves	 in	both	ß-arrestin	and	calcium	mobilization	assay.	MSX-155	should	be	 investigated	
as	an	antagonist	in	calcium	assay	only,	as	mentioned	previously.	The	most	interesting	antagonists	for	
now	are	oxyphenbutazone,	 KD165,	 (S)-(-)-Pindolol	 and	 SDZ	220-040.	According	 to	Gaucher	 et	 al.209	
oxyphenbutazone	 reaches	 as	 high	 as	 0.75	µg/ml	 in	 CSF	 i.e	 2.31	 µM,	which	 is	 higher	 than	 the	 EC50	
value	in	the	overexpressing	ß-arrestin	cell	line	of	2.18	µM	but	considerably	lower	than	38.6	µM,	the	




oxyphenbutazone	 is	 an	 analgesic	 and	 anti-inflammatory	 drug.	 However,	 this	 high	 concentration	 in	
CSF	 should	 be	 critically	 judged.	 All	 in	 all,	 it	 is	 tempting	 to	 suggest	 that	 finding	 and	 optimizing	 an	
antagonist	is	possible	but	more	efforts	should	be	done	in	this	direction	in	the	future.	
The	SAR	of	our	new	agonists	 led	us	 to	a	 fourth	and	 last	deorphanization	attempt	of	 the	MRGPRX4	
receptor.	 The	 suggested	 physiological	 ligand	 is	 adenosine	 monophosphate	 (AMP)	 because	 it	
represents	 all	 characteristics	 necessary	 to	 activate	 MRGPRX4	 (adenosine	 plus	 phosphate)	 as	




pronounced	 positive	 selection	 in	 the	 extracellular	 loops	 of	 MRGPRX	 receptors	 that	 has	 been	
previously	reported.21	In	fact,	members	of	MRGPR	receptor	family	have	been	described	as	sequence	
related	 7TMR	 with	 structurally	 dissimilar	 ligands.122	 Nevertheless,	 proving	 AMP	 as	 a	 physiological	
ligand	 is	 a	 very	 formidable	 task	 for	 several	 reasons.	 AMP	has	 already	 been	 screened	 at	MRGPRX4	
receptor	by	DiscoverX®	 in	 their	deorphanization	campaign	and	 failed	 to	be	 identified	as	a	hit.95	No	
precise	concentration,	at	which	AMP	was	screened,	has	been	given	but	the	inability	to	detect	AMP	as	
an	agonist	could	have	been	due	to	the	low	concentration	used	(usually	1	or	10	µM),	which	results	in	
an	 S/N	 ratio	 below	 1.4	 (to	 be	 considered	 as	 a	 hit).	 To	make	matters	worse,	 there	 have	 been	 two	
previous	 deorphanizations	 in	 the	 literature	 proposing	 AMP	 as	 a	 physiological	 ligand.	 GPR99	 was	
suggested	 to	 be	 a	 novel	 nucleotide	 receptor,	 suggested	 to	 be	 renamed	 to	 P2Y15,	 which	 could	 be	
activated	by	both,	adenosine	and	AMP.	[32P]AMP	was	shown	to	bind	GPR99	with	a	Kd	value	of	18.8	
µM.236	This	deorphanization	was	discredited	and	α-ketoglutarate	was	subsequently	shown	to	be	the	
native	 ligand.237-239	 In	 2012	 AMP	 was	 suggested	 to	 activate	 A1	 adenosine	 receptors.240	 	 This	
deorphanization	has	not	been	discounted	in	a	publication	but	results	from	our	lab	indicate	no	binding	
of	 AMP	 to	 A1	 adenosine	 receptor	 (data	 not	 shown).	 Although	 AMP	 was	 reported	 to	 have	




ADP	 or	 ATP,	 all	 of	which	 have	 their	 defined	 7TMRs.245,246	 The	metabolism	 of	 extracellular	 AMP	 to	
adenosine	is	physiologically	regulated	by	different	ecto-phosphohydrolases	like	ecto-5'-nucleotidase	
(NT5E),	 prostatic	 acid	 phosphatases	 and	 more	 than	 one	 type	 of	 alkaline	 phosphatases.247,248	 The	
pattern	of	expression	of	these	enzymes	in	different	tissues	and	cells	represents	a	further	complexity	
for	 determining	 a	 role	 for	 AMP.	 Among	 the	 AMP-degrading	 phosphatases,	 NT5E	 is	 the	 best	
investigated	one	and	the	rate-limiting	enzyme	in	generating	extracellular	adenosine.	NT5E	has	a	Km	
value	in	the	lower	micromolar	range.247	NT5E	is	upregulated	by	IL-1ß,	TNF-α	and	downregulated	by	
INF-γ	 and	 IL-4.249,250	 Therefore,	 it	 would	 be	 useful	 to	 look	 at	 its	 expression	 in	 the	 DRG,	 immune	
system	and	tumor	cells	(the	three	areas	natively	expressing	MRGPRX4	that	were	found	in	this	thesis).	
In	the	DRG	it	was	found	that	the	small	diameter	neurons	(peptidergic	and	non-peptidergic)	express	
NT5E	 and	 that	 this	 enzyme	 is	 responsible	 for	 regulating	 AMP	 in	 nociceptive	 circuits	 and	 thus	
inhibiting	 pain	 by	 producing	 adenosine.251,252	 In	 the	 immune	 system,	 NT5E	 is	 a	 known	maturation	
marker	of	T	and	B	cells	and	has	also	been	found	in	many	other	 immune	cells.114,247,253	 Interestingly,	
the	 expression	 of	 this	 enzyme	 in	 CD56bright	 NK	 cells	 has	 recently	 been	 described.	 The	 role	 of	
CD56bright	cells	as	cytokine	releasers	has	already	been	reported	but	there	are	indications	that	these	
cells	 play	 a	 regulartory	 role	 in	 the	 immune	 system.	 Morandi	 et	 al.	 proposed	 this	 regulatory	 role	
(inducing	 proliferation	 of	 CD4+	 T-cells)	 to	 be	 mediated	 via	 adenosine	 receptors.	 To	 address	 this	
hypothesis,	 the	 expression	 of	 NT5E	 and	 its	 ability	 to	 efficiently	 degrade	 AMP	 to	 adenosine	 was	
demonstrated	in	these	cells	in	contrary	to	CD56dim	cells.	Moreover,	patients	with	juvenile	idiopathic	
arthritis	showed	CD56bright	NK	cells	with	a	reduced	NT5E	activity	and	adenosine	production	in	the	
synovial	 fluid.254	Chatterrjee	et	al.	proposed	that	the	percentage	of	NT5E-expressing	NK	cells	 is	 low	
(ca.	1%)	but	upon	contact	with	mesenchymal	 stem	cells	 the	NT5E-expressing	NK	cells	 increased	 to	
10%	and	the	ability	to	degrade	AMP	increased	as	well.	Therefore,	a	subpopulation	of	NK	cells	aquire	



















The	 International	 Union	 of	 Basic	 and	 Clinical	 Pharmacology	 (IUPHAR)	 published	 recently	
recommendations	 for	 deorphanizing	 a	 7TMR.	 The	 deorphanization	 should	 ideally	 include	 a	
radioligand	 binding	 assay	 plus	 functional	 assays,	 both	 in	 vitro	 and	 in	 native	 tissues.	 The	 putative	
ligand	should	be	present	in	the	tissues	in	appropriate	concentration.	Further	evidence	could	be	from	
anatomical	 level,	 and	plausible	mechanisms	 for	 ligand	 to	 reach	physiological	 concentrations	 in	 the	
tissues.	Deleting	the	gene	encoding	the	receptor	in	mice,	exploiting	a	naturally	occurring	deletion	in	
human	tissues,	or	RNA	silencing	should	abolish	receptor	characteristics,	such	as	radioligand	binding	
or	 physiologic	 and/or	 pharmacological	 actions	 of	 the	 endogenous	 ligand	 in	 functional	 assays.	
Conversely,	receptor	overexpression	may	be	expected	to	potentiate	these	actions.267	Since	AMP	as	a	
radioligand	did	not	work	due	to	its	too	low	affinity	(see	chapter	2.4.11),	it	is	possible	to	show	binding	
using	 another	potent	 ligand.	We	have	performed	 two	 functional	 assays	 in	 an	 artificial	 system	 that	




concentration	of	AMP	 in	 the	DRG,	 the	microenvironment	of	 tumor	or	on	 the	surface	of	NK	cells	 in	
secondary	lymphoid	tissues	is	difficult	to	measure.	In	the	literature,	AMP	in	the	plasma	was	reported	
to	be	between	1.3	to	0.6	µM.268,269	The	concentration	of	AMP	in	the	CSF	according	to	Eells	et	al.	is	<	





concentration	 at	 the	 site	 of	 action.	 Another	 point	 is	 the	 inability	 to	 perform	 calcium	moblilization	
assays	using	AMP	in	the	native	LN229	cell	line	because	the	signal	was	detected	only	at	1	mM.	These	
are	formidable	barriers	for	a	deorphanization	proposing	AMP	as	a	cognate	ligand.	Nevertheless,	our	
deorphanization	proposal	 could	 be	 substantiated.	 The	 first	 step	 is	 to	 develop	 a	 radioligand	 and	 to	
demonstrate	a	specific	binding	of	AMP	at	MRGPRX4	receptors.	The	phosphonate	analog	of	Yazh	473	
could	 be	 a	 suitable	 candidate.	 The	 second	 step	 is	 to	 synthesize	 a	 non-hydrolysable	 phosphonate	
analog	 of	 AMP,	 for	 which	 the	 EC50	 should	 be	 determinable.	 Such	 a	 compound	 can	 be	 a	 plausible	
argument.	For	now	8-Br-AMP	seems	to	be	the	most	potent	AMP-derivative.	It	would	be	plausible	to	
systematically	 synthesize	 such	derivatives	with	 small	modifications	of	AMP,	 in	a	 similar	way	 to	 the	
adenine	 derivatives,273	 because	 they	 would	 probably	 not	 be	 degraded	 as	 efficiently	 as	 the	
physiological	AMP.	The	third	step	is	to	find	a	physiological	function	for	native	MRGPRX4	which	could	
be	 induced	by	AMP	or	a	very	similar	derivative	of	AMP	and	then	to	demonstrate	that	this	 function	
could	 be	 abolished	 via	 a	 selective	 antagonist	 (unfortunately	 till	 now	 we	 do	 not	 have	 one)	 or	 via	
siRNA.	 Lymphocytes	 could	 be	 candidates	 for	 a	 physiological	 function	 like	 increasing	 the	 release	 of	
cytokines,	 and	 LN229	 cells	 could	 also	 be	 candidates	 for	 proliferation	 assays	 or	 inducing	 apoptosis.	









elucidating	 the	 (patho)physiological	 roles	 of	 these	 receptors.	 In	 this	 PhD	 thesis	 the	 four	 human	
MRGPRX	 receptors	were	pharmacologically	 investigated.	The	primary	assay	employed	 in	 this	 study	
was	 the	 ß-arrestin	 assay	 using	 ß-galactosidase	 complementation	 due	 to	 its	 high	 specificity	 for	 the	
expressed	 receptor.	 Additional	 assays	 like	 calcium	mobilization	 and	 cAMP	 accumulation	were	 also	
employed.	
MRGPRX1	 is	 the	 best	 investigated	member	 of	 the	MRGPRX	 subfamily	 of	 7TMRs.	Our	 efforts	were	
focused	 on	 screening	 several	 compound	 libraries	 in	 order	 to	 identify	 new	 antagonists	 for	 this	
receptor	 subtype.	 Only	 one	 compound,	 MIRA-1,	 was	 found	 to	 have	 an	 antagonistic	 activity	 at	
MRGPRX1	 in	the	performed	ß-arrestin	assays.	However,	 the	chemical	structure	(instable	ester)	and	
the	 steep	 concentration-response	 curve	 made	 us	 refrain	 from	 further	 investigation	 of	 this	 hit	








an	 establishment	 of	 SARs	 and	 to	 successive	 optimization	 of	 the	 parent	 compound.	 The	 best	
antagonist	so	far	(CD63)	exhibited	an	IC50	value	of	6.38	nM	as	shown	in	figure	60.	The	mode	of	action	
of	 these	 antagonists	 was	 determined	 to	 be	 competitive	 versus	 CST-14.	 In	 addition,	 initial	
pharmacokinetic	data	of	the	best	three	antagonists	were	determined.	Lastly,	the	recently	proposed	






































antagonists	 may	 contribute	 as	 tool	 compounds	 to	 expand	 the	 research	 and	 deepen	 the	
understanding	of	this	receptor	and	its	functions.	These	antagonists	could	be	of	crucial	importance	for	
animal	 experiments	 if	 they	 keep	 their	 affinity	 for	 the	 murine	 MRGPRB2	 receptor.	 In	 the	 future,	
further	 improvement	 could	 result	 in	 compounds	 with	 improved	 properties.	 Some	 issues	 like	 low	
water	solubility,	and	metabolic	instability	have	to	be	addressed.	Developing	a	radioligand	should	not	




The	MRGPRX3	receptor	 is	an	orphan	receptor	with	no	reported	pharmacological	 tool	 for	now.	This	











of	 this	 thesis	 resulted	 in	 no	 progress	 until	 MSX-3	 was	 identified	 as	 an	 artificial	 agonist.	 Related	
compounds	 subsequently	 were	 tested	 and	 initial	 SARs	 were	 established.	 Our	 efforts	 led	 to	 the	
optimization	 of	 both,	 efficacy	 and	 potency	 of	 the	 agonists.	 The	 best	 stable	 phosphonate	 agonist,	
JH	14102,	 shows	 EC50	 values	 in	 the	 nanomolar	 range	 in	 both,	 ß-arrestin	 and	 calcium	mobilization	
assays.	 Using	 these	 agonists	 we	 demonstrated	 only	 Gq	 coupling	 for	 this	 7TMR.	 Further	 synthesis	
resulted	in	the	phosphate	derivative	Yazh	473,	which	demonstrated	the	best	signal-to-noise	ratio	in	
the	ß-arrestin	assay	so	far	 indicating	high	efficacy	of	the	compound.	For	a	deeper	understanding	of	





an	 evidently	 invaluable	 tool	 for	 investigating	 MRGPRX4,	 which	 enabled	 us	 to	 demonstrate	 the	
susceptibility	 of	 this	 7TMR	 to	 agonist-induced	 desensitization	 and	 endocytosis.	Moreover,	 calcium	
mobilization	 assays	 showed	 a	 high	 signal	with	 efficient	 Gq	 coupling.	 These	 natively	 expressing	 cell	
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of	 AMP	 and	 regarding	 physiological	 and	 pathophysiological	 concentration	 of	 this	 nucleotide.	 In	
addition,	 improving	 the	 potency	 of	 our	 agonists	 with	 the	 goal	 to	 prepare	 a	 radioligand	 should	 be	
pursued.		


































































Istradefylline	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
JH	14102,	JH	14021	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	








MSX-2,	MSX-3,	MSX-4,	MSX-155	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
NECA		 Sigma-Aldrich,	E2387	





































































































































mM),	 0.185	 g	CaCl2	 (1.25	mM),	 0.35	 g	NaHCO3	 (4.2	mM),	 0.4	 g	KCl	 (5.4	mM),	 0.06	 g	KH2PO4	 (0.44	















aliquots	 and	 these	 aliquots	 were	 stored	 in	 -20°C.	 The	 preparation	 should	 be	 done	 under	 light	
protection	since	Oregon	Green	is	light-sensitive.	
Fluo-4	AM	Solution	









242	 g	 TRIS	 (2	M),	 14.61	 g	 EDTA	 (50	mM)	 and	 57.1	ml	 acetic	 acid	 (glacial)	 are	 added	 to	 deionized	














PathHunter®	 CHO-K1	 MRGPRX1	 β-Arrestin	 Cell	
Line	
DiscoveRx,	93-0919C2	
PathHunter®	 CHO-K1	 MRGPRX2	 β-Arrestin	 Cell	
Line	
DiscoveRx,	93-0309C2	
PathHunter®	 CHO-K1	 MRGPRX3	 β-Arrestin	 Cell	
Line	
Cloned	within	this	thesis	
PathHunter®	 CHO-K1	 MRGPRX4	 β-Arrestin	 Cell	
Line	
DiscoveRx,	93-0541C2A	






































passed	 into	 new	 flasks.	 This	 is	 done	 by	 decanting	 the	 medium	 and	 rinsing	 the	 cells	 with	 PBS	 to	
remove	residual	medium.	A	0.05	%	trypsin	/	0.6	mM	EDTA	solution	is	added	and	cells	are	incubated	
for	 3-5	 minutes	 at	 37	 °C.	 In	 order	 to	 adhere	 to	 surfaces	 cells	 require	 integrin	 structures.	 These	
structures	are	digested	by	 trypsin	which	belongs	 to	 the	 family	of	 serine	proteases.	 In	addition,	 the	
concentration	 of	 divalent	 cations	which	 are	 crucial	 for	 integrin	 stability	 is	 reduced	 by	 EDTA.	Once	







via	 a	 detachment	 buffer	 without	 trypsin.	 Hence,	 PBS	 buffer	 containing	 2	 mM	 EDTA	 and	 10	 mM	
Glucose	was	used	in	this	case.	
4.2.2	Membrane	preparation	





dish.	 Once	 the	 content	 of	 all	 dishes	 is	 unified	 in	 a	 beaker,	 the	 cell	 suspension	 is	 treated	 with	 an	
ultraturrax	for	1	min	at	24,000	/	min	and	homogenized	via	a	dounce	homogenizer	subsequently.	To	
remove	nuclei	and	other	 larger	organelles	and	cell	debris	 the	homogenate	 is	centrifuged	at	1000	g	
for	10	min	(4	°C).	The	supernatant	is	collected	and	centrifuged	at	48,400	g	for	1	h	(4	°C).	The	resulting	


















































DNA	 midipreparation:	 	 Invitrogen™,	 PureLink™	 HiPure	 Plasmid	 Filter	 Purification	 Kits.	 The	
components	 of	 the	 kit	 were	 resuspension	 buffer	 with	 RNase	 A,	 Lysis	 buffer,	 precipitation	 buffer,	






Both	mini-	 and	midipreparations	 aim	 at	 extracting	 the	 plasmid	 DNA	 from	 the	 bacteria.	 The	most	
utilized	principle	is	the	alkaline	lysis	of	the	bacterial	cell	wall.	
DNA-Recovery:	ZYMO	RESEARCH	CORP.	Zymoclean™	Gel	DNA	Recovery	Kit.	This	kit	is	used	to	extract	











































































restriction	 enzymes	 (bold)	 used	 for	 each	 gene	 as	 well	 as	 the	 recognition	 sites	 of	 these	 enzymes	
(underlined).	 The	 pCMV-ProLink™	 series	 are	 suitable	 for	 subcloning	 the	 7TMR	 of	 interest	 and	 the	
resulting	plasmid,	when	expressed	in	a	mammalian	cell,	will	have	a	ProLink	tag	on	the	C-terminus	of	
the	 7TMR.	 It	 is	 important	 to	 design	 the	 primer	 sothat	 the	 stop	 codon	 of	 the	 7TMR	 is	 omitted.	
Moreover,	the	7TMR	should	be	in	frame	with	the	ProLink	tag.	
The	gene	and	the	vector	of	interest	were	then	digested	with	the	restriction	endonuclease	enzymes.	
The	 total	 volume	was	 20	µl	 and	 the	 reaction	was	 performed	 according	 to	 the	manufacturer	 (New	
England	 Biolabs)	 protocol	 for	 1	 hour	 in	 the	 room	 temperature.	 The	 digested	 genes	 were	 then	
subjected	to	the	gel	electrophoresis	 in	order	to	separate	them	from	the	restriction	enzymes	and	to	























loading	dye	are	 loaded	 into	the	pockets	and	the	gel	 is	run	at	a	100	V.	DNA	bands	are	visualized	by	
exposure	to	UV	light	using	the	Bio-Rad	Gel	doc	system.	
4.3.7	LB	medium	
25	 g	 of	 LB	 medium	 are	 dissolved	 in	 1	 l	 deionized	 water	 according	 to	 manufacturer’s	 protocol.	




E.Coli	 genotype	 TOP10	was	 used,	 from	which	 50	 μl	 of	 a	 glycerol	 culture	 were	 given	 into	 4	ml	 LB	


























either	 from	 agar	 colonies	 or	 previous	 bacterial	 cultures	 and	 transferred	 to	 the	 desired	 amount	 of	
medium.	Cultures	are	then	incubated	at	37	°C	and	220	rpm	overnight.	
4.3.11	Sequencing	
All	 sequencing	 analyses	 were	 performed	 by	 GATC	 Biotech	 AG,	 Germany.	 Samples	 were	 prepared	
according	to	the	manufacture’s	specifications.	
4.3.12	Glycerol	Stocks	























In	 general,	 lipofection	with	 LipofectamineTM	 2000	was	 performed	 according	 to	 the	manufacturer’s	
protocol,	 as	 described	 in	 the	 following:	 one	 day	 before	 transfection,	 1-2	 106	 cells	were	 seeded	 in	
seeding	medium	using	25	cm2	flask	and	cultivated	over	night	 (1).	On	the	following	day,	 the	culture	
medium	was	exchanged	against	F12	plus	FCS	(no	antibiotic)	several	hours	before	transfection	(2).	In	a	
tube	 600	 µl	 LipofectamineTM	 2000	 was	 added	 to	 25	 µl	 F12	 without	 any	 supplements,	 mixed	 by	
inverting	and	 incubated	 for	5	min	 (3).	 In	 the	meanwhile,	 the	DNA	solution	 (containing	10	µg	DNA)	
was	prepared	by	adding	the	required	amount	of	DNA	into	F12	without	any	supplement	in	a	second	
tube	sothat	the	final	volume	is	625	µl	(4).	Subsequently,	the	LipofectamineTM	2000	solution	was	given	




























µM	was	 used	 to	 determine	 the	 unspecific	 binding.	 The	 incubation	 time	was	 60	minutes.	 The	 final	
concentration	of	the	radioligand	was	10	nM.	The	filtration	took	place	under	reduced	pressure	over	


















The	 β-arrestin	 recruitment	 assay	 is	 based	 on	 the	 detection	 of	 the	 interaction	 of	 a	 7TMR	 with	 β-
arrestin	 by	 β-galactosidase	 fragment	 complementation	 (β-arrestin	 Path	 Hunter	 assay,	 DiscoverX,	
Fremont,	 CA,	 U.S.A.).	 The	 7TMR	 of	 interest	 is	 fused	 to	 the	 ProLink	 tag,	 the	 N-terminal	 part	 of	 β-
galactosidase,	 and	β-arrestin	 is	 fused	 to	 the	enzyme	acceptor,	which	 is	β-galactosidase	 lacking	 the	
first	41	amino	acids.	Upon	receptor	activation,	β-arrestin	is	recruited	to	the	receptor	which	leads	to	





the	 cells	 in	 a	 volume	 of	 10	 μL,	 followed	 by	 incubation	 for	 90	min	 at	 37	 °C.	 For	 determination	 of	




used.	 During	 the	 incubation	 period,	 the	 detection	 reagent	 was	 prepared.	 For	 determination	 of	 β-
arrestin	 recruitment	 the	 detection	 reagent	 for	 the	 respective	 receptor	 was	 prepared	 (see	 below).	
After	 the	 addition	 of	 50	 μL/well	 detection	 reagent	 to	 the	 cells,	 the	 plate	 was	 incubated	 for	 an	
additional	 60	 min	 at	 room	 temperature.	 Finally	 luminescence	 was	 determined	 in	 a	 luminometer	
(TopCount	NXT,	Packard/Perkin-Elmer).	
For	 the	determination	of	antagonistic	properties	of	 tested	compounds	the	assay	was	performed	as	














Cells	 were	 removed	 from	 a	 confluent	 175-cm2	 flask,	 transferred	 into	 a	 50-ml	 Falcon	 tube,	 and	
centrifuged	at	200g,	for	5	minutes.	After	removal	of	the	supernatant,	the	cell	pellet	was	resuspended	
in	DMEM-F12	medium.	The	cell	suspension	(500	µl,	∼200,000	cells	per	well)	was	transferred	to	24-
well	 plates	 and	 incubated	 for	 24	 hours	 at	 37°C.	 After	 removal	 of	 the	 culture	medium,	 cells	 were	
washed	 HBSS	 buffer	 and	 then	 incubated	 with	 230	 µl	 HBSS	 buffer	 for	 2	 h	 at	 37°C.	 The	
phosphodiesterase	 inhibitor	Ro20-1724	 (final	 concentration	40	μM)	dissolved	 in	100%	HBSS	buffer	
was	added	 to	each	well	and	 incubated	 for	10	min.	Thereafter,	25	μl	of	 the	agonist	was	added	and	
incubated	for	20	min.	After	incubation	with	the	agonist,	the	final	DMSO	concentration	did	not	exceed	
1.4%.	For	investigating	the	Gi	coupling	cAMP	production	was	stimulated	by	addition	of	forskolin	(final	




nM	final	concentration)	 in	 lysis	buffer	and	40	μl	of	cAMP-binding	protein	 in	the	same	buffer	(75	μg	
protein	 per	 vial)	 were	 added.	 Total	 binding	 was	 determined	 with	 50	 μl	 of	 lysis	 buffer,	 30	 μl	 of	
[3H]cAMP	solution,	and	40	μl	of	cAMP-binding	protein	containing	solution.	Nonspecific	filter	binding	
was	determined	with	90	μl	of	lysis	buffer	and	30	μl	of	[3H]cAMP	solution.	For	a	cAMP	standard	curve,	





















room	 temperature	 under	 light	 protection.	 In	 the	mean	 time	 a	 dilution	 of	 the	 test	 compound	was	
prepared.	Fluorescence	intensity	was	measured	at	520	nm	for	60	s	at	0.4	s	intervals.	PBS	was	used	as	




ml	 using	 the	 culture	medium.	 The	 volume	 of	 cell	 suspension	 corresponding	 to	 5	million	 cells	 was	
transferred	into	a	sterile	solution	basin	and	sufficient	nutrient	medium	added	to	give	a	final	volume	
of	21	ml.	Using	an	8-channel	pipette	and	sterile	filtered	tips,	200	µl	of	cell	suspension	were	pipetted	
into	 each	well	 of	 a	 sterile	 96-well	 corning	 3340	microplate	with	 clear	 bottom	 and	 incubated	 over	
night	(37	°C,	5	%	CO2,	96	%	rel.	humidity).	
The	 cells	 at	 the	 bottom	 of	 the	 96-well	 microplate	 were	 examined	 under	 a	 microscope.	 If	 they	
appeared	viable,	the	experimental	set-up	was	proceeded	with	by	inverting	the	microplate	on	tissue	











2	 µl	 of	 the	 antagonist	 dilution	 and	 the	 microplate	 incubated	 at	 room	 temperature	 under	 light	
exclusion.	During	this	time,	the	reagent	plate	was	prepared	by	pipetting	40	µl	of	Yazh	473	solution	
(5.32	µM)	or	HBSS	buffer	into	each	well	of	a	V-shaped	96-well	microplate.	For	agonist	assays,	180	µl	
HBSS	buffer	were	 transferred	 into	wells	and	 the	serial	dilution	of	 the	agonist	was	prepared	 in	a	V-




example.170,171	 In	 the	 case	 of	 the	 less	 pure	 IL-1ß,	 the	 5	 µg	 of	 IL-1ß	 were	 dissolved	 in	 water	 and	
subjected	 to	 filtration	 using	 a	 3	 kDa	 cutoff	 Amicon®	 Ultra	 according	 to	 the	 instructions	 of	 the	





see	 chapter	 2.4.5).	 The	 solution	 was	 then	 filtrated	 using	 a	 3	 kDa	 cutoff	 Amicon®	 Ultra.	 The	 two	









Number	 Name	 Composition	 Characteristics	
1	 TOCRIS	 1120	 small	molecules	with	proven	
physiological	activities	
2	 Xanthine	 352	 Drug-like	xanthine	derivatives	
3	 ChemBridge	 689	 Drug-like	small	molecules	
4	 ChemDiv	 555	 Drug-like	small	molecules	
5	 Herdewijn	 354	 Drug-like	small	molecules	
6	 Interbioscreen	 346	 Drug-like	small	molecules	
7	 Approved	drugs	 440	 Commercially	available	approved	
drugs	
8	 Dipeptides	 53	 Nitrile	amino	acid	derivatives	
9	 Briel	and	RaghuPrasad	 38	 Drug-like	small	molecules	
10	 Natural	products	 88	 Natural	products	with	reported	
physiological	activity		
11	 Lipid	 49	 Lipids	with	reported	physiological	
activity	





























































































































3. Oldham,	 W.M.;	 Hamm,	 H.E.	 Heterotrimeric	 G	 protein	 activation	 by	 G-protein-coupled	
receptors.	Nat.	Rev.	Mol.	Cell.	Biol.	2008,	9,	60-71	










10. Adams,	 J.L.;	 Smothers,	 J.;	 Srinivasan,	 R.;	 Hoos,	 A.	 Big	 opportunities	 for	 small	 molecules	 in	
immuno-oncology.	Nat.	Rev.	Drug	Discov.	2015,	14,	603-22	
11. van	 Hecke,	 O.;	 Austin,	 SK.;	 Khan,	 R.A.;	 Smith,	 BH.;	 Torrance,	 N.	 Neuropathic	 pain	 in	 the	
general	population:	a	systematic	review	of	epidemiological	studies.	Pain	2014,	155,	654-62	
12. Calvo,	M.;	Dawes,	 J.M.;	 Bennett,	D.L.	 The	 role	 of	 the	 immune	 system	 in	 the	 generation	of	
neuropathic	pain.	Lancet	Neurol.	2012,	11,	629-42	
13. Torrance,	 N.;	 Smith,	 B.H.;	 Bennett,	 M.I.;	 Lee,	 A.J.	 The	 epidemiology	 of	 chronic	 pain	 of	
predominantly	neuropathic	origin.	Results	from	a	general	population	survey.	J.	Pain	2006,	7,	
281-9	
14. Sacerdote,	 P.;	 Franchi,	 S.;	Moretti,	 S.;	 Castelli,	M.;	 Procacci,	 P.;	Magnaghi,	 V.;	 Panerai,	 A.E.	




16. Xiao,	 B.;	 Patapoutian,	 A.	 Scratching	 the	 surface:	 a	 role	 of	 pain-sensing	 TRPA1	 in	 itch.	Nat.	
Neurosci.		2011,	14,	540-2	
17. Dong,	 X.;	 Han,	 S.K.;	 Zylka,	 M.J.;	 Simon,	 M.I.;	 Anderson,	 D.J.	 A	 Diverse	 Family	 of	 GPCRs	
Expressed	in	Specific	Subsets	of	Nociceptive	Sensory	Neurons.	Cell,	2001,	106,	619–632	
18. Lembo,	P.M.;	Grazzini,	E.;	Groblewski,	T.;	O'Donnell,	D.;	Roy,	M.O.;	Zhang,	J.;	Hoffert,	C.;	Cao,	















23. Burstein,	 E.S.;	 Otto,	 T.R.;	 Feddock,	 M.;	 Ma,	 J.N.;	 Fuhs,	 S.;	 Wong,	 S.;	 Schiffer,	 H.H.;	 Braun,	
M.R.;	Nash,	N.R.	Characterization	of	 the	Mas-related	gene	 family:	 structural	 and	 functional	
conservation	of	the	human	and	rhesus	MrgX	receptors.	Br.	J.	Pharmacol.	2006,	147,	73-82	
24. Zylka	 MJ,	 Dong	 X,	 Southwell	 AL,	 Anderson	 DJ.	 Atypical	 expansion	 in	 mice	 of	 the	 sensory	
neuron-specific	 Mrg	 G	 protein-coupled	 receptor	 family.	 Proc.	 Natl.	 Acad.	 Sci.	 2003,	 100,	
10043-8	
25. Molliver,	 D.C.;	 Wright,	 D.E.;	 Leitner,	 M.L.;	 Parsadanian,	 A.S.;	 Doster,	 K.;	 Wen,	 D.;	 Yan,	 Q.;	















Q.	 Mechanisms	 of	 compartmentalized	 expression	 of	 Mrg	 class	 G-protein-coupled	 sensory	
receptors.	J.	Neurosci.	2008,	28,	125-32	
32. Liu,	Q.;	 Tang,	 Z.;	 Surdenikova,	 L.;	 Kim,	 S.;	 Patel,	 K.N.;	 Kim,	A.;	 Ru,	 F.;	Guan,	 Y.;	Weng,	H.J.;	
Geng,	 Y.;	 Undem,	 B.J.;	 Kollarik,	 M.;	 Chen,	 Z.F.;	 Anderson,	 D.J.;	 Dong,	 X.	 Sensory	 neuron-
specific	GPCRs	Mrgprs	are	 itch	receptors	mediating	chloroquine-induced	pruritis.	Cell	2009,	
7,	1353-65	
33. Wilson,	 S.R.;	 Gerhold,	 K.A.;	 Bifolck-Fisher,	 A.;	 Liu,	 Q.;	 Patel,	 K.N.;	 Dong,	 X.;	 Bautista,	 D.M.		







36. Shinohara,	 T.;	 Harada,	 M.;	 Ogi,	 K.;	 Maruyama,	 M.;	 Fujii,	 R.;	 Tanaka,	 H.;	 Fukusumi,	 S.;	
Komatsu,	 H.;	 Hosoya,	 M.;	 Noguchi,	 Y.;	 Watanabe,	 T.;	 Moriya,	 T.;	 Itoh,	 Y.;	 Hinuma,	 S.	
Identification	of	a	G	protein-coupled	receptor	specifically	responsive	to	beta-alanine.	J.	Biol.	
Chem.	2004,	279,	23559-64	
37. Lautner,	 R.Q.;	 Villela,	 D.C.;	 Fraga-Silva,	 R.A.;	 Silva,	 N.;	 Verano-Braga,	 T.;	 Costa-Fraga,	 F.;	
Jankowski,	 J.;	 Jankowski,	 V.;	 Sousa,	 F.;	 Alzamora,	 A.;	 Soares,	 E.;	 Barbosa,	 C.;	 Kjeldsen,	 F.;	
Oliveira,	A.;	Braga,	J.;	Savergnini,	S.;	Maia,	G.;	Peluso,	A.B.;	Passos-Silva,	D.;	Ferreira,	A.;	Alves,	
F.;	Martins,	A.;	Raizada,	M.;	Paula,	R.;	Motta-Santos,	D.;	Klempin,	F.;	Pimenta,	A.;	Alenina,	N.;	
Sinisterra,	 R.;	 Bader,	 M.;	 Campagnole-Santos,	 M.J.;	 Santos,	 R.A.	 Discovery	 and	











40. von	 Kügelgen,	 I.;	 Schiedel,	 A.C.;	 Hoffmann,	 K.;	 Alsdorf,	 B.B.;	 Abdelrahman,	 A.;	Müller,	 C.E.	
Cloning	and	 functional	 expression	of	 a	novel	Gi	protein-coupled	 receptor	 for	 adenine	 from	
mouse	brain.	Mol.	Pharmacol.	2008,	73,	469-77	
41. Thimm,	 D.;	 Knospe,	 M.;	 Abdelrahman,	 A.;	 Moutinho,	 M.;	 Alsdorf,	 B.B.;	 von	 Kügelgen,	 I.;	
Schiedel,	A.C.;	Müller,	C.E.	Characterization	of	new	G	protein-coupled	adenine	 receptors	 in	
mouse	and	hamster.	Purinergic	Signal.	2013,	9,	415-26	
42. Han,	 S.K.;	 Dong,	 X.;	 Hwang,	 J.I.;	 Zylka,	M.J.;	 Anderson,	D.J.;	 Simon,	M.I.	Orphan	G	protein-
coupled	 receptors	 MrgA1	 and	 MrgC11	 are	 distinctively	 activated	 by	 RF-amide-related	
peptides	through	the	Galpha	q/11	pathway.	Proc.	Natl.	Acad.	Sci.		2002,	99,	14740-5	
43. Grazzini,	E.;	Puma,	C.;	Roy,	M.O.;	Yu,	X.H.;	O'Donnell,	D.;	Schmidt,	R.;	Dautrey,	S.;	Ducharme,	









46. Hook,	V.;	Funkelstein,	L.;	 Lu,	D.;	Bark,	S.;	Wegrzyn,	 J.;	Hwang,	S.R.	Proteases	 for	processing	







enkephalins	 from	bovine	adrenal	medulla:	purification	and	 structure	of	docosa-	 (BAM-22P)	
and	 eicosapeptide	 (BAM-20P)	 with	 very	 potent	 opiate	 activity.	 Biochem.	 Biophys.	 Res.	
Commun.	1980,	97,	1283-90	
50. Davis,	 T.P.;	 Hoyer,	 G.L.;	 Davis,	 P.;	 Burks,	 T.F.	 Proenkephalin	 A-derived	 peptide	 E	 and	 its	
fragments	alter	opioid	contractility	in	the	small	intestine.	Eur.	J.	Pharmacol.	1990,	191,	253-
61	





Aunis,	 D.;	 Metz-Boutigue,	 M.H.	 The	 C-terminal	 bisphosphorylated	 proenkephalin-A-(209-





related	 gene-X1	 receptors	 resist	 agonist-promoted	 endocytosis.	Mol.	 Pharmacol.	 2010,	 2,	
249-59	
55. Kunapuli,	P.;	Lee,	S.;	Zheng,	W.;	Alberts,	M.;	Kornienko,	O.;	Mull,	R.;	Kreamer,	A.;	Hwang,	JI.;	









58. Hong,	 Y.;	 Dai,	 P.;	 Jiang,	 J.;	 Zeng,	 X.	 Dual	 effects	 of	 intrathecal	 BAM22	 on	 nociceptive	
responses	 in	 acute	 and	 persistent	 pain--potential	 function	 of	 a	 novel	 receptor.	 Br.	 J.	
Pharmacol.	2004,	141,	423-30	
59. Cai,	M.;	Chen,	T.;	Quirion,	R.;	Hong,	Y.	The	involvement	of	spinal	bovine	adrenal	medulla	22-
like	 peptide,	 the	 proenkephalin	 derivative,	 in	modulation	 of	 nociceptive	 processing.	 Eur.	 J.	
Neurosci.	2007,	26,	1128-38	
60. Cai,	Q.;	Jiang,	J.;	Chen,	T.;	Hong,	Y.	Sensory	neuron-specific	receptor	agonist	BAM8-22	inhibits	
the	development	and	expression	of	 tolerance	 to	morphine	 in	 rats.	Behav.	Brain	Res.	2007,	
178,	154-9	
61. Chen,	 T.;	 Hu,	 Z.;	 Quirion,	 R.;	 Hong,	 Y.	 Modulation	 of	 NMDA	 receptors	 by	 intrathecal	






agonism	 at	 central	 terminals	 of	 primary	 sensory	 neurons	 inhibits	 neuropathic	 pain.	 Pain	
2014,	155,	534-44	
64. Hager,	 U.A.;	 Hein,	 A.;	 Lennerz,	 J.K.;	 Zimmermann,	 K.;	 Neuhuber,	 W.L.;	 Reeh,	 P.W.	
Morphological	 characterization	 of	 rat	 Mas-related	 G-protein-coupled	 receptor	 C	 and	
functional	analysis	of	agonists.	Neuroscience	2008,	151,	242-54	
65. Ndong,	 C.;	 Pradhan,	 A.;	 Puma,	 C.;	 Morello,	 J.P.;	 Hoffert,	 C.;	 Groblewski,	 T.;	 O'Donnell,	 D.;	
Laird,	 J.M.	 Role	 of	 rat	 sensory	 neuron-specific	 receptor	 (rSNSR1)	 in	 inflammatory	 pain:	
contribution	of	TRPV1	to	SNSR	signaling	in	the	pain	pathway.	Pain	2009,	143,	130-7	
66. Chen,	 H.;	 Ikeda,	 S.R.	Modulation	 of	 ion	 channels	 and	 synaptic	 transmission	 by	 a	 human	
sensory	 neuron-specific	 G-protein-coupled	 receptor,	 SNSR4/mrgX1,	 heterologously	
expressed	in	cultured	rat	neurons.	J.	Neurosci.	2004,	24,	5044-53	
67. Solinski,	H.J.;	Zierler,	S.;	Gudermann,	T.;	Breit,	A.	Human	sensory	neuron-specific	Mas-related	
G	 protein-coupled	 receptors-X1	 sensitize	 and	 directly	 activate	 transient	 receptor	 potential	
cation	channel	V1	via	distinct	signaling	pathways.	J.	Biol.	Chem.	2012,	287,	40956-71	




69. Sikand,	 P.;	 Dong,	 X.;	 LaMotte,	 R.H.	 BAM8-22	 peptide	 produces	 itch	 and	 nociceptive	
sensations	in	humans	independent	of	histamine	release.	J.	Neurosci.	2011,	31,	7563-7	
70. Wroblowski,	 B.;	 Wigglesworth,	 M.J.;	 Szekeres,	 PG.;	 Smith,	 G.D.;	 Rahman,	 S.S.;	 Nicholson,	
N.H.;	Muir,	A.I.;	Hall,	A.;	Heer,	 J.P.;	Garland,	 S.L.;	Coates,	W.J.	 The	discovery	of	 a	 selective,	
small	molecule	agonist	for	the	mas-related	gene	X1	receptor.	J.	Med.	Chem.	2009,	3,	818-25	




of	 2,4-diaminopyrimidine	derivatives	 as	novel	 SNSR4	antagonists.	Bioorg.	Med.	Chem.	 Lett.	
2011,	21,	2102-5	
73. Wen,	W.;	Wang,	Y.;	Li,	Z.;	Tseng,	P.Y.;	McManus,	O.B.;	Wu,	M.;	Li,	M.;	Lindsley,	C.W.;	Dong,	




ethoxyphenyl)benzamide,	 ML382:	 a	 potent	 and	 selective	 positive	 allosteric	 modulator	 of	
MrgX1.	Chem.	Med.	Chem.	2015,	10,	57-61	
74. Breit,	 A.;	 Gagnidze,	 K.;	 Devi,	 L.A.;	 Lagacé,	 M.;	 Bouvier,	 M.	 Simultaneous	 activation	 of	 the	
delta	opioid	receptor	(deltaOR)/sensory	neuron-specific	receptor-4	(SNSR-4)	hetero-oligomer	
by	 the	 mixed	 bivalent	 agonist	 bovine	 adrenal	 medulla	 peptide	 22	 activates	 SNSR-4	 but	
inhibits	deltaOR	signaling.	Mol.	Pharmacol.	2006,	70,	686-96	
75. Hindson,	 B.J.;	 Ness,	 K.D.;	 Masquelier,	 D.A.;	 Belgrader,	 P.;	 Heredia,	 N.J.;	 Makarewicz,	 A.J.;	
Bright,	 I.J.;	 Lucero,	 M.Y.;	 Hiddessen,	 A.L.	 High-throughput	 droplet	 digital	 PCR	 system	 for	
absolute	quantitation	of	DNA	copy	number.	Anal.	Chem.	2011,	83,	8604-10	
76. de	Lecea,	L.;	Criado,	J.R.;	Prospero-Garcia,	O.;	Gautvik,	K.M.;	Schweitzer,	P.;	Danielson,	P.E.;	







Kitano,	 K.;	 Fujino,	 M.	 Identification	 and	 characterization	 of	 a	 novel	 human	 cortistatin-like	
peptide.	Biochem.	Biophys.	Res.	Commun.	1997,	1,	157-63	






81. Robas,	 N.;	Mead,	 E.;	 Fidock,	M.	MrgX2	 is	 a	 high	 potency	 cortistatin	 receptor	 expressed	 in	
dorsal	root	ganglion.	J.	Biol.	Chem.	2003,	45,	44400-4	
82. Broglio,	 F.;	 Papotti,	 M.;	 Muccioli,	 G.;	 Ghigo,	 E.	 Brain-gut	 communication:	 cortistatin,	
somatostatin	and	ghrelin.	Trends	Endocrinol.	Metab.	2007,		6,	246-51	
83. Broglio,	 F.;	Grottoli,	 S.;	Arvat,	 E.;	Ghigo,	 E.	 Endocrine	 actions	of	 cortistatin:	 in	 vivo	 studies.	
Mol.	Cell.	Endocrinol.	2008,		1-2,	123-7	
84. Siehler,	 S.;	 Nunn,	 C.;	 Hannon,	 J.;	 Feuerbach,	 D.;	 Hoyer,	 D.	 Pharmacological	 profile	 of	
somatostatin	and	cortistatin	receptors.	Mol.	Cell.	Endocrinol.	2008,		1-2,	26-34	
85. Gahete,	M.D.;	Durán-Prado,	M.;	 Luque,	R.M.;	Martínez-Fuentes,	A.J.;	Vázquez-Martínez,	R.;	
Malagón,	 M.M.;	 Castaño,	 J.P.	 Are	 somatostatin	 and	 cortistatin	 two	 siblings	 in	 regulating	
endocrine	secretions?	In	vitro	work	ahead.	Mol.	Cell.	Endocrinol.	2008,		1-2,	128-34	
86. Volante,	 M.;	 Rosas,	 R.;	 Allìa,	 E.;	 Granata,	 R.;	 Baragli,	 A.;	 Muccioli,	 G.;	 Papotti,	 M.	
Somatostatin,	 cortistatin	 and	 their	 receptors	 in	 tumours.	Mol.	 Cell.	 Endocrinol.	2008,	 	1-2,	
219-29	
87. Baranowska,	 B.;	 Bik,	 W.;	 Baranowska-Bik,	 A.;	 Wolinska-Witort,	 E.;	 Chmielowska,	 M.;	
Martynska,	L.	Cortistatin	and	pituitary	hormone	secretion	in	rat.	J.	Physiol.	Pharmacol.	2009,	
1,	151-6	


























96. Johnson,	 T.;	 Siegel,	 D.	 Complanadine	 A,	 a	 selective	 agonist	 for	 the	Mas-related	G	 protein-
coupled	receptor	X2.	Bioorg.	Med.	Chem.	Lett.	2014,	15,	3512-5	
97. Okayama,	 Y.;	 Saito,	 H.;	 Ra,	 C.	 Targeting	 human	 mast	 cells	 expressing	 g-protein-coupled	
receptors	in	allergic	diseases.	Allergol.	Int.	2008,	3,	197-203	





CD88	antagonist	and	an	agonist	 for	Mas-related	gene	2	 (MrgX2)	 in	human	mast	cells.	Mol.	
Pharmacol.	2011,	6,	1005-13	













Kuroda,	 K.;	 Nunomura,	 S.;	 Hayama,	 K.;	 Terui,	 T.;	 Ra,	 C.;	 Okayama,	 Y.	 Expression	 of	 Mas-
related	 gene	 X2	 on	 mast	 cells	 is	 upregulated	 in	 the	 skin	 of	 patients	 with	 severe	 chronic	
urticaria.	J.	Allergy.	Clin.	Immunol.	2014,	3,	622-633	
105. Nothacker,	 H.P.;	 Wang,	 Z.;	 Zeng,	 H.;	 Mahata,	 S.K.;	 O'Connor,	 D.T.;	 Civelli,	 O.	
Proadrenomedullin	N-terminal	peptide	and	cortistatin	activation	of	MrgX2	receptor	is	based	
on	a	common	structural	motif.	Eur.	J.	Pharmacol.	2005,	1-2,	191-3	
106. McNeil,	 B.D.;	 Pundir,	 P.;	 Meeker,	 S.;	 Han,	 L.;	 Undem,	 B.J.;	 Kulka,	 M.;	 Dong,	 X.	
Identification	 of	 a	 mast-cell-specific	 receptor	 crucial	 for	 pseudo-allergic	 drug	 reactions.	
Nature	2015,	519,	237-41	
107. Kaisho,	Y.;	Watanabe,	T.;	Nakata,	M.;	Yano,	T.;	Yasuhara,	Y.;	Shimakawa,	K.;	Mori,	I.;	
Sakura,	 Y.;	 Terao,	 Y.;	 Matsui,	 H.;	 Taketomi,	 S.	 Transgenic	 rats	 overexpressing	 the	 human	









Y.;	 Itoh,	 M.;	 Kawaji,	 H.;	 Tsujikawa,	 M.;	 Nishida,	 K.	 Discovery	 of	 molecular	 markers	 to	
discriminate	corneal	endothelial	cells	in	the	human	body.	PLoS	One	2015,	10,	e0117581	
110. Khulan,	B.;	Cooper,	W.N.;	Skinner,	B.M.;	Bauer,	J.;	Owens,	S.;	Prentice,	A.M.;	Belteki,	
G.;	 Constancia,	 M.;	 Dunger,	 D.;	 Affara,	 N.A.	 Periconceptional	 maternal	 micronutrient	
supplementation	is	associated	with	widespread	gender	related	changes	in	the	epigenome:	a	
study	of	a	unique	resource	in	the	Gambia.	Hum.	Mol.	Genet.	2012,	21,	2086-101	
111. Hsu,	 Y.H.;	 Liu,	 Y.;	Hannan,	M.T.;	Maixner,	W.;	 Smith,	 S.B.;	Diatchenko,	 L.;	Golightly,	
Y.M.;	 Menz,	 H.B.;	 Kraus,	 V.B.;	 Doherty,	 M.;	 Wilson,	 A.G.;	 Jordan,	 J.M.	 Genome-wide	
association	meta-analyses	to	identify	common	genetic	variants	associated	with	hallux	valgus	
in	 Caucasian	 and	 African	 Americans.	 J.	 Med.	 Genet.	 2015,	 doi:	 10.1136/jmedgenet-2015-
103142	
112. Kroeze,	 W.K.;	 Sassano,	 M.F.;	 Huang,	 X.P.;	 Lansu,	 K.;	 McCorvy,	 J.D.;	 Giguère,	 P.M.;	
Sciaky,	 N.;	 Roth,	 B.L.	 PRESTO-Tango	 as	 an	 open-source	 resource	 for	 interrogation	 of	 the	
druggable	human	GPCRome.	Nat.	Struct.	Mol.	Biol.	2015,	22,	362-9	
113. Gylfe,	 A.E.;	 Kondelin,	 J.;	 Turunen,	 M.;	 Ristolainen,	 H.;	 Katainen,	 R.;	 Pitkänen,	 E.;	
Kaasinen,	E.;	Rantanen,	V.;	Tanskanen,	T.;	Varjosalo,	M.;	Lehtonen,	H.;	Palin,	K.;	Taipale,	M.;	
Taipale,	 J.;	 Renkonen-Sinisalo,	 L.;	 Järvinen,	 H.;	 Böhm,	 J.;	 Mecklin,	 J.P.;	 Ristimäki,	 A.;	
Kilpivaara,	 O.;	 Tuupanen,	 S.;	 Karhu,	 A.;	 Vahteristo,	 P.;	 Aaltonen,	 L.A.	 Identification	 of	
candidate	 oncogenes	 in	 human	 colorectal	 cancers	 with	 microsatellite	 instability.	
Gastroenterology	2013,	145,	540-3	




M.M.;	 Ziegler,	 E.;	 Butzmann,	 L.;	 Gessulat,	 S.;	 Marx,	 H.;	 Mathieson,	 T.;	 Lemeer,	 S.;	
Schnatbaum,	 K.;	 Reimer,	 U.;	 Wenschuh,	 H.;	 Mollenhauer,	 M.;	 Slotta-Huspenina,	 J.;	 Boese,	
J.H.;	Bantscheff,	M.;	Gerstmair,	A.;	Faerber,	F.;	Kuster,	B.	Mass-spectrometry-based	draft	of	
the	human	proteome.	Nature	2014,	509,	582-7	









119. Honkanen,	 R.E.	 Cantharidin,	 another	 natural	 toxin	 that	 inhibits	 the	 activity	 of	
serine/threonine	protein	phosphatases	types	1	and	2A.	FEBS	Lett.	1993,	330,	283-6	
120. Brown,	G.R.;	Bamford,	A.M.;	Bowyer,	 J.;	 James,	D.S.;	Rankine,	N.;	Tang,	E.;	Torr,	V.;	
Culbert,	E.J.	Naphthyl	ketones:	a	new	class	of	Janus	kinase	3	inhibitors.	Bioorg.	Med.	Chem.	
Lett.	2000,	10,	575-9	
121. Bourne,	 H.;	 Horuk,	 R.;	 Kuhnke,	 J.;	 Michel,	 H.	 GPCRs:	 from	 deophanization	 to	 lead	
structure	identification,	2006,	Springer	Verlag	
122. Civelli,	 O.;	 Reinscheid,	 R.K.;	 Zhang,	 Y.;	 Wang,	 Z.;	 Fredriksson,	 R.;	 Schiöth,	 H.B.G	
protein-coupled	receptor	deorphanizations.	Annu.	Rev.	Pharmacol.	Toxicol.	2013,	53,	127-46	
123. Romine,	J.L.;	Martin,	S.W.;	Meanwell,	N.A.;	Gribkoff,	V.K.;	Boissard,	C.G.;	Dworetzky,	





BMS-191011:	 opener	 of	 large-conductance	 Ca(2+)-activated	 potassium	 (maxi-K)	 channels,	
identification,	solubility,	and	SAR.	J.	Med.	Chem.	2007,	50,	528-42	
124. Möller,	 K.;	Wienhöfer,	 G.;	Westerhaus,	 F.;	 Junge,	 K.;	 Beller,	M.	 Oxidation	 of	 1,2,4-
trimethylbenzene	 (TMB),	 2,3,6-trimethylphenol	 (TMP)	 and	 2-methylnaphthalene	 to	 2,3,5-
trimethylbenzoquinone	(TMBQ)	and	menadione	(vitamin	K3).	Catal.	Today.	2011,	173,	68-75	
125. Loor,	G.;	Kondapalli,	J.;	Schriewer,	J.	M.;	Chander,	N.	S.;	Hoek,	T.	L.	V.;	Schumacker,	P.	
T.	 Menadione	 triggers	 cell	 death	 through	 ROS-dependent	 mechanisms	 involving	 PARP	
activation	without	requiring	apoptosis.	Free	Radic.	Biol.	Med.	2010,	49,	1925-1936.	
126. Lee,	 J.;	 Lee,	 M.;	 Chung,	 S.;	 Chung,	 J.	 Menadione-Induced	 Vascular	 Endothelial	
Dysfunction	and	Its	Possible	Significance.	Toxicol.	Appl.	Pharmacol.	1999,	161,	140-145.	
127. McAmis,	 W.;	 Schaeffer	 Jr,	 R.	 C.;	 Baynes,	 J.	 W.;	 Wolf,	 M.	 B.	 Menadione	 causes	
endothelial	 barrier	 failure	by	a	direct	 effect	on	 intracellular	 thiols,	 independent	of	 reactive	
oxidant	production.	Biochim.	Biophys.	Acta.	2003,	1641,	43-53.	
128. Cerqueira,	E.	C.;	Netz,	P.	A.;	Diniz,	C.;	Canto,	V.	P.;	Follmer,	C.;	Molecular	insights	into	
human	 monoamino	 oxidase	 (MAO)	 inhibition	 by	 1,4-naphthoquinone:	 Evidences	 for	
menadione	 (vitamin	 K3)	 acting	 as	 a	 competitive	 and	 reversible	 inhibitor	 of	 MAO.	 Bioorg.	
Med.	Chem.	2011,	19,	7416-7424.	
129. Vita,	 M.	 F.;	 Nagachar,	 N.;	 Avramidis,	 D.;	 Delwar,	 Z.	 M.;	 Cruz,	 M.	 H.;	 Siden,	 Å.;	
Paulsson,	K.	M.;	Yakisich,	J.	S.	Pankiller	effect	of	prolonged	exposure	to	menadione	on	glioma	
cells:	potentiation	by	vitamin	C.	Invest.	New	Drugs.	2011,	29,	1314-1320.	





132. Kenakin,	 T.;	 Jenkinson,	 S.;	 Watson,	 C.	 Determining	 the	 potency	 and	 molecular	
mechanism	of	action	of	insurmountable	antagonists.	J.	Pharmacol.	Exp.	Ther.	2006,	319,	710-
23	
133. Colquhoun,	 D.	 Why	 the	 Schild	 method	 is	 better	 than	 Schild	 realised.	 Trends	
Pharmacol.	Sci.	2007,	28,	608-14	
134. Conn,	P.J.;	Lindsley,	C.W.;	Meiler,	J.;	Niswender,	C.M.	Opportunities	and	challenges	in	
the	 discovery	 of	 allosteric	modulators	 of	GPCRs	 for	 treating	 CNS	disorders.	Nat.	 Rev.	Drug	
Discov.	2014,	13,	692-708	
135. Kenakin,	 T.;	 Christopoulos,	 A.	 Signalling	 bias	 in	 new	 drug	 discovery:	 detection,	
quantification	and	therapeutic	impact.	Nat.	Rev.	Drug	Discov.	2013,	12,	205-16	
136. Yoshimi,	 Y.;	 Watanabe,	 S.;	 Shinomiya,	 T.;	 Makino,	 A.;	 Toyoda,	 M.;	 Ikekita,	 M.	
Nucleobase	adenine	as	a	trophic	factor	acting	on	Purkinje	cells.	Brain	Res.	2003,	991,	113-22	
137. Yoshikuni,	M.;	 Ishikawa,	K.;	 Isobe,	M.;	Goto,	T.;	Nagahama,	Y.	Characterization	of	1-
methyladenine	binding	in	starfish	oocyte	cortices.	Proc.	Natl.	Acad.	Sci.	U	S	A.	1988,	85,	1874-
7	
138. Matthews,	 E.A.;	 Dickenson,	 A.H.	 Effects	 of	 spinally	 administered	 adenine	 on	 dorsal	
horn	neuronal	responses	in	a	rat	model	of	inflammation.	Neurosci.	Lett.	2004,	356,	211-4	
139. Wengert,	M.;	Adão-Novaes,	J.;	Assaife-Lopes,	N.;	Leão-Ferreira,	L.R.;	Caruso-Neves,	C.	
Adenine-induced	 inhibition	 of	 Na(+)-ATPase	 activity:	 Evidence	 for	 involvement	 of	 the	 Gi	
protein-coupled	receptor	in	the	cAMP	signaling	pathway.	Arch.	Biochem.	Biophys.	2007,	467,	
261-7	
140. Watanabe,	 S.;	 Ikekita,	M.;	 Nakata,	 H.	 Identification	 of	 specific	 [3H]adenine-binding	
sites	in	rat	brain	membranes.	J.	Biochem.	2005,	137,	323-9	
141. Gorzalka,	S.;	Vittori,	S.;	Volpini,	R.;	Cristalli,	G.;	von	Kügelgen,	I.;	Müller,	C.E.	Evidence	






J.L.;	 Guillemot,	 J.C.;	 Ferrara,	 P.;	 Monsarrat,	 B.	 Isolation	 and	 structure	 of	 the	 endogenous	
agonist	of	opioid	receptor-like	ORL1	receptor.	Nature	1995,	377,	532-5	
143. Reinscheid,	R.K.;	Nothacker,	H.P.;	Bourson,	A.;	Ardati,	A.;	Henningsen,	R.A.;	Bunzow,	








Battenberg,	 E.L.;	Gautvik,	 V.T.;	 Bartlett,	 F.S.;	 Frankel,	W.N.;	 van	 den	 Pol,	 A.N.;	 Bloom,	 F.E.;	












D.S.;	 Jacobs,	M.B.;	Philipp,	M.T.	 Inflammation	 in	the	pathogenesis	of	 lyme	neuroborreliosis.	
Am.	J.	Pathol.	2015,	185,	1344-60	












156. Steiner,	 R.F;	 Frattali;	 V.	 Purification	 and	properties	 of	 soybean	protein	 inhibitors	 of	
Proteolytic	enzymes.	J.	Agr.	Food	Chem.	1969,	3,	315-18	
157. Murzin,	 A.G.;	 Lesk,	 A.M.;	 Chothia,	 C.	 beta-Trefoil	 fold,	 Patterns	 of	 structure	 and	
sequence	 in	 the	 Kunitz	 inhibitors	 interleukins-1	 beta	 and	 1	 alpha	 and	 fibroblast	 growth	
factors.	J.	Mol.	Biol.	1992,	2,	531-43	
158. McMahan,	C.J.;	Slack,	J.L.;	Mosley,	B.;	Cosman,	D.;	Lupton,	S.D.;	Brunton,	L.L.;	Grubin,	








160. Huang,	 J.;	 Gao,	 X.;	 Li,	 S.;	 Cao,	 Z.	 Recruitment	 of	 IRAK	 to	 the	 interleukin	 1	 receptor	
complex	requires	inter	leukin	1	receptor	accessory	protein.	Proc.	Natl.	Acad.	Sci.	U	S	A.	1997,	
24,	12829-32.	
161. Volpe,	 F.;	 Clatworthy,	 J.;	 Kaptein,	 A.;	 Maschera,	 B.;	 Griffin,	 AM.;	 Ray,	 K.	 The	 IL1	
receptor	 accessory	 protein	 is	 responsible	 for	 the	 recruitment	 of	 the	 interleukin-1	 receptor	
associated	kinase	to	the	IL1/IL1	receptor	I	complex.	FEBS	Lett.	1997,	1,	41-4.	
162. Munts,	 A.G.;	 	 Zijlstra,	 F.J.;	 Nibbering,	 P.H.;	 Daha,	M.R.;	Marinus,	 J.;	 Dahan,	 A.;	 van	
Hilten,	J.J.	Analysis	of	cerebrospinal	fluid	inflammatory	mediators	in	chronic	complex	regional	
pain	syndrome	related	dystonia.	Clin.	J.	Pain.	2008,	1,	30-4	
163. Balosso,	 S.;	 Maroso,	 M.;	 Sanchez-Alavez,	 M.;	 Ravizza,	 T.;	 Frasca,	 A.;	 Bartfai,	 T.;	
Vezzani,	 A.	 A	 novel	 non-transcriptional	 pathway	 mediates	 the	 proconvulsive	 effects	 of	
interleukin-1beta.	Brain	2008,	131,	3256-65	
164. Yan,	 X.;	 Weng,	 H.R.	 Endogenous	 interleukin-1β	 in	 neuropathic	 rats	 enhances	
glutamate	release	from	the	primary	afferents	in	the	spinal	dorsal	horn	through	coupling	with	
presynaptic	N-methyl-D-aspartic	acid	receptors.	J.	Biol.	Chem.	2013,	288,	30544-57	
165. Copray,	 J.C.;	Mantingh,	 I.;	Brouwer,	N.;	Biber,	K.;	Küst,	B.M.;	Liem,	R.S.;	Huitinga,	 I.;	
Tilders,	F.J.;	Van	Dam,	A.M.	Boddeke,	H.W.	Expression	of	interleukin-1	beta	in	rat	dorsal	root	
ganglia.	J.	Neuroimmunol.	2001,	118,	203-11	
166. Takeda,	 M.;	 Takahashi,	 M.;	 Matsumoto,	 S.	 Contribution	 of	 activated	 interleukin	
receptors	in	trigeminal	ganglion	neurons	to	hyperalgesia	via	satellite	glial	 interleukin-1	beta	
paracrine	mechanism.	Brain	Behav.	Immun.	2008,	22,	1016-23	




is	 important	 for	both	chaperone	activity	and	substrate	specificity.	 J.	Biol.	Chem.	2006,	281,	
39943-52	
169. Sahoo,	 S.K.;	 Shaikh,	 S.A.;	 Sopariwala,	 D.H.;	 Bal,	 N.C.;	 Bruhn,	 D.S.;	 Kopec,	 W.;	
Khandelia,	 H.;	 Periasamy,	 M.	 The	 N	 Terminus	 of	 Sarcolipin	 Plays	 an	 Important	 Role	 in	
Uncoupling	 Sarco-endoplasmic	 Reticulum	 Ca2+-ATPase	 (SERCA)	 ATP	 Hydrolysis	 from	 Ca2+	
Transport.	J.	Biol.	Chem.	2015,	290,	14057-67	
170. Schönbeck,	U.;	Mach,	F.;	Libby,	P.	Generation	of	biologically	active	IL-1	beta	by	matrix	









174. Khokha,	R.;	Murthy,	A.;	Weiss,	A.	Metalloproteinases	and	 their	natural	 inhibitors	 in	
inflammation	and	immunity.	Nat.	Rev.	Immunol.	2013,	13,	649-65	
175. Chattopadhyay,	S.;	Myers,	R.R.;	Janes,	J.;	Shubayev,	V.	Cytokine	regulation	of	MMP-9	
in	 peripheral	 glia:	 implications	 for	 pathological	 processes	 and	 pain	 in	 injured	 nerve.	 Brain	
Behav.	Immun.	2007,	21,	561-8	
176. Kawasaki,	Y.;	Xu,	Z.Z.;	Wang,	X.;	Park,	J.Y.;	Zhuang,	Z.Y.;	Tan,	P.H.;	Gao,	Y.J.;	Roy,	K.;	
Corfas,	G.;	 Lo,	 E.H.;	 Ji,	 R.R.	Distinct	 roles	of	matrix	metalloproteases	 in	 the	early-	 and	 late-
phase	development	of	neuropathic	pain.	Nat.	Med.	2008,	14,	331-6	
177. Nishida,	 K.;	 Kuchiiwa,	 S.;	Oiso,	 S.;	 Futagawa,	 T.;	Masuda,	 S.;	 Takeda,	 Y.;	 Yamada,	K.	








179. Liu,	 Y.C.;	 Berta,	 T.;	 Liu,	 T.;	 Tan,	 P.H.;	 Ji,	 R.R.	 Acute	 morphine	 induces	 matrix	





181. McQuibban,	G.A.;	Gong,	 J.H.;	Wong,	 J.P.;	Wallace,	 J.L.;	 Clark-Lewis,	 I.;	Overall,	 C.M.	
Matrix	 metalloproteinase	 processing	 of	 monocyte	 chemoattractant	 proteins	 generates	 CC	
chemokine	receptor	antagonists	with	anti-inflammatory	properties	in	vivo.	Blood	2002,	100,	
1160-7	
182. Starr,	 A.E.;	 Dufour,	 A.;	 Maier,	 J.;	 Overall,	 C.M.	 Biochemical	 analysis	 of	 matrix	
metalloproteinase	 activation	 of	 chemokines	 CCL15	 and	 CCL23	 and	 increased	
glycosaminoglycan	binding	of	CCL16.	J.	Biol.	Chem.	2012,	287,	5848-60	
183. Cox,	 J.	 H.;	 Overall,	 C.	 M.	 Cytokine	 Substrates:	 MMP	 Regulation	 of	 Inflammatory	
Signaling	Molecules,	The	Cancer	Degradome:	Proteases	and	Cancer	Biology,	2008,	517−538.	
Springer	Verlag	
184. Fortelny,	N.;	 Pavlidis,	 P.;	Overall,	 C.M.	The	path	of	no	 return--Truncated	protein	N-
termini	and	current	ignorance	of	their	genesis.	Proteomics	2015,	15,	2547-52	
185. Tanco,	 S.;	 Gevaert,	 K.;	 Van	 Damme,	 P.	 C-terminomics:	 Targeted	 analysis	 of	 natural	
and	posttranslationally	modified	protein	and	peptide	C-termini.	Proteomics	2015,	15,	903-14	
186. Marino,	 G.;	 Eckhard,	 U.;	 Overall,	 C.M.	 Protein	 Termini	 and	 Their	 Modifications	
Revealed	by	Positional	Proteomics.	ACS	Chem.	Biol.	2015,	10,	1754-64	
187. Repnik,	 U.;	 Starr,	 A.E.;	 Overall,	 C.M.;	 Turk,	 B.	 Cysteine	 Cathepsins	 Activate	 ELR	
Chemokines	and	Inactivate	Non-ELR	Chemokines.	J.	Biol.	Chem.	2015,	290,	13800-11	
188. Reddy,	 V.B.;	 Sun,	 S.;	 Azimi,	 E.;	 Elmariah,	 S.B.;	 Dong,	 X.;	 Lerner,	 E.A.	 Redefining	 the	
concept	 of	 protease-activated	 receptors:	 cathepsin	 S	 evokes	 itch	 via	 activation	 of	Mrgprs.	
Nat.	Commun.	2015,	doi:	10.1038/ncomms8864	
189. Kay,	 J.;	 Calabrese,	 L.	 The	 role	 of	 interleukin-1	 in	 the	 pathogenesis	 of	 rheumatoid	
arthritis.	Rheumatology	2004,	43,	Suppl	3:iii2-iii9	
190. Roberts,	D.J.;	 Jenne,	C.N.;	 Léger,	C.;	Kramer,	A.H.;	Gallagher,	C.N.;	Todd,	S.;	Parney,	
I.F.;	 Doig,	 C.J.;	 Yong,	 V.W.;	 Kubes,	 P.;	 Zygun,	 D.A.	 Association	 between	 the	 cerebral	
inflammatory	and	matrix	metalloproteinase	responses	after	severe	traumatic	brain	injury	in	
humans.	J.	Neurotrauma	2013,	30,	1727-36	
191. Symons,	 J.A.;	 Eastgate,	 J.A.;	 Duff,	 G.W.	 Purification	 and	 characterization	 of	 a	 novel	
soluble	receptor	for	interleukin	1.	J.	Exp.	Med.	1991,	174,	1251-4	
192. Jobling,	 S.A.;	 Auron,	 P.E.;	 Gurka,	 G.;	 Webb,	 A.C.;	 McDonald,	 B.;	 Rosenwasser,	 L.J.;	
Gehrke,	 L.	 Biological	 activity	 and	 receptor	 binding	 of	 human	 prointerleukin-1	 beta	 and	
subpeptides.	J.	Biol.	Chem.	1988,	263,	16372-8	
193. Pertwee,	 R.G.;	 Howlett,	 A.C.;	 Abood,	 M.E.;	 Alexander,	 S.P.;	 Di	 Marzo,	 V.;	 Elphick,	
M.R.;	 Greasley,	 P.J.;	 Hansen,	 H.S.;	 Kunos,	 G.;	 Mackie,	 K.;	 Mechoulam,	 R.;	 Ross	 R.A.	
International	 Union	 of	 Basic	 and	 Clinical	 Pharmacology.	 LXXIX.	 Cannabinoid	 receptors	 and	
their	ligands:	beyond	CB₁	and	CB₂.	Pharmacol.	Rev.	2010,	62,	588-631	
194. Ross,	R.A.	 The	enigmatic	pharmacology	of	GPR55.	Trends	Pharmacol.	 Sci.	2009,	30,	
156-63	
195. Lile,	J.A.;	Kelly,	T.H.;	Hays,	L.R.	Separate	and	combined	effects	of	the	GABAA	positive	






new	 water-soluble	 prodrug	 of	 the	 adenosine	 A2A	 receptor	 antagonist	 MSX-2.	Molecules	
2008,	2,	348-59	
197. Müller,	 C.E.;	 Sauer,	 R.;	 Maurinsh,	 Y.;	 Huertas,	 R.;	 Fülle,	 F.;	 Klotz,	 K.N.;	 Nagel,	 J.;	
Hauber,	 W.	 A2A-selective	 adenosine	 receptor	 antagonists:	 development	 of	 water-soluble	
prodrugs	and	a	new	tritiated	radioligand.	Drug	Dev.	Res.	1998,	45,	190-7	
198. Sauer,	 R.;	 Maurinsh,	 Y.;	 Reith,	 U.;	 Fülle,	 F.;	 Klotz,	 K.N.;	 Müller,	 C.E.	 Water	 soluble	









E.	 Evidence	 for	 the	 involvement	 of	 ecto-5'-nucleotidase	 (CD73)	 in	 drug	 resistance.	 Int.	 J.	
Cancer	1996,	68,	493-500	
202. 	Chambers,	S.M.;	Fasano,	C.A.;	Papapetrou,	E.P.;	Tomishima,	M.;	Sadelain,	M.;	Studer,	
L.	Highly	 efficient	 neural	 conversion	 of	 human	 ES	 and	 iPS	 cells	 by	 dual	 inhibition	 of	 SMAD	
signaling.	Nat.	Biotechnol.	2009,	27,	275-80	
203. Chambers,	 S.M.;	 Qi,	 Y.;	 Mica,	 Y.;	 Lee,	 G.;	 Zhang,	 X.J.;	 Niu,	 L.;	 Bilsland,	 J.;	 Cao,	 L.;	
Stevens,	E.;	Whiting,	P.;	Shi,	S.H.;	Studer,	L.	Combined	small-molecule	inhibition	accelerates	
developmental	 timing	 and	 converts	 human	 pluripotent	 stem	 cells	 into	 nociceptors.	 Nat.	
Biotechnol.	2012,	30,	715-20	
204. Young,	G.T.;	Gutteridge,	A.;	 Fox,	H.D.;	Wilbrey,	A.L.;	 Cao,	 L.;	 Cho,	 L.T.;	 Brown,	A.R.;	
Benn,	C.L.;	Kammonen,	L.R.;	Friedman,	 J.H.;	Bictash,	M.;	Whiting,	P.;	Bilsland,	 J.G.;	Stevens,	
E.B.	Characterizing	human	stem	cell-derived	sensory	neurons	at	 the	single-cell	 level	 reveals	
their	ion	channel	expression	and	utility	in	pain	research.	Mol.	Ther.	2014,	22,	1530-43	
205. Kumar,	 T.S.;	 Zhou,	 S.Y.;	 Joshi,	 B.V.;	 Balasubramanian,	 R.;	 Yang,	 T.;	 Liang,	 B.T.;	









the	 complex	 formed	between	phospholipase	A2	and	oxyphenbutazone	at	1.6	A	 resolution.	
Biochemistry	2004,	43,	14577-83	
209. Gaucher,	 A.;	 Netter,	 P.;	 Faure,	 G.;	 Schoeller,	 J.P.;	 Gerardin,	 A.	 Diffusion	 of	
oxyphenbutazone	 into	 synovial	 fluid,	 synovial	 tissue,	 joint	 cartilage	and	cerebrospinal	 fluid.	
Eur.	J.	Clin.	Pharmacol.	1983,	25,	107-12	
210. Walter,	 M.;	 Lemoine,	 H.;	 Kaumann,	 A.J.	 Stimulant	 and	 blocking	 effects	 of	 optical	
isomers	 of	 pindolol	 on	 the	 sinoatrial	 node	 and	 trachea	 of	 guinea	 pig.	 Role	 of	 beta-
adrenoceptor	 subtypes	 in	 the	 dissociation	 between	 blockade	 and	 stimulation.	 Naunyn	
Schmiedebergs	Arch.	Pharmacol.	1984,	327,	159-75	







M.A.	 The	 selectivity	 in	 vitro	 of	 the	 stereoisomers	 of	 the	 beta-3	 adrenoceptor	 agonist	 BRL	
37344.	J.	Pharmacol.	Exp.	Ther.	1996,	277,	22-7	
213. Urwyler,	S.;	Laurie,	D.;	Lowe,	D.A.;	Meier,	C.L.;	Müller,	W.	Biphenyl-derivatives	of	2-
amino-7-phosphonoheptanoic	 acid,	 a	 novel	 class	 of	 potent	 competitive	 N-methyl-D-
aspartate	 receptor	 antagonist--I.	 Pharmacological	 characterization	 in	 vitro.	
Neuropharmacology	1996,	35,	643-54	
214. Stebbins,	 J.L.;	 De,	 S.K.;	 Machleidt,	 T.;	 Becattini,	 B.;	 Vazquez,	 J.;	 Kuntzen,	 C.;	 Chen,	
L.H.;	 Cellitti,	 J.F.;	 Riel-Mehan,	 M.;	 Emdadi,	 A.;	 Solinas,	 G.;	 Karin,	 M.;	 Pellecchia,	 M.	
Identification	of	a	new	JNK	 inhibitor	 targeting	the	JNK-JIP	 interaction	site.	Proc.	Natl.	Acad.	
Sci.	U	S	A.	2008,	105,	16809-13	





217. Jaakola,	 V.P.;	 Griffith,	 M.T.;	 Hanson,	 M.A.;	 Cherezov,	 V.;	 Chien,	 E.Y.;	 Lane,	 J.R.;	
Ijzerman,	 A.P.;	 Stevens,	 R.C.	 The	 2.6	 angstrom	 crystal	 structure	 of	 a	 human	A2A	 adenosine	
receptor	bound	to	an	antagonist.	Science	2008,	5905,	1211-7	
218. Xu,	 F.;	 Wu,	 H.;	 Katritch,	 V.;	 Han,	 G.W.;	 Jacobson,	 K.A.;	 Gao	 Z.G.;	 Cherezov,	 V.;	
Stevens,	 R.C.	 Structure	 of	 an	 agonist-bound	 human	 A2A	 adenosine	 receptor.	 Science	 2011,	
6027,	322-7	
219. Doré,	 A.S.;	 Robertson,	 N.;	 Errey,	 J.C.;	 Ng,	 I.;	 Hollenstein,	 K.;	 Tehan,	 B.;	 Hurrell,	 E.;	
Bennett,	K.;	Congreve,	M.;	Magnani,	F.;	Tate,	C.G.;	Weir,	M.;	Marshall,	F.H.	Structure	of	the	
adenosine	A(2A)	 receptor	 in	 complex	with	 ZM241385	and	 the	 xanthines	XAC	and	 caffeine.	
Structure	2011,	19,	1283-93	
220. Zhang,	K.;	Zhang,	J.;	Gao,	Z.G.;	Zhang,	D.;	Zhu,	L.;	Han,	G.W.;	Moss,	S.M.;	Paoletta,	S.;	
Kiselev,	 E.;	 Lu,	 W.;	 Fenalti,	 G.;	 Zhang,	 W.;	 Müller,	 C.E.;	 Yang,	 H.;	 Jiang,	 H.;	 Cherezov,	 V.;	














of	 the	 first	 coculture	 between	 human	 primary	 keratinocytes	 and	 the	 dorsal	 root	 ganglion-
derived	neuronal	cell	line	F-11.	Neuroscience	2012,	210,	47-57	
226. Feng,	Y.;	De	Franceschi,	G.;	Kahraman,	A.;	 Soste,	M.;	Melnik,	A.;	Boersema,	P.J.;	de	









229. Knizhnik,	 A.V.;	 Roos,	W.P.;	 Nikolova,	 T.;	Quiros,	 S.;	 Tomaszowski,	 K.H.;	 Christmann,	
M.;	 Kaina,	 B.	 Survival	 and	 death	 strategies	 in	 glioma	 cells:	 autophagy,	 senescence	 and	
apoptosis	triggered	by	a	single	type	of	temozolomide-induced	DNA	damage.	PLoS	One	2013,	
8,	e55665	
230. Kenakin,	T.	 Efficacy	at	G-protein-coupled	 receptors.	Nat.	Rev.	Drug	Discov.	2002,	1,	
103-10	
231. Raehal,	 K.M.;	 Walker,	 J.K.;	 Bohn,	 L.M.	 Morphine	 side	 effects	 in	 beta-arrestin	 2	
knockout	mice.	J.	Pharmacol.	Exp.	Ther.	2005,	314,	1195-201	
232. Bohn,	 L.M.;	 Lefkowitz,	 R.J.;	 Gainetdinov,	 R.R.;	 Peppel,	 K.;	 Caron,	 M.G.;	 Lin,	 F.T.	
Enhanced	morphine	analgesia	in	mice	lacking	beta-arrestin	2.	Science	1999,	286,	2495-8	
233. Rajagopal,	 K.;	Whalen,	 E.J.;	 Violin,	 J.D.;	 Stiber,	 J.A.;	 Rosenberg,	 P.B.;	 Premont,	 R.T.;	





of	 extracellular	 signal-regulated	 kinases	 1	 and	 2.	 Proc.	 Natl.	 Acad.	 Sci.	 U	 S	 A.	 2003,	 100,	
10782-7	
235. Boerrigter,	 G.;	 Lark,	M.W.;	Whalen,	 E.J.;	 Soergel,	 D.G.;	 Violin,	 J.D.;	 Burnett,	 J.C.	 Jr.	
Cardiorenal	actions	of	TRV120027,	a	novel	ß-arrestin-biased	ligand	at	the	angiotensin	II	type	I	
receptor,	 in	healthy	and	heart	 failure	 canines:	 a	novel	 therapeutic	 strategy	 for	acute	heart	
failure.	Circ.	Heart	Fail.	2011,	4,	770-8	
236. Inbe,	 H.;	 Watanabe,	 S.;	 Miyawaki,	 M.;	 Tanabe,	 E.;	 Encinas,	 J.A.	 Identification	 and	
characterization	 of	 a	 cell-surface	 receptor,	 P2Y15,	 for	 AMP	 and	 adenosine.	 J.	 Biol.	 Chem.	
2004,	279,	19790-9	











241. Moody,	 C.J.;	 Meghji,	 P.;	 Burnstock,	 G.	 Stimulation	 of	 P1-purinoceptors	 by	 ATP	
depends	partly	on	 its	conversion	 to	AMP	and	adenosine	and	partly	on	direct	action.	Eur.	 J.	
Pharmacol.	1984,	97,	47-54	
242. Salter,	M.W.;	Henry,	 J.L.	 Effects	 of	 adenosine	5'-monophosphate	 and	 adenosine	5'-
triphosphate	 on	 functionally	 identified	 units	 in	 the	 cat	 spinal	 dorsal	 horn.	 Evidence	 for	 a	
differential	 effect	 of	 adenosine	 5'-triphosphate	 on	 nociceptive	 vs	 non-nociceptive	 units.	
Neuroscience	1985,	15,	815-25	





245. Mustafa,	 S.J.;	 Nadeem,	 A.;	 Fan,	M.;	 Zhong,	 H.;	 Belardinelli,	 L.;	 Zeng,	 D.	 Effect	 of	 a	
specific	 and	 selective	 A(2B)	 adenosine	 receptor	 antagonist	 on	 adenosine	 agonist	 AMP	 and	








247. Zimmermann,	 H.	 Extracellular	 metabolism	 of	 ATP	 and	 other	 nucleotides.	 Naunyn.	
Schmiedebergs	Arch.	Pharmacol.	2000,	362,	299-309	
248. Latini,	 S.;	 Pedata,	 F.	 Adenosine	 in	 the	 central	 nervous	 system:	 release	mechanisms	
and	extracellular	concentrations.	J.	Neurochem.	2001,	79,	463-84	
249. Savic,	V.;	Stefanovic,	V.;	Ardaillou,	N.;	Ardaillou,	R.	 Induction	of	ecto-5'-nucleotidase	
of	 rat	 cultured	 mesangial	 cells	 by	 interleukin-1	 beta	 and	 tumour	 necrosis	 factor-alpha.	
Immunology	1990,	70,	321-6	
250. Christensen,	 L.D.;	 Andersen,	 V.;	 Nygaard,	 P.;	 Bendtzen,	 K.	 Effects	 of	
immunomodulators	 on	 ecto-5'-nucleotidase	 activity	 on	 blood	 mononuclear	 cells	 in	 vitro.	
Scand.	J.	Immunol.	1992,	35,	407-13	
251. Sowa,	 N.A.;	 Taylor-Blake,	 B.;	 Zylka,	 M.J.	 Ecto-5'-nucleotidase	 (CD73)	 inhibits	
nociception	by	hydrolyzing	AMP	 to	adenosine	 in	nociceptive	 circuits.	 J.	Neurosci.	2010,	30,	
2235-44	




production	 by	 human	 B	 cells	 and	 B	 cell-mediated	 suppression	 of	 activated	 T	 cells.	 Blood	
2013,	122,	9-18	
254. Morandi,	 F.;	 Horenstein,	 A.L.;	 Chillemi,	 A.;	 Quarona,	 V.;	 Chiesa,	 S.;	 Imperatori,	 A.;	






256. Stella,	 J.;	 Bavaresco,	 L.;	 Braganhol,	 E.;	 Rockenbach,	 L.;	 Farias,	 P.F.;	 Wink,	 M.R.;	
Azambuja,	 A.A.;	 Barrios,	 C.H.;	 Morrone,	 F.B.;	 Oliveira	 Battastini,	 A.M.	 Differential	
ectonucleotidase	expression	in	human	bladder	cancer	cell	lines.	Urol.	Oncol.	2010,	28,	260-7	
257. Mikhailov,	 A.;	 Sokolovskaya,	 A.;	 Yegutkin,	 G.G.;	 Amdahl,	 H.;	 West,	 A.;	 Yagita,	 H.;	
Lahesmaa,	 R.;	 Thompson,	 L.F.;	 Jalkanen,	 S.;	 Blokhin,	 D.;	 Eriksson,	 J.E.	 CD73	 participates	 in	
cellular	multiresistance	program	and	protects	against	TRAIL-induced	apoptosis.	 J.	 Immunol.	
2008,	181,	464-75	
258. Sadej,	 R.;	 Spychala,	 J.;	 Skladanowski,	 A.C.	 Expression	 of	 ecto-5'-nucleotidase	 (eN,	
CD73)	in	cell	lines	from	various	stages	of	human	melanoma.	Melanoma	Res.	2006,	16,	213-22	
259. Jin,	 D.;	 Fan,	 J.;	 Wang,	 L.;	 Thompson,	 L.F.;	 Liu,	 A.;	 Daniel,	 B.J.;	 Shin,	 T.;	 Curiel,	 T.J.;	
Zhang,	 B.	 CD73	 on	 tumor	 cells	 impairs	 antitumor	 T-cell	 responses:	 a	 novel	 mechanism	 of	
tumor-induced	immune	suppression.	Cancer	Res.	2010,	70,	2245-55	
260. Kondo,	T.;	Nakazawa,	T.;	Murata,	 S.I.;	 Katoh,	R.	 Expression	of	CD73	and	 its	 ecto-5'-
nucleotidase	activity	are	elevated	 in	papillary	 thyroid	carcinomas.	Histopathology	2006,	48,	
612-4	
261. Fukuda,	 K.;	 Sakakura,	 C.;	Miyagawa,	 K.;	 Kuriu,	 Y.;	 Kin,	 S.;	 Nakase,	 Y.;	 Hagiwara,	 A.;	
Mitsufuji,	S.;	Okazaki,	Y.;	Hayashizaki,	Y.;	Yamagishi,	H.	Differential	gene	expression	profiles	
of	 radioresistant	 oesophageal	 cancer	 cell	 lines	 established	 by	 continuous	 fractionated	
irradiation.	Br.	J.	Cancer	2004,	91,	1543-50	
262. Spychala,	 J.;	 Kitajewski,	 J.	Wnt	 and	 beta-catenin	 signaling	 target	 the	 expression	 of	





263. Ludwig,	 H.C.;	 Rausch,	 S.;	 Schallock,	 K.;	 Markakis,	 E.	 Expression	 of	 CD	 73	 (ecto-5'-
nucleotidase)	 in	 165	 glioblastomas	 by	 immunohistochemistry	 and	 electronmicroscopic	
histochemistry.	Anticancer	Res.	1999,	19,	1747-52	








Battastini,	 A.M.	 Altered	 extracellular	 ATP,	 ADP	 and	 AMP	 catabolism	 in	 glioma	 cell	 lines.	
Cancer	Lett.	2003,	198,	211-8	
267. Davenport,	 A.P.;	 Alexander,	 S.P.;	 Sharman,	 J.L.;	 Pawson,	 A.J.;	 Benson,	 H.E.;	
Monaghan,	A.E.;	Liew,	W.C.;	Mpamhanga,	C.P.;	Bonner,	T.I.;	Neubig,	R.R.;	Pin,	J.P.;	Spedding,	
M.;	Harmar,	A.J.	International	Union	of	Basic	and	Clinical	Pharmacology.	LXXXVIII.	G	protein-
coupled	 receptor	 list:	 recommendations	 for	new	pairings	with	 cognate	 ligands.	Pharmacol.	
Rev.	2013,	65,	967-86	
268. Yegutkin,	 G.G.;	 Samburski,	 S.S.;	 Mortensen,	 S.P.;	 Jalkanen,	 S.;	 González-Alonso.	 J.	
Intravascular	ADP	and	soluble	nucleotidases	contribute	to	acute	prothrombotic	state	during	
vigorous	exercise	in	humans.	J.	Physiol.	2007,	579,	553-64	
269. Harkness,	 R.A.;	 Coade,	 S.B.;	 Webster,	 A.D.,ATP,	 ADP	 and	 AMP	 in	 plasma	 from	
peripheral	venous	blood.	Clin.	Chim.	Acta.	1984,	143,	91-8	




cerebrospinal	 fluid	metabolome.	 J.	 Chromatogr.	 B	 Analyt.	 Technol.	 Biomed.	 Life	 Sci.	 2008,	
871,	164-73	
272. Rodríguez-Núñez,	A.;	 Cid,	 E.;	 Rodríguez-García,	 J.;	 Camiña,	 F.;	 Rodríguez-Segade,	 S.;	
Castro-Gago,	M.	 Concentrations	 of	 nucleotides,	 nucleosides,	 purine	 bases,	 oxypurines,	 uric	




and	 deazaadenine	 derivatives	 as	 ligands	 for	 adenine	 receptors,	 a	 new	 purinergic	 receptor	
family.	J.	Med.	Chem.	2009,	52,	5974-89	
274. Olson,	 K.R.;	 Eglen,	 R.M.	 Beta	 galactosidase	 complementation:	 a	 cell-based	
luminescent	assay	platform	for	drug	discovery.	Assay	Drug	Dev.	Technol.	2007,	5,	137-44	
	
	
	
	
	
	
	
	
	
	
	
	
	
Literature	
177	
	
	
	
	
	
	
	
	
	
	
Throughout the time of this thesis I was lucky to be surrounded by many people who greatly 
contributed to its final form and to whom I will stay deeply indebted. 
 
Prof. Christa Müller was always supportive, encouraging and highly motivating. This thesis is as hers 
as mine since she chose the challenging projects, constantly provided insight, valuable advice and 
was willing to make every effort within her group as well as in collaboration with other scientific 
groups to bring the thesis to its current form. 
 
I am also thankful to PD. Dr. Anke Schiedel for her help introducing the mas‐related gene receptors 
to me and guiding my first steps in this thesis. Discussions and tips from Anke were very useful and 
illuminating. Lastly, Anke agreed to be the second supervisor of this thesis. 
 
I am indebted to Dr. Sonja Hinz who has contributed via various discussions and ideas to planning 
and designing of some of the important experiments and was always ready to sacrifice some of her 
time for spontaneous questions and explanations. 
 
During my work in the lab I had the opportunity to supervise some of the students who contributed 
to some of the most exciting findings. Hamid Shah from Pakistan conducted the antagonist screening 
at MRGPRX2 receptor and was able to identify the first hits at this receptor. Jose Bonet Giner from 
Spain conducted the antagonist screening at MRGPRX4 receptor and despite his short stay he was 
able to generate valuable data. Sara Caeiro from Portugal conducted initial screening at MRGPRX2 
receptor. I would like to thank all these colleagues whole‐heartedly and wish them all success in their 
future. 
 
In the final stage of the thesis we collaborated with different groups to whom I am enormously 
grateful. 
 
Professor Ullrich Wüllner from University clinic in Bonn provided us with different cerebrospinal fluid 
samples. 
 
Professor Oliver Brüstle, Dr. Michael Peitz and Swetlana Ritzenhofen from the Institute of 
reconstructive neurobiology in Bonn have conducted the differentiation experiments of fibroblasts to 
neurons. The lab work was performed mainly by Swetlana, who was able to reach exciting results. 
 
The native cell line LN229 cell line was kindly provided by Professor Björn Scheffler and Dr. Anja 
Wieland from Life and Brain center in Bonn. This cell line proved to be an interesting tool. For this 
and the proliferation assay I would like to express my gratitude to them. 
 
The investigation of the  mas‐related gene X4  in the immune system was carried out in the group of 
Professor Jacob Nattermann. The FACS experiments were done by Dr. Benjamin Krämer. Benjamin 
was always friendly, collaborative and made every effort to find a native expression of the receptor.  
 
I am deeply grateful to Dr. Marc Sylvester from the biochemical institute in Bonn who was constantly 
ready to answer my questions regarding mass spectrometry and introduced me in a course to the 
important techniques in his field.  
 
During the first 21 months of my PhD I got a scholarship from the graduate school of chemical 
biology. I am grateful to all who supervised me during the time of this scholarship. 
 
For all the important novel agonists and antagonists I owe a debt to several talented chemists.  
 
In the group of professor Müller Dr. Thanigaimalai Pillaiyar synthesized most of the novel agonists at 
MRGPRX4 receptor that led to a better understanding of the structure activity relationship. Dr. Jörg 
Hockenmeyer and Daniel Marx synthesized JH14102, the most potent agonist at MRGPRX4 in this 
work.  
 
Dr. Younis Baqi has provided valuable suggestions and advice for elucidating the structure activity 
relationships. He synthesized MSX‐3, MSX‐155 as well as BI03. Dr. Enas Malik and Dr. Ali El‐Tayeb 
have also provided me with compounds for screening. 
 
Dr. Steven De Jonghe and Dr. Piotr Leonczak from the lab of professor Piet Herdewijn in Belgium 
synthesized the antagonists at MRGPRX2 receptor. I would like to thank them for their constant 
cooperation and helpful feedback during the work together. 
 
The daily work in the lab was made easier and provided occasional fun due to the nice team in the 
lab to whom I would be always thankful. 
 
During my PhD Dr. Sangyong Lee, Dr. Nader Boshta, Dr. Amelie Fiene and Dr. Mario Funke were my 
colleagues in the office. Their presence was a nice companion to me in the 4 years period and the 
friendly atmosphere they created in the office was of great value. 
 
In the whole PhD period I supervised undergraduates in the seventh semester. During this time I 
came in contact with a dedicated team that I enjoyed working with. Dr. Ralf Mayer was our head of 
the lab who gave us  a big space for ourselves to organize the practical sessions. Other PhD 
candidates who shared the supervision with me made this duty enjoyable. Here I would like to 
mention Dr. Dominik Thimm, Dr.  Viktor Rempel, Dr. Wenjin Li, Dr. Sabrina Gollos, Marianne 
Freundlieb, Dr. Claudia Spanier, Dr. Daniel Stölting, The Hung Vu, Clara Schöder, Samer Alshaibani 
and Dr. Meryem Köse.  
 
It was a pleasure to work with several  colleagues like Azeem Danish, Muhammad Rafehi, Mahmoud  
Rashed and York Ammon. All these guys were ready to help privately as well as in the lab. I wish 
them all success.  
 
Stephanie Weinhausen and Elisabetta De Philipo were always friendly and ready give every possible 
help in the lab and shared their knowledge. 
 
Markus Kuschak joined our group recently and was ,as an IT expert and friendly person, always on 
my side.  
 
The technicians were a great source for smooth work in the lab on daily basis. Here I thank Anika 
Püsche for her patience in my four and half years in the lab throughout my master and PhD. She and 
Angelika  Fischer corrected my mistakes and hectic in a kind way for which I am thankful. Katharina 
Sylvester provided a great help during my work in the lab. To both Katharina and Marc, her husband, 
I would like express my gratitude. Christin Vielmuth was from the first day I her in the compound 
library a nice and dedicated colleague who tried to answer my questions as quickly and precisely as 
possible. Many thanks are due to Stefanie Weyer and Inge Renner for their contributions. 
 
My ultimate thanks and infinite gratitude are due to those who were the source of limitless love and 
care not only during my PhD but since I knew them. To those people no words would be able to shed 
light on my abysmal indebtedness to them. 
 
My father, a Greek among Romans, had given me an immense support, confidence and faith all along 
my way.  
 
My mother was always my refuge in any case of difficulty or problem. She is always able to calm me 
and boost my confidence. For her priceless standby I would be in eternal debt. 
 
To my brother and two sisters I owe a lot of support, nostalgic times and beautiful memories. 
 
Nurcan, my wife, was the real motivator behind me during the downs and she was more relieved 
than me during the ups of this thesis. She was always ready to sacrifice time and take every step to 
enable me make this thesis possible. For her encouragement, intelligence, support and love I will be 
always thankful. 
 
